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ABSTRACT  
The rate of HIV infection in South Africa remains high despite the continued efforts to prevent 
its transmission. Conversely, the rate of AIDS related mortality has been on the decline since 
the country introduced its comprehensive care and treatment plan. Among other things, the 
comprehensive plan seeks to coordinate activities to prevent further infection and facilitate 
health and social support services for the infected and affected. Despite this, South Africa has 
an increasing number of people living with HIV (PLWH) and is home to the largest population of 
HIV infected people in the world. Consequently, there is a growing shift of focus of HIV/AIDS 
response programmes from issues of survival and death prevention to the quality of survival of 
PLWH. This point accentuates the need for patient evaluation of their wellbeing and quality of 
life in the context of the country’s HIV/AIDS response services. There are HIV-specific quality of 
life assessment tools like the WHOQOL-HIV, but these tools are subject to cultural variations 
and have not been validated across South Africa’s multicultural society. The available tools are 
often too long and cannot be used in routine care and support of PLWH. In the absence of 
validated and efficient quality of life assessment tools, there is over reliance on biomedical 
markers of HIV/AIDS like the CD4 cell count and viral load. These biomedical indicators do not 
provide a complete view of the impact of the disease given the multidimensional consequences 
of HIV and AIDS.  
 
With the above background, this study sought to firstly explore the health related quality of life 
(HRQOL) and the experiences of PLWH in seeking care and support services, and secondly, to 
validate the ability of the WHOQOL-HIV instrument to measure the health related quality of life 
of PLWH among the three cultural groups in Limpopo Province over a specified time period.  
 
The study was divided into two, with the first and second studies using qualitative and 
quantitative research approaches respectively. Both studies divided their participants into three 
groups, with each group representing each of the three main ethnic groups in Limpopo 
Province (Pedi, Tsonga and Venda). The qualitative study used focus group discussions (FGDs) 
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to solicit information and grounded theory to guide its participant selection, number of FGDs 
conducted and the interpretation of its findings.  
 
The second study was a longitudinal follow up of participants in the three groups from the point 
of treatment initiation over 12 months. In the second study, there were three points of data 
collection (baseline, six and twelve months). The participants were conveniently selected and 
interviewed repeatedly with the WHOQOL-HIV and MOS-HIV instruments. The study findings 
were mostly presented in tables and t-tests and ANOVA were used to compare quality of life 
scores in different groupings while correlation and limits of agreements were used to establish 
instrument validity. Item-total correlation coefficient and alpha if item deleted, was used to 
explore the possibility of shortening the WHOQOL-HIV instrument in an attempt to suggest a 
shorter and more user friendly version of the instrument.  
 
The key findings of the qualitative study are that the quality of life of PLWH in Limpopo is 
determined by three groups of factors (physical, mental and external). The frequency and 
severity of these factors are determined by the participants’ duration on treatment, disclosure 
of their HIV status and socioeconomic status. The physical factors were mostly constituted by 
biological symptoms of the disease. The most commonly cited symptoms were diarrhoea, pain 
and fatigue. The study also noted marked differences in the occurrence of the symptoms 
through the trajectory of the disease revealing four main stages: pre-treatment; treatment 
initiation; early treatment; and treatment maintenance stages. The study also noted that the 
impact of the determinants of the quality of life on an individual is influenced by intervening 
factors which can be altered by a set of modifying factors. In all, the quality of life determinants 
identified by this study replicates those that constitute the WHOQOL-HIV instrument. This 
finding hence obviates the need for the modification of existing quality of life instruments to 
suit the three South African ethnic groups investigated by this study. 
 
The quantitative study showed high reliability of the WHOQOL-HIV among the three ethnic 
groups with alpha ranging from 0.79 to 0.94 in the six domains of the instrument. The study 
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also showed that the quality of life varied by socio-demographic characteristics such as ethnic 
group, sex, marital status, number of children, employment status and membership of 
HIV/AIDS support groups. The observed difference reflects poor financial capacity and activity 
tolerance across the various categories of the participants and at different times. While 
significant changes in the quality of life was noted between the baseline data and the six and 
twelve months data respectively, little or no improvements were seen between the six and 
twelve months data. The participants were actually more likely to have a better quality of life at 
six months when compared to their quality of life at twelve months. In the same manner, the 
median CD4 cell count and viral load were very similar at six and twelve months but differed 
significantly with the baseline reports. Over time and across cultural groups, the participants 
reported lower quality of life in the level of dependence domain and financial support subscale. 
There were little or no associations between the biomedical markers and HRQOL indicators. In 
addition, the quality of life tended to increase with increase in CD4 cell count. The validation of 
the WHOQOL-HIV using the MOS-HIV through a correlation of similar domains and their limits 
of agreement largely suggests that the WHOQOL-HIV is valid but both instruments are not exact 
replicas in their measurements. The multidimensional nature hypothesized by the original 
WHOQOL-HIV instrument study was also demonstrated by the factor analysis component 
matrix. Attempts to shorten the WHOQOL-HIV proved to be impossible as the items with 
highest item-total correlation varied with the participants’ duration on treatment.  
 
In conclusion, this study suggested the needs and factors that contribute to the quality of life of 
PLWH in Limpopo and how those factors can be harnessed through a set of modifying factors. 
With this, an individual’s quality of life is determined by the delicate balance between 
intervening and modifying factors. The linkages between the observed determinants of quality 
of life suggest a vicious circle where one determinant may exacerbate the effect of another 
determinant. The study also showed that the WHOQOL-HIV instrument is valid and reliable in 
measuring the quality of life of PLWH in the province. The observed poor to no associations 
between the health related quality of life indicators and the biomedical makers show that they 
cannot be direct proxies of each other. Finally, the study discourages any further shortening of 
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the WHOQOL-HIV instrument on the basis that HIV-infected people are not a homogenous 
group as their bio-psychosocial needs vary with time and their position along the trajectory of 
the disease.  
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CHAPTER ONE 
INTRODUCTION 
1.1 Background 
1.1.1 HIV and AIDS epidemic in South Africa 
South Africa faces a mature and generalized HIV and AIDS epidemic which has also been 
described as one of the worst AIDS epidemics in the world (UNAIDS, 2006). It was estimated 
that 5.5 million South Africans were living with HIV in 2005 while about 320,000 people died of 
AIDS-related illnesses in South Africa in 2005 alone. AIDS related mortality in South Africa 
however dropped to about 250,000 in 2008 (STATSA, 2009). In 2009, about 5.7 million people 
were living with the virus in South Africa (UNAIDS, 2010). These figures suggest a rising 
prevalence of HIV infection and decreasing AIDS related deaths. HIV prevalence in the country 
also varies with age and sex with higher prevalence noted among females and people in the 
childbearing age group. For instance, about 15% of persons aged between 15 and 49 are known 
to be HIV positive and approximately one-in-three females aged between 25 and 29 are  HIV 
infected (HSRC, 2009). 
  
In response to the HIV epidemic, the South African government has instituted various policies 
and programmes to halt and begin to reverse the epidemic. One of the key HIV response 
document in the country is the Operational Plan for Comprehensive Care and Treatment (DOH, 
2003).  
 
The Operational Plan for Comprehensive Care and Treatment was launched in 2003. The plan 
hopes to: 
- ensure that the majority of South Africans who are currently not infected with HIV 
remain uninfected, through effective interventions to change lifestyles and behaviour 
and through programmes that reduce poverty and inequity; 
- increase efforts to provide prophylaxis and treatment of opportunistic infections, 
improved nutrition and lifestyle options; and 
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- promote the effective management of those HIV infected individuals who have 
developed AIDS-defining illnesses, through appropriate treatment of AIDS-related 
conditions (including using antiretroviral therapy to prolong life), and providing suitable 
palliative and terminal care. 
 
To complement the operational plan, the HIV & AIDS and STI Strategic Plan for South Africa for 
2007 to 2011 was introduced in 2006 (DOH, 2006). The strategic plan highlights the country’s 
multi-sectoral response to the HIV/AIDS epidemic. The National Strategic Plan (NSP) hopes to 
provide clarity and guidance to all government departments and civil society on what needs to 
be done and how to build on the gains of various response initiatives. The NSP focuses on four 
key priority areas namely, prevention; treatment, care and support; human and legal rights; 
and research, monitoring and surveillance (DOH, 2006). 
  
The above documents created the platform for the comprehensive implementation of South 
Africa’s ART programme which is described as the largest in the world. It was estimated that 28 
percent of HIV infected people were receiving ART at the end of 2007. This number has 
continued to increase with the accreditation and opening of more treatment sites in the 
country in an effort to meet the growing demand for ART.  
 
When the ART programme was launched in South Africa in 2003, it was recommended that 
patients should be initiated to treatment when their CD4 cell count falls below 200 cells/µl. This 
recommendation was changed to 350 cells/µl in 2010 given the known benefits of early 
treatment initiation. This concession applies to pregnant women and people co-infected with 
tuberculosis and HIV. Despite this, late treatment initiation remains widespread due to health 
systems related and psychosocial barriers to accessing treatment, including stigma. The new 
policy on early treatment initiation, however, comes with economic costs to the country and 
more pressure on an over stretched health system (HSRC, 2009).  
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The combination of the array of the health and social services available through the policies and 
programmes is meant to prolong life and ameliorate the impact of HIV and AIDS. The gains of 
the policies and programmes can already be seen in improved survival of people living with HIV 
(PLWH) in South Africa. There is, however, very limited evidence to substantiate the extent to 
which the available services target the preferred health outcome of PLWH. Ditto et al (1996) 
explained that, in general, patients may wish to maintain a tolerable quality of life than go 
through the pain of seeking certain services. This assertion is worrying given the reported 
difficulties associated with seeking care and support services by PLWH in South Africa (Maluleke 
et al., 2006; UNAIDS, 2006). Other authors have raised concerns that modern medical practice, 
policies and guidelines do not adequately consider patients’ health related needs, choices and 
the relative importance patients place on different health dimensions (Sherbourne et al., 1999; 
Owen 1998; Nease et al, 1995; Kleinman, 1981). These issues have a major bearing on the 
mental health of patients, which is a known determinant of health related quality of life 
(HRQOL) and utility of service (Wells et al., 1996; Fryback et al., 1993).  
 
In the context of the above concerns, Coulter (2005) provided a model to help explore factors 
affecting care and support services. This model interrogates specific patient experiences with 
elements of care and support, such as access to services, effectiveness of treatment, patient 
and family involvement in care activities, comprehension of information, attention to physical 
and environmental needs and continuum of care. These points underscore the need for a 
comprehensive exploration of similar circumstances within the framework of the South African 
HIV and AIDS response paradigm and in its socio-cultural milieu.  
 
1.1.2 Linking biological markers of HIV and AIDS with measures of quality of Life 
Against the above considerations, surrogate measures such as the CD4 count and viral burden 
have remained the major markers of disease progression and wellbeing of PLWH. Such clinical 
indicators have also been deemed to provide an incomplete view of disease impact (Katz et al., 
2004; Blaiss et al., 1997). To bridge this gap, HRQOL measures are increasingly being 
incorporated in the traditional clinical measures of health. This shift is aimed at providing a 
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greater depth of information on the impact of the disease on the physical, social and emotional 
wellbeing of individuals (Katz et al., 2004). This kind of information is essential to ensure a 
higher efficiency, responsiveness and precision of the delivery of care and support services such 
as counselling, treatment of opportunistic infections, nutritional interventions, the provision of 
disability grants and anti-retroviral therapy (ARV). These services are the key components of 
South Africa’s comprehensive HIV and AIDS care plan (DOH, 2003). 
  
The value of HRQOL measurement in HIV and AIDS management is again heightened by the 
improved survival of PLWH and the need to measure their quality of survival and support 
requirements. There are various instruments and methods of measuring HRQOL and these 
include the standard gamble (SG); visual analogue scale (VAS); medical outcome study (MOS); 
health utility index (HUI); EuroQol and the quality of well-being scale (Rashidi et al, 2006; Wu et 
al, 1998). These instruments were developed in recognition of the importance of patient 
reported information such as experiences with seeking care, long term health outcomes as well 
as the effectiveness and efficiency of health care interventions (Horsman et al, 2003; Revicki, et 
al, 1998).  The usefulness of HRQOL instruments is, however, predicated on the extent to which 
they have been standardized together with their level of reliability and validity (Schwartz et al, 
1999). On the basis of this requirement, the World Health Organisation developed a HRQOL 
instrument for PLWH (WHOQOL-HIV) (WHO, 2004). The WHOQOL-HIV is made up of 120 
questions, and 30 questions in its long and brief versions respectively and these are divided into 
six domains, namely: physical, psychological, level of dependence, social relationships, 
environment and spirituality. The long length of the WHOQOL-HIV questionnaire may prohibit 
its use in the routine health services in South Africa given the large number of PLWH, their vast 
social and health care needs and the limited number of health workers.  
 
The WHOQOL-HIV has been validated across different cultures and settings around the world 
(WHOQOL-HIV Group, 2004). The cross-cultural validation of the instrument is in view of the 
widely reported cultural variations and limitations of HRQOL instruments (Collinge et al, 2002; 
de Haes and Olschewski, 1998; Vanhem et al, 1996). This concern is underscored by the 
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definition of HRQOL as “an individual’s perceptions of their position in life in the context of the 
culture and value systems in which they live and in relation to their goals, expectations, 
standards and concerns”. With this, the value of validating the WHOQOL-HIV becomes critical in 
South Africa given its multicultural composition. The only known use of the WHOQOL-HIV in 
South Africa was in IsiXhosa Language in the Eastern Cape Province (Peltzer and Phaswana-
Mafuya, 2008; Friend-du Preez and Peltzer; 2009). The later study showed that the tool had 
moderate to low reliability in some domains. On the converse, a pilot study of the tool in 
Zambia found the tool to be highly reliable (Mweemba et al., 2011). 
 
Furthermore, quality of life studies in HIV have mostly been cross-sectional in nature and 
focused mainly on issues such as functioning, adherence to treatment and perceptions about 
HRQOL (Louwagie et al., 2007; Hughes et al., 2004; Nicholas et al., 2004; O’Keefe and Wood., 
1996; Phaladze et al., 1996). The use of cross-sectional designs contradicts the argument that 
authenticating the relationship between clinical measure of HIV and AIDS and HRQOL would 
require concurrent repeated measurements of the variables (Weinfurt et al, 1999). This 
assertion should also be read against the backdrop that the bio-psychosocial effects of  HIV vary 
over time (Gurunathan et al., 2009; Murdaugh., 1998). The available literature in South Africa 
mostly used the EuroQol, visual analogue scale (VAS) and medical outcome study (MOS) 
instruments in their measurement of HRQOL among PLWH at one point in time. These 
instruments are generic and have their limitations in measuring HRQOL in specific situations 
such as HIV and AIDS (Rutishauser, 1998; McSweeny and Creer, 1995; Guyatt et al, 1993). 
Among the limitations of generic tools are their inability to measure change following defined 
interventions over time and their failure to capture specific disease related parameters. 
 
1.2 Problem statements and research opportunities 
There is no record of a qualitative identification of quality of life determinants as well as the 
health and social support needs and constraints of PLWH in the context of the country’s 
HIV/AIDS response programmes. This gap does not allow for a proper understanding of the 
scope and effect of the known quantitative determinants of quality of life and the 
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responsiveness of the existing programmes. Such information is also needed to validate the 
application of existing HRQOL instruments in South Africa and suggests the need for a new or 
revised quantitative instrument. The study background also highlighted the usefulness of the 
WHOQOL-HIV questionnaire. There is, however, no record of its validation across South Africa’s 
multicultural societies. Without this information, it becomes difficult to establish if the 
questionnaire can be used in South Africa given its unique HIV/AIDS response programmes, 
cultural diversity and state of its AIDS epidemic. In the same context, very few studies have 
tried to link biomedical markers of the HIV and AIDS disease progression and HRQOL in 
developing counties in comparison to the number of such studies conducted in developed 
countries where the health and social support systems are well established. In this regard, the 
available body of knowledge about the link between both markers may not be applicable to 
developing countries. In addition, the long length of the existing WHOQOL-HIV questionnaire 
does not permit its use in routine patient care. Given that the biomedical and HRQOL markers 
of HIV infected people also vary over time, there is also a limited record of studies that have 
examined how both measures change or interact over time. The WHOQOL-HIV instrument has 
never been tested over time among PLWH to assess its stability and applicability through the 
bio-psychosocial trajectory of HIV/AIDS.  
 
1.3 General Objective 
The general objective of this study was firstly to identify factors influencing the HRQOL of PLWH 
and their experiences with seeking care and support services and, secondly, to validate the 
ability of the WHOQOL-HIV instrument in measuring HRQOL of PLWH among the three cultural 
groups in Limpopo Province.  
 
The specific objectives of this study were grouped into Study I and II: 
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1.3.1 Study I specific objectives    
Study I specific objectives were further divided into Parts A and B  
Part A:  Identification of factors influencing the HRQOL of PLWH and their experiences with 
care and support services 
. The objectives of study I, Part A were to:  
1. explore the HRQOL, health care needs, constraints and experiences with HIV and 
AIDS care and support services;  
2. explore cultural definitions and quantifications of HRQOL; and 
3. code participants’ report into items and categories to constitute the psychometric 
instruments for HRQOL and experience with HIV and AIDS care and support services. 
 
Part B:  Piloting of items identified in Part A in the development of psychometric 
instruments for HRQOL and experiences with care and support services. According 
to Petersen et al., (2005), the aim of the piloting of a newly identified psychometric 
test included to: 
1. determine the nature of scaling;  
2. determine the ease or difficulty with which questions are answered;  
3. analyze the scale structure with exploratory confirmatory factor and Rasch analyses; 
and 
4. choose the most relevant items for a field test version of the instruments.   
 
1.3.2 Study II specific objectives 
The objectives Study II were to: 
1. describe the health related quality of life of people living with HIV and AIDS in 
Limpopo Province;  
2. establish the relationship between changes in CD4 count, viral burden and 
HRQOL over time; 
3. Validate the index instruments for HRQOL developed in study I Part B; 
4. validate the WHOQOL-HIV in the predominantly spoken local languages in 
Limpopo province which are, Northern Sotho, Tshivenda and Xitsonga; and 
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5. develop a shorter version of the WHOQOL-HIV that adequately replicates the 
domains of the long versions of the WHOQOL-HIV through item removal 
techniques. 
1.4 Significance of the study 
The significance of this study is that it seeks to develop a comprehensive and responsive health 
assessment instrument based on the opinions and perceptions of PLWH in South Africa. This 
effort will help articulate the intricate health care needs, choices and constraints of PLWH 
within the South African HIV and AIDS response paradigms. This effort is important, given the 
value of patient reported information in ensuring the quality, effectiveness and efficiency of 
care delivery (Horsman et al, 2003; Revicki, et al, 1998).  
 
This study’s plan to develop a shorter version of the WHOQOL-HIV is geared towards the 
promotion of efficiency in its use in routine health surveys and screening activities. The shorter 
WHOQOL-HIV will augment the current dependence on CD4 count as the eligibility criterion for 
disability grants in South Africa. In this regard, the shorter WHOQOL-HIV may serve as a 
measure of function, the ability to withstand accessing care and support services or earn a 
livelihood in the absence of a government grant. Such an alternative or complementary 
measure is important as there are suggestions that South Africa’s reliance on CD4 count as the 
eligibility criterion for disability grants could be discouraging adherence to treatment among 
PLWHA and may not be a true reflection of the ability of these individuals to support 
themselves (Nattrass, 2006). 
 
In all, the instrument to be developed in this study could be used in routine patient care to 
accurately measure relevant parameters of care and hopefully help to improve the quality of 
care “through the eyes of the patients” and perhaps help ensure a more tolerable HRQOL and 
optimum CD4 counts and viral burden among PLWHA.     
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1.5 Study outline  
Given the background and objectives, this study was divided into Study I and II. Study I was a 
qualitative exploration of HRQOL, access to services, health care needs and constraints of 
PLWHA and the development and texting of psychometric instruments to measure the 
variables. Study I was also in two parts: Part A involved item generation while Part B was 
designed to focus on piloting the items generated. Study II was a follow-up of a cohort of 
PLWHA that has been newly commenced on ARV treatment to describe, validate and shorten 
the WHOQOL-HIV and measure changes in CD4 counts, viral load and HRQOL over time  
 
Study II followed up PLWHA from the point of treatment initiation through a period of twelve 
months. This effort was to help gain a better understanding of their health care needs, 
constraints and how the HRQOL and biomedical markers of HIV and AIDS disease progression of 
the study cohort changed over time. The decision to follow the study cohort over a period of 
twelve months was based on experiences from previous studies that have reported changes in 
CD4 count and viral load within an average of twelve months following the initiation of 
treatment (Schiffer et al., 2004; Weinfurt et al., 2000). The main components and stages of this 
research project are illustrated by Figure 1.1 below 
 
Figure 1.1: Illustration of the different stages of the research project  
 
 
 
Study I Part A: Qualitative 
exploration and item 
identification for index 
HRQOL instrument  
Study I Part B: Piloting of 
index instrument 
Study II: Validation and 
shortening of the 
instruments and follow up 
of a new ART initiates for 
12 Months  
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Following the figure above, the contents of this report are structured into the following 
chapters: 
- Chapter One contains the introduction, problem statements, objectives, significance and 
outcome;  
- Chapter Two is the literature review focusing on the key components of the study;  
- Chapter Three contains research methodology used in the study;  
- Chapter Four presents the findings and discussions of Study I; 
- Chapter Five details the findings and discussions of Study II; and 
- Chapter Six provides the conclusions and recommendations of Study I and II 
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CHAPTER TWO 
LITERATURE REVIEW  
 
2.1 Introduction 
This chapter provides a literature overview of the key components of this study which are the 
biological and psychological trajectory of HIV and AIDS; the determinants of HIV disease 
progression; biological markers of HIV disease progression; antiretroviral treatment; the 
definitions of quality of life; effect of culture on the perceptions of health related quality of life; 
and the considerations for instrument development, selection and modification.  
 
The decision to cover the above subjects is to provide relevant information on them given this 
study’s focus on HIV and AIDS in South Africa with a view to better understand the trajectory of 
HIV disease progression from the point of treatment initiation over a 12 month period across 
three cultural groups. This is also linked to the fact that the quality of life will be measured 
together with how the study cohort’s biological and psychological markers of disease 
progression may have changed from the point of treatment initiation. This chapter also covers 
the considerations for instrument selection and development given its intention to compare 
quality of life measuring instruments and explore the possibility of removing some of the items 
in the instruments to ensure their better efficiency.  
 
2.2 Biological trajectory of HIV infection  
AIDS is a syndrome caused by the human immunodeficiency virus. This syndrome is marked by 
a continuous reduction of the CD4 T-lymphocytes.  The resulting depletion is followed by a 
commensurate reduction of the individual’s immuno-competence and increased susceptibility 
to infections. Various research efforts have tried to understand the natural history of HIV 
infection, a collection of such studies was presented in a desk review by Gurunathan et al., 
(2009).  The clinical trajectory of HIV infection has been divided into three phases, including the 
acute phase, the chronic/clinically latent phase and AIDS in the absence of treatment. 
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2.2.1 The Acute Phase  
The manifestations of the acute stage or primary infection will vary from asymptomatic 
seroconversion to severe illness. The symptoms of this phase include viral infections, fever, 
lymphadenopathy, headache, generalized body pain and weakness, anorexia, rash and 
diarrhoea (Grossman et al., 2006; Hel et al., 2006; Picker 2006). During this stage, the infected 
person also experiences high titres of plasma vireamia resulting from the HIV infection. Viral 
replication and dissemination is high and widespread at this stage (Pilcher et al., 2004; Stafford 
et al., 2000; Little et al., 1999; Kaufmann et al., 1998). The viral load in the acute stage can 
range from 100,000 to 10,000,000 copies/ml. The noted increase in viral load is sharp during 
the second to the fourth week post-exposure to the infection. The increase declines and 
stabilizes in four to six months after the infection. The stabilization of viral replication and 
dissemination will mark the beginning of the latent phase. The acute phase also experiences 
transient decrease in the CD4 cells with small increase in viral load which may allow 
opportunistic infections to begin to develop (Vento, 1993).  
 
2.2.2 The Chronic Phase 
The chronic phase is mainly characterized by the absence of symptoms. In the absence of 
treatment, this phase has been noted to have a median duration of about 10 years before 
progressing to AIDS in young adults (Gupta et al., 2007; Djomand et al, 2006; Gray et al., 2005; 
Grobler et al., 2004). This duration may range from six months to 28 years. The viral load in this 
phase can also range from undetectable to several thousands and varies from person to person 
(Lyles et al., 2000). Another study showed a 0.15% increase in viral load per week (Schacker et 
al., 1998). The reported viral load among HIV infected individuals in this phase has been noted 
to be lower in developing countries when compared to the figures from developed countries 
(Gray et al., 2005). The variations have been further attributed to set-point definitions in 
techniques used for viral load determination, virus subtypes, as well as other intrinsic factors 
(Gurunathan et al., 2009).This phase sees a progressive weakening of the immune system 
following the gradual depletion of the CD4 cells. HIV infected people in the stage have also 
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been shown to have a CD4 cell count that is below the mean CD4 cell count of sero-negative 
individuals (Moss et al., 1988). 
 
2.2.3 The AIDS Phase  
In the absence of treatment, the clinically latent phase will progress to AIDS (CDC 1987, 1993). 
At this stage, the CD4 cell count is often <200 cells /µl. This is followed by an increase in viral 
load and AIDS by two to five years. This progression has been altered by the introduction of 
antiretroviral treatment (ART). The initiation of ART has been based on a prognosis of disease 
free survival determined by the CD4 cell count. Other considerations for ART initiation are viral 
burden, treatment readiness, possible risks and benefits of starting treatment for asymptomatic 
people (including short and long term side effects), availability of psychosocial and treatment 
adherence support (Phillips, 2004; Egger et al, 2002). ART drastically reduces viral load to very 
low or undetectable levels to allow for immune reconstruction and recovery.   
 
2.3 Determinants of HIV disease progression  
The progression of HIV to AIDS is driven by various factors most of which have been grouped 
under host and viral factors. The host factors include things like age at infection, gender, 
ethnicity, mode of acquisition, and genetic factors. Age at infection determines whether a 
person gets infected through blood transfusion, blood products or sexual intercourse 
(Gurunathan et al., 2007; Morgan et al., 2002; Hessol et al., 1994). For instance, perinatally 
infected infants will progress either early or late. Early progression involves a median 
progression to AIDS at four months while the late progression has a median onset of AIDS in 6  
years (Berk et al., 2005; Faye et al., 2004). Age also plays a key role considering the function of 
the thymus in the reconstitution of CD4 cells that are depleted by the infection (Haynes et al., 
2000; Douek et al., 1998). A 25 year old with a CD4 cell count of less than 200/µl has about a 
thirty percent chance of progressing to AIDS when compared to a person aged 55 years old. In 
addition, older people are more likely to have a lower CD4 count at similar times from 
seroconversion (Geskus et al., 2005; Touloumi et al., 1998).  The age differences are, however, 
minimized by the introduction of ART (Geskus et al., 2005; CASCADE collaboration, 2003). 
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The mean HIV-RNA has been noted to differ between males and females at a given CD4 strata 
(Touloumi et al., 2004; Sterling et al., 2001
1
; Anastos, 2000). For instance, a low CD4 cell count 
in females is associated with higher mean HIV-RNA when compared to males with similar CD4 
cell counts. In the same way, it was added that females have higher viral load if their CD4 cell 
count was <50 cells/µl and lower viral load if their CD4 cell count was >350 cells/µl when 
compared to males (Donnelly et al., 2005). Despite the variations by sex, studies have not been 
able to show differences in the rate of disease progression at a given CD4 cell count (Donnelly 
et al., 2005; Sterling et al, 2001
2
). 
 
In terms of ethnicity, the rate of progression has been noted to be shorter in Haiti when 
compared to Thailand (Rangsin et al., 2004; Deschamps et al., 2000).  These differences have 
been attributed to host immunogenetics, co-infections, viral and environmental factors. Other 
factors like poor satisfaction with health services, low psychosocial support, stressful life 
events, depression and denial based coping strategies have all been associated with poor 
treatment outcomes (Ironson et al., 2005; Ashton et al., 2005). Studies have also linked poor 
adherence with singleness, depression and homelessness (Parruti et al., 2006; Anastos et al., 
2005). 
 
There is growing evidence of the role of genes in HIV disease progression. Currently, there is an 
increasing list of AIDS restricting genes (ARGs). Some of these genes affect a person’s 
susceptibility to HIV infection, rate of progression from HIV to AIDS and pathogenesity at 
different stages of the disease (Hutcheson et al., 2008). People with two copies of CCR5-∆32 
allele are highly resistant to HIV -1 infection while a copy of the same gene provides minimal 
resistance (Liu et al., 1996; Dean et al., 1996; Huang et al., 1996). People with mutated copies 
of CCR2 have demonstrated a slow progression to AIDS (Smith et al., 1997). Similarly, 
individuals with copies of CCR5-∆32 and CCR2-∆641 alleles have low risk of progression to AIDS 
(Ioannidis et al., 2001). 
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While the HLA-B*27 and *57 have been linked to low viral load and good prognosis, HLA-B*35 
have been associated with rapid progression to AIDS (Gao et al., 2005; Carrington and O’Brien, 
2003; Tang et al., 2002). 
 
With regards to the virus, differences in its biological properties such as its replication rate, 
syncytium-inducing (SI) capacity and cytotrophism contribute to its infectivity and progression 
to AIDS in infected people (Tersmette et al., 1989). SI isolates have been observed among 
individuals who have progressed rapidly to AIDS. In the same way, subtype D has been found to 
cause a faster progression to AIDS when compared to subtype A (Kaleebu et al., 2002; Kaleebu 
et al., 2001). Another study in Thailand has shown a faster progression from HIV infection to 
AIDS or death with HIV-1 subtype E (Todd et al., 2007; Rangsin et al., 2004; Costello et al., 
2004). 
  
2.4 Markers of HIV disease progression 
Different indicators of HIV disease progression have been suggested. The various factors can be 
grouped as clinical or biological markers. Multiple research studies have demonstrated the link 
between the severity and duration of illness in the acute phase with the rate of HIV progression 
to AIDS (Lavreys et al., 2006; Pedersen et al., 1989). In this regard, it has been shown that the 
speed of HIV progression to AIDS is higher among people with symptom duration greater than 
14 days when compared to those who have a mild illness or who are free of symptoms 
(Henrard et al., 1995). 
 
Similarly, the progression of HIV infection to AIDS can be shown by changes in biological 
markers like CD4 cells, viral load, combination of viral load and CD4 count, HIV-1 proviral DNA 
levels and generalized immune activation. Low CD4 count remains the first and most popularly 
used biological marker of HIV progression to AIDS (Giorgi et al., 2002; Anastos et al., 1999). CD4 
cell count percentages are known to correlate with AIDS defining conditions (Mellors et al., 
1997). CD4 cell counts are hence recommended for case definition of AIDS and criterion for 
decision-making for HIV treatment. With this, newly HIV-infected people with low CD4 count at 
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baseline are known to advance to AIDS in two to three years (Goujard et al., 2006; Rouzioux et 
al., 2005). Furthermore, the ability of CD4 count to predict HIV infection is also known to be 
poor in the early part of the infection. The mucosal tissues also experience CD4 cells count 
depletion three weeks after the HIV infection and this can be used as an early prognostic 
marker but will need early detection of infection and endoscopic biopsies from the colon 
mucosa (Brenchley et al., 2004; Mehandru et al., 2004; Veazey et al., 2004). In all, HIV-infected 
persons with a CD4 cell count of 350 – 500/µl have demonstrated a risk of less than or equal to 
5% of progressing to AIDS and the risk is much greater when the CD4 cell count falls below 
200/µl (CASCADE collaboration, 2004).  
 
Furthermore, CD4 cell count has been effectively used to monitor the efficacy of treatment 
(Bartlett et al., 2005; Moore and Chaisson, 1999). CD4 values at six months after treatment 
initiation have been described as predictors of further viral suppression and immunological 
progression (Duncombe et al., 2005; Grabar et al., 2000). On the other hand, very low CD4 cell 
counts have been linked with virologic failure (Battegay et al., 2006). This finding emphasizes 
the benefits of early treatment initiation before a total depletion of the immune system 
response to therapy.  
 
Viral load measurement through the quantification of HIV RNA was made possible through new 
laboratory technology. Among such technology are reverse transcriptase polymerase chain 
reaction (RT-PCR), branched DNA and the nucleic acid sequence-based assay (NASBA). These 
assays allow for the measurement of the HIV RNA circulating in the plasma. Changes in daily 
viral load are known to be very small to negligible at approximately 0.4log10.  However, the 
natural history of HIV infection has shown that peak viral load is reached within 30 days of 
exposure to HIV-infection (Little et al., 1999; Kaufman et al., 1998; Piatak et al., 1993). On the 
other hand, a viral load set point is reached within 4 to 6 months after HIV infection. 
 
Best practice evidence is increasingly suggesting that the prognosis of HIV infected people is 
more accurate through the combination of CD4 cell count and viral load (Madec et al., 2005; 
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Buchacz et al., 2004). Despite this, the correlation between the viral load and progression to 
AIDS is weaker when the viral load is evaluated late in the course of the infection and in 
patients with low CD4 cell counts (Cozzi et al., 1998). In the combined use of both markers, the 
viral load indicates the extent of destruction of the immune systems while the CD4 cell count 
reflects the rate of immunodeficiency (Simon et al., 2006). 
 
Peripheral blood mononuclear cells (PBMC) are also used to study the cell-associated reservoir 
among HIV infected people (Gibellini et al., 2008; Sarmati et al., 2005; Gougeon et al., 2001). 
Like the earlier methods discussed, the values of the PBMC has been effectively used to predict 
disease progression, absolute point for treatment initiation and success of ART. In this context, 
different studies have shown an association between HIV DNA loads and the risk of disease 
progression independent of CD4 cell counts and viral load (Katzenstein et al., 2002; Kostrikis et 
al., 2002). In all a combination of the CD4 cell count, viral load and HIV DNA values have been 
reported as the best measure of HIV disease progression (Peter and Sevall 2004).  
 
HIV-1 infection causes significant increases in immune activation with resulting proliferation 
and turnover of CD4 cells and other markers of immune activation. Among asymptomatic 
persons a number of markers have also been noted and include: serum β2 microglobulin, 
serum and urine neopterin soluble CD8, soluble IL-2 receptor, interferon-α and serum levels of 
IgA (Ullum et al., 2000; Liu et al., 1997). Other markers like CD38 molecules per CD8 T 
lymphocytes are very useful markers in the later stage of the infection but may be equally 
useful during the early stage (Roussanov et al., 2007).  
 
2.5 The psychosocial trajectory of the disease  
Similar to the trend seen in the biological trajectory and markers of HIV and AIDS, there is 
growing evidence of such effect on the psychological domain of HIV infected people. This is 
evidenced by the observed changes in the psychological wellbeing of HIV infected persons 
(Murdaugh, 1998).  Living with HIV/AIDS challenges the entire existence of the infected person. 
The absence of a cure and chronic nature of the disease through the support of antiretroviral 
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therapy (ART) hence demand that the infected person will need to make adjustments in order 
to live effectively with the disease. Living with this condition is however, compounded by the 
sense of loss and social stigma associated with the disease (Cochran and May, 1991). The stress 
on family units and the complexities of interacting with the health system all add to the 
challenges of living with HIV/AIDS.   
 
Furthermore, there is a growing understanding on adaptive responses to HIV and AIDS and their 
consequences.  One such early studies was qualitative and naturalistic, identifying five themes: 
mastery over the disease, spiritual journey towards understanding, self acceptance, staying 
active and involved and positive thinking (Kendal et al., 1989). In another study on the 
uncertainties of living with HIV/AIDS, it was noted that uncertainty and its ramifications had 
greater impact on the quality of life of HIV infected people when compared to people with 
other chronic conditions (Weitz, 1989). The study by Nokes and Carver (1990) reported 
recurring themes like: thoughts about mortality surface and subside, relationships fluctuate and 
priorities change and shifting expectations lead to thoughts of spirituality. A phenomenological 
study on coping with HIV identified three processes: living with dying, fighting the sickness and 
getting worn out (McCain and Gramling, 1992).  
 
 Murdaugh (1998) describes the trajectory of events associated with optimally adjusting to the 
challenges of living with HIV/AIDS. In her writing, she describes the combination of events as 
“achieving a balance” and to include processes of constantly adjusting to the demands of the 
disease without letting the disease dominate one’s life. This process creates a sense of control, 
predictability in the face of the many changes and the disease progression patterns. This 
process involves the trajectory of psychosocial experiences with adjusting to the disease from 
the point of diagnosis to the respective stage of disease progression in relation to their quality 
of life. Through this, the adjustment process highlights factors that may positively or negatively 
alter the quality of life over the HIV-illness trajectory. 
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According to Murdaugh (1998), the process of achieving a balance occurs in four stages. She 
added that the process does not necessarily occur in one direction but that people move forth 
and back. With this, people move in and out of balance as a result of the disease and its 
emotional and physical consequences. The stages are disintegrating, renormalizing, coming to 
terms and creating meaning. 
 
During the disintegration stage, the person is destabilized and out of balance following a HIV 
positive diagnosis. This stage is characterized by hopelessness, devastation, disappointment 
and preoccupation with the anticipation and fear of dying.   Two key elements of this stage are 
mourning loss and finding relief. In this stage, people are purported to mourn the loss of future 
hopes and plans following HIV diagnosis and its potential effect on their health, well-being and 
survival. Despite this, people are also expected to get a sense of relief knowing that the fear of 
being HIV positive is true.  
 
Following the above, it is expected that people gradually begin to move towards renormalizing 
as they begin to seek information about the disease. Social support was noted to be essential in 
this stage and that people begin to use the available information to consider how to live with 
the disease. Such support could come from friends, family, support groups of people living with 
HIV and health care workers. With these changes, the person begins to rebalance their 
activities to become as normal as possible. This stage is hence characterized by the individual’s 
attempt to control the disease, reduce abnormality, involve in regular activities and maintain 
social networks (Murdaugh, 1998; Davis, 1963). Unlike the previous stage, this stage is hopeful 
about the future. The key elements of this stage are focusing on self, containing investment (or 
making short term goals), keeping up with activities and pacing to accommodate the disease.  
 
The third stage or coming to terms results from repeated failed attempts to renormalize. The 
un-resolving realities of the disease progression force the individual to begin to appreciate and 
accept the manifestation of HIV/AIDS. The individual accepts that life cannot return to absolute 
normal with the experiences of fatigue, weight loss, treatment regimen demand and complex 
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interaction with health systems. The key elements of this stage are “putting one’s house in 
order” and “changing priorities”.  People may write their wills at this stage, make funeral 
arrangements, make plans for the future of their children and changing jobs to meet their new 
capabilities and health status.  
 
In the fourth stage, individuals begin to create meaning in their life beyond HIV. People here 
begin to make the best of every moment and reach out to others. This stage is a reflection, the 
restoration of self-worth and purpose in life. Furthermore, persons at this stage begin to value 
good quality life against quantity.  
 
The stages described above provide good information to guide the planning of a more 
responsive psychosocial intervention to deal with the mitigating manifestation of each stage 
proactively and potentially fast track HIV infected persons from the “disintegration” stage to 
the “creating  meaning” stage.  
 
2.6 Antiretroviral treatment 
2.6.1 Timing ART initiation 
Choosing when to initiate patients on ART requires clinicians to weigh the benefits of the 
treatment outcome against its risks like toxicity, resistance, drug interaction, costs and the 
inconvenience of lifelong treatment. The goal of treatment of ART is to restore and/or preserve 
immune function, decrease opportunistic infection and mortality. The motivation for using 
antiretroviral drugs is in their ability to suppress viral replication. Furthermore, a near-perfect 
adherence to ART is required for an optimal treatment outcome. On the other hand, the failure 
to attain the required level of adherence has been linked with aggravated immunosuppression, 
the development of drug resistant strains of HIV and the increased risk of viral transmission 
(Bangsberg et al.,2001; Paterson et al.,2000; Mannheimer et al., 2002; Howard et al, 2002; 
Walsh & Sherr 2002). Other benefits of adherence in AIDS treatment include that: 
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- there is a far higher likelihood of virologic failure among non-adherent patients when 
compared to adequately adherent patients (Igumbor et al., 2011; Mannheimer et al., 
2002; Howard et al, 2002; Walsh & Sherr 2002; Paterson et al., 2000);  
- suitable improvement in adherence will result in a reduction in the risk of progression to 
AIDS (Bangsberg, 2000; 2001);  
- increase in adherence will result in increased CD4 count (Haubrich et al., 1999); 
- non-adherence has been associated with increased frequency of hospitalisation and 
longer stay on hospital admission (Paterson et al., 2000);  
- in the event of virologic failure, persistent use of antiretroviral drugs by optimally 
adherent patients may delay patients’ progression to AIDS (Deeks et al., 2000);  
- the odds of developing viral resistance increase with the level of non-adherence and this 
occurrence has the propensity to exhaust the treatment options of HIV-infected persons 
(Pach et al., 2003);  
- .    
 
Recent advances in ART have continued to provide treatment combinations that promote 
adherence, improve treatment potency, tolerance, more stable viral suppression and better 
safety with early treatment initiation. These gains have seen the reduction in the risks of ART 
but increased concerns about the risks of prolonged untreated viraemia (Thompson et al., 
2010). It has been shown that unmanaged HIV proliferation and immune activation results in 
chronic inflammation and subsequently in end-stage organ damage and other co-morbidities 
that are not directly related to AIDS. This chain of events perpetuates chronic immune 
activation and potentially permanent immune damage associated with protracted immune 
depletion (Harrison et al., 2010; Bhaskaran et al., 2008; Lohse et al., 2007). With this, it has 
been found that mortality from non-AIDS related morbidities is higher when compared to the 
morbidities from AIDS related opportunistic diseases (Palella et al., 2010; Kitahata et al., 2009).    
 
Consequently, many recent studies support early initiation of treatment (Levin, 2010; 
Johansson et al., 2010). It has for example, been demonstrated that initiating treatment at CD4 
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cell counts of 500/µl and from 350/µl to 500µl decreased mortality by 94% and 69% 
respectively (Kitahata et al., 2009; Hammer et al., 2008). The study also showed that the 
majority of the deaths resulted from non-AIDS defining conditions. These studies have also 
shown poor treatment outcome among patients who received treatment at CD4 cell counts of 
less than 350/µl. Some considerations for initiating treatment regardless of CD4 cell count are 
rapid decline in CD4 cell count and high HIV-1 RNA (Hammer et al., 2008). Old age is also a risk 
factor for rapid progression to AIDS and non-AIDS related deaths.  Pregnant women should be 
treated at least by the second trimester and treatment continued after delivery (Bhaskaran et 
al., 2008; Ferry et al., 2009; Monforte et al., 2008). 
 
2.6.2 Choice of initial treatment 
The choice of treatment on which to initiate HIV-infected people has serious implications for 
future treatment options (Thompson et al., 2010). Best practice expects that the choice of 
initial treatment should be based on resistance testing results, predicted virologic efficacy, 
toxicity, tolerability, pill burden, dosing frequency, drug-drug interaction, comorbidity as well as 
patient and health practitioners’ preference (Thompson et al., 2010). Other considerations are 
availability and affordability.  
 
Nucleoside and nucleotide reverse transcriptase inhibitors (nRTI) like Tenofovir are active 
against HIV-1 and have long intercellular half life. The potency of the nRTI (like Tenofovir and 
Emtricitabine) is increased when a third agent is added. This combination better sustains viral 
suppression and CD4 cell count increases (Zimmermann, 2006). A combination of three or four 
nTRI is, however, not advised given its low virologic potency and high toxicity (Cooper, 2009; 
Hammer et al., 2008). Tenofovir is available in fixed-dose, once daily treatments with 
Emtricitabine and with Emtricitabine and Efavirenz. Tenofovir may, however, not be a safe 
option for people with renal dysfunction. Prolonged use of Abacavir has also been associated 
with myocardial infarction (Worm et al., 2010). Lamivudine and Emtricitabine are notably well 
tolerated in most of the above studies. On the other hand, Zidovudine as an initial treatment is 
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restricted by concerns about its tolerance and risks for lipodystrophy and hyperlipdemia 
(Hammmer et al., 2008). 
 
Many studies have shown very positive treatment outcomes of using nonnucloeside reverse 
transcriptase inhibitor (NNRTI) like Efavirenz as an initial regimen (Cassetti et al., 2008). 
Efavirenz is known to be a more effective antiretroviral drug than Ritonavir-boosted Lopinavir 
and similar to Atazanavir and Raltegravir (Daar et al., 2010; Sax et al., 2009; Lennox et al., 
2009). Some of the side effects noted with Efavirenz are rash and central nervous system 
problems and are contraindicated during the first trimester of pregnancy and among women 
trying to conceive (Perinatal HIV Guideline Working Group, 2010). NNRTI has also been 
reported to have strong virologic potentials but has been linked with serious hepatic side 
effects within the first few weeks of treatment initiation (Hirsch et al., 2008).  
 
Protease inhibitors like Atazanavir have been reported to have stronger virologic properties 
when they are boosted by two nRTI (Malan et al., 2008). Patients on Atazanavir have shown 
hyperbilirubinemia, sclera icterus or frank jaundice. On the other hand, boosted Lopinavir has 
lesser virologic abilities but has better CD4 count response and fewer resistant mutations than 
Efavirenz (von Wyl et al., 2007). Some side effects of boosted Lopinavir may include diarrhoea, 
insulin resistance and hyperlipidaemia and increased risk of cardiac problems (Lang et al., 
2009).  
 
In all, fixed dose combinations are better for convenience and to promote adherence to 
treatment with less pill burden.  With this, it is recommended to use the Tenofovir and 
Emtricitabine in the initial therapy (A1a) (Thompson et al., 2010). If this combination cannot be 
used, Abacavir can be used with Lamivudine. A combination of Zidovudine and Lamivudine 
should be reserved for when Tenofovir and Abacavir cannot be used. Boosted Lopinavir are 
good alterative third-component choices and Nevirapine can be used as an initial pretreatment 
option in circumstances defined by CD4 cell count levels. Table 2.1 provides South Africa’s 
treatment guideline for adults and adolescents.  
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Table 2.1: Standardised national ART regimens for adults and adolescents in South Africa 
 
Source: DOH, 2010. The South African Antiretroviral treatment guideline 2010. Pretoria: DOH 
 
2.6.3 Treatment monitoring  
Effective treatment should bring about a reduction in branched DNA to less than 75 copies/µl 
or PCR to less than 50 copies/mL in less than six months after treatment initiation (Thompson 
et al., 2010). For timely detection of treatment failure, frequent monitoring of the biological 
markers is recommended during the first year of treatment (Gupta et al., 2009). The CD4 cell 
count should be monitored at three to four months intervals in the first year of treatment 
initiation particularly among people with CD4 cell counts of less than 200. This is to establish 
the patients’ need for continued opportunistic infection prophylaxis (Kaplan et al., 2009; Aberg 
et al., 2009). The monitoring interval can be increased to every six months if there is viral 
suppression and the CD4 cell count is over 350/µL. This change is on the basis that patients who 
maintain a stable viral load and increased CD4 cell count in one year are more likely to remain 
stable (Reekie et al., 2008). More monitoring may however be required for patients who may 
have changed treatment regimens (Reekie et al., 2010). 
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The drug toxicity monitoring is based on the known toxicity level of the particular drug and its 
underlying comorbidity. It has however been suggested that drug toxicity monitoring should be 
done between two and eight weeks after treatment initiation and six to 12 months after the 
patient has become stable (Aberg et al., 2009).  
 
2.6.4 Treatment change 
Treatment change is often warranted by virologic failure or adverse reactions. It is, however, 
encouraging to note that advances in ART almost guarantee viral suppression even in cases of 
multi-treatment failures but viral rebound remains equally common (Wittkop et al., 2009; 
Yazdanpanah et al., 2009; Steigbigel et al., 2008). Some causes of viral rebound include poor 
adherence, drug-drug interaction, concurrent infections and recent vaccinations. Given the 
transient nature of these causes, they need to be established before initiating an unnecessary 
treatment change. In making this decision, clinicians need to consider the stage of the disease, 
CD4 cell count, comorbidity, treatment history, current and previous drug resistance tests and 
concomitant medications (Thompson et al., 2010). Any change resulting from a full 
consideration of the above factors should include three or at least two fully active drugs from 
new classes. Stavudine and Didanosine should not be hastily included in the revised treatment 
given known higher level of toxicity. NNRTI failures are usually treated with combinations of 
two active nRTI and a PI.  In the event of PI failure, sequencing of PIs can be used because of 
their varying tolerance and toxicity. If this is not feasible, a NNRTI may be included after 
considering the drug interactions of such combinations.  
 
2.7 Definitions and Components of Quality of Life  
The role of treatment is to bring about total healing or symptom alleviation and hopefully 
improve on the quality of life of ailing individuals. This may not always be the case as the 
meaning and definition of quality of life is complex and contentious. This assertion is largely due 
to the multidimensional views regarding its contributors and determinants (Tyrrell et al., 2005; 
Kimmel 2000; Ferrans and Power 1992). This position challenges efforts to quantify, compare 
and fully understand the concept of quality of life (Kring, 2008). 
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Despite the continued obscurity on global and precise definitions of the quality of life concept, 
efforts have continuously been made to describe it. Ferrans and Power (1992) have for 
instance, presented it as a concept that reflects an individual’s state of satisfaction and 
happiness. Kring (2008) adds that happiness and satisfaction are not direct synonyms but 
expressions of pleasure originating and manifesting at different psychosocial domains. Upon 
this premise, happiness was viewed to manifest as a fleeting unstable emotion while 
satisfaction is mostly a permanent feelings arising from a person’s core values and beliefs. 
Health professionals have taken note of both concepts given their key importance in measuring 
health care outcomes.  
 
In the context of the above, a few more components have been added to the definition of 
quality of life in an effort to better contextualize the concept in terms of the health and well-
being of an individual (Ferrans, 2005). The added components are psychosocial adjustment, 
physical functioning, symptoms, well-being and health status. An earlier literature review by 
Ferrans and Power (1985) added that the above components of quality of life are driven by 
factors like socioeconomic status, physical health, perceived stress, friendship, family, marriage, 
life goals, housing and neighborhood, city and nation, self esteem, depression, psychological 
defense mechanism and coping.    
 
The added components all seek to provide better clarity to the definitions of quality of life with 
regards to health. This effort narrows the definition of quality of life on the basis that a person’s 
health is only a part of the sum of the person. This narrowed description led to the term “health 
related quality of life” to refer to the role of health, illness and health interventions on the 
quality of life of an individual (Ferrans, 2005; Philips, 2001). This may, however, be restrictive 
given the strong links and interplay of other attributes of the sum of an individual such as their 
political, cultural and social attributes (Kring, 2008).  
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The phrase “quality of life” and “health related quality of life” are often used interchangeably 
(Drayer et al., 2006; Morsch et al., 2006). Kring (2008) adds that the phrases are often used to 
describe (i) “a holistic global framework” or (ii) “a disease-based, deficit framework”, 
respectively and that it is critical to specify which framework is implied in their use.  This 
assertion was further illustrated by Wilson and Cleary’s (1995) health related quality of life 
conceptual model focusing on the disease-based, deficit framework (Figure 2.1). This model 
concentrates on the physical aspects of the individual and the impact of health and disease on 
the quality of life. 
 
 
Figure 2.1: Interplay between the quality of life domains by Wilson and Cleary  
Source: Wilson IB and Cleary PD (1995) Linking clinical variables with health-related quality of 
life: a conceptual model of patient outcomes. Journal of American  Medical Association, 273:59 
– 65.  
 
The challenge with defining this concept is also reflected in the efforts to measure it. The 
various measures of health related quality of life have incorporated different measurement 
scales and domains (Guillemin et al., 1993). Over 160 different measure of quality of life were 
used in articles published in 1991 alone (Spiker et al., 1992). Despite these differences, the 
common domains that characterize QOL tools are the physical, psychological, spiritual, social, 
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economic and family domains (Ferrans, 2007). In addition, each domain is often constituted and 
defined by its subscales (Ferrans, 2007). For instance, a physical domain may contain items 
assessing symptoms, functioning, adjustment or illness.  
 
The interconnections between the various domains are illustrated by Wilson and Cleary’s 
(1995) patient model linking the biological, physical, psychosocial and general wellbeing 
domains (Figure 2.1). The model also emphasizes that the domains are influenced by individual 
and environmental characteristics.  
 
2.8 Effect of culture on the perceptions of health and health related quality of life 
Quality of life measurement is known to vary across cultures given the differences in disease 
expression among cultural groups (Guillemin et al., 1993). This assertion stems from the fact 
that culture prescribes the way of life of a people partly with the aim of ensuring their survival 
and well-being (Spector, 2004; Kagawa-Singer, 2006). The ability of culture to perform these 
functions is routed in its strong beliefs and values that give meaning and purpose to the 
different aspects of life and existence. In the same context, culture defines behaviours as either 
“good” or “bad” and hence defines strategies that promote health and prevent diseases 
(Kagawa-Singer, 1995). These contributions of culture to health also tie in with the definitions 
of HRQOL as “an individual’s perceptions of their position in life in the context of the culture 
and value systems in which they live and in relation to their goals, expectations, standards and 
concerns” (WHO, 1993). The above definition is clearly open-ended to allow for cultural 
variations in the definition of quality of life.  
 
The above descriptions of culture and their implications for health should also be viewed 
against the backdrop that each culture has its distinguishing beliefs, values and practices 
(Kawage-Singer et al., 2010). Even when different cultures share certain attributes, such 
similarities may occur with varying graduation of differences. Eventually, the vast or subtle 
cultural differences result in variations in personal goals, expectations and concerns and hence 
differences in health practices and definitions of health, well-being and quality of life. This 
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assertion is in agreement with schools of thought that have recognized that culture contributes 
to perceptions of health and illness, interpretation of symptoms, HRQOL and expectations of 
care (Berzon et al., 1995).  
 
The four commonly cited domains of quality of life (including physical, mental/psychological, 
social and global perception of function and well-being) are mostly culturally defined (Kagawa-
Singer et al., 2010). Furthermore, individuals’ HRQOL of life is formed as they strive to fulfill 
needs of (1) safety and security, (2) a sense of integrity and (3) a sense of belonging as an 
integral member of one’s socio-cultural network (Kagawa-Singer, 2002). Similarly, the Ashing-
Giwa (2005) model of HRQOL has described culture as a macro component of HRQOL. It was 
further proposed that examining HRQOL across cultures will provide a better understanding of 
the constructs and its utility for specific groups.  
 
The debates around culture and HRQOL question the validity of most instruments used for 
measuring instruments (Kagawa-Singer et al., 2010). Universally applicable or cross-culturally 
valid instruments can be developed through rigorous multi-culture testing of guiding 
assumptions. Studying cross-cultural differences and similarities is vital as it provides a better 
understanding of cross-cutting psychosocial problems and forms the basis for further 
examination of culture specific determinants of psychosocial well-being (Collings, 1994). 
 
2.9 Considerations for instrument selection, development and modifications 
There are many health related quality of life assessment questionnaires and with varying 
subscales and dimensions. This trend provides a variety of questionnaires to choose from but 
making the choice between questionnaires can be daunting for researchers and a wrong 
questionnaire can compromise an intended study or measurement.  Pesudovs et al. (2007) have 
suggested a variety of considerations to guide the selection of an appropriate questionnaire, 
including the need to: 
1. select an instrument that is suitable for the measurement objectives;  
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2. ensure that the instrument can be used for the target population i.e. the instrument 
was developed for a target population similar to the proposed study’s target population;  
3. ensure that the proper item selection and reduction techniques have been used; and   
4. ensure that the instrument is sufficiently reliable and valid. 
 
Different methods and statistical techniques have also been suggested to guide the efficiency of 
the above considerations, and such components and techniques are:  
 
- Intended population characteristics, 
- Actual content area,  
- Item identification, 
- Item selection,  
- Unidimensionality, and  
- Instrument validity and reliability (Pesudovs et al., 2007) 
  
2.9.1 Intended population characteristics 
Pesudovs et al., (2007) emphasize that the above criteria should facilitate a systematic review 
of instruments to identify those that are best suited for a defined research intention and target 
population. They stress that instruments are not universal and may not apply to all populations 
as some populations may have unique components that may be missing in the instrument. An 
example of this could be the poor performance of the visual impairment questionnaire among 
people with clinical glaucoma (Lamoureux et al., 2007). This instrument was originally designed 
to target people with low vision. Pesudovs et al., (2004) add that variations still exist within 
subsets of a population. This consideration calls for a careful inclusion of all subsets of the 
particular population in the design of an instrument to ensure its generalisability in the target 
population. For example, an instrument for measuring the quality of life in the different modes 
of correction of refractive error should take into consideration all the different items relevant 
to all forms of refractive correction (for instance, spectacles, contact lenses and corrective 
surgery) to better guarantee that the items in the questionnaire are relevant to all subsets in 
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this population (Pesudovs et al., 2007). This consideration may also apply to HIV and AIDS. This 
is on the basis that an instrument specifically designed to measure the quality of life of 
treatment naïve people with AIDS may not be very helpful in measuring the quality of life of HIV 
infected persons who have successfully been on treatment for over 12 months.   
 
2.9.2.1 Reliability  
Reliability of an instrument is the degree of consistency or dependability with which an 
instrument measures the attribute it is designed to measure (Polit and Hungler, 1995). There 
are two main methods of measuring reliability: the inter- and intra- rater reliability methods. 
The inter-rater reliability is calculated by having two or more trained data collectors monitor 
the same event at the same time and independently scoring the same event using a 
predetermined coding system. The independent scores are then used to compute an index of 
equivalent or agreement. Correlation techniques are often used to compute such indexes that 
demonstrate the strength of the relationship between the rating of the observers (Polit and 
Hungler, 1995).  Unlike the inter-rater reliability, the intra-rater reliability uses the repeated 
ratings of a single observer to measure the index of agreement or equivalence of the 
instrument of interest.     
 
2.9.2.2 Validity 
The validity of an instrument is important in the selection of questionnaires. The commonly 
used measures of validity are face, construct and content validity (Katzenellenbogen et al., 
1997; Polit and Hungler, 1995). The face validity says that an instrument should appear to 
measure what it seeks to measure and this is simply done by inspecting the instruments. Face 
validity may be the weakest form of validity assessment but it establishes if the instrument 
makes logical sense and assesses the overall structure of the instrument, including the scales 
and wordings of the instrument (Katzenellenbogen et al., 1997; Polit and Hungler, 1995). 
 
Construct validity is used to describe the extent to which an instrument measures what it 
intends to measure.  Testing construct validity will require that an instrument or item should 
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correlate with another instrument or item that has been validated and known to measure the 
construct of interest. There are different methods of construct validity testing such as 
concurrent, convergent, predictive and discriminant validities. These various forms of validity all 
contribute to the establishment of the construct validity of an instrument or item 
(Katzenellenbogen et al., 1997; Polit and Hungler, 1995). 
 
Convergent validity is a form of validity testing involving the correlation of the index instrument 
or item with a standard measurement of the construct of interest.  This method uses statistic 
tests like Pearson correlation coefficient for continuous variables, chi-square analysis for 
dichotomous data and Phi coefficient as a measure of correlation. In assessing convergent 
validity, a correlation of >0.9 may not  be as good as  it may suggest because of the fact that the 
instrument is so similar to the gold standard that it  may not be providing more information. In 
this regard, a moderate correlation may be more useful than a high correlation. On the other 
hand, a low correlation may mean that the items or factors of interest may not be well 
correlated. Pesudovs et al. (2007) have suggested a cut off of 0.3 as the minimum correlation 
between two different items or latent factors measuring the same construct.  
 
Discriminant validity is the extent to which an instrument differs from an instrument that 
measures a different construct. Unlike the convergent validity test, a low correlation coefficient 
will be desirable in discriminant validity testing (Katzenellenbogen et al., 1997; Polit and 
Hungler, 1995). 
 
Predictive validity seeks to establish if the instrument can make future predictions with some 
degree of accuracy. For instance, a score on physical function can be used to predict the need 
for financial and social support. This is very important in the application of assessment 
instruments into therapeutic decision making. Basic correlation is also very important in 
establishing the predictive validity of an instrument. Dichotomous variables can rely on the chi-
square tests and odd ratios in demonstrating the predictive power of an instrument 
(Katzenellenbogen et al., 1997; Polit and Hungler, 1995). 
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Concurrent validity is used to demonstrate an instrument’s capacity to differentiate groups that 
it is theoretically designed to distinguish. This may involve distinguishing between individuals 
with or without a specific condition (Katzenellenbogen et al., 1997; Polit and Hungler, 1995). 
  
2.9.3 Item identification 
In the context of quality of life assessment, one can only say that quality of life has been 
measured if all the dimensions of quality of life have been covered. Construct under- 
representation is used to describe instances when an instrument fails to cover all the 
dimensions of the phenomenon of interest (Downing & Haladyna, 2004). While the inclusion of 
the same number of important items is important in an instrument, all the items included 
should also be relevant. A good instrument should therefore strive to balance these 
considerations. Item generation techniques are essential in ensuring that only relevant items 
are included in the questionnaire. The commonly used item generation techniques are the 
statements and opinions of the target population, from key informants and experts, and 
through the literature. Focus group discussions (FGD) are useful in eliciting the opinions at the 
individual and expert level.  FGD’s help to obtain responses common to a group of individuals 
and may be a more useful source of information than in-depth individual interviews (Krueger, 
1994). For a more robust instrument, it is important to include the opinion of the patients and 
experts for better item inclusion. Studies have, for instance, shown that instruments developed 
by talking to clinicians tended to focus more on symptoms and problems (Garamendi et al., 
2006). On the other hand, instruments developed from the patients’ opinion mostly covered 
issues like convenience, cost, heath concerns and wellbeing (Pesudovs et al., 2004).   
 
The next logical step after item generation will be a pilot of the items identified. The item 
generation results in collecting so many items of which some may be redundant and irrelevant. 
Piloting the questionnaire helps to remove poorly discriminating, invalid and unreliable items. 
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2.9.4 Item reduction 
Item reduction is important in instrument development to improve item quality, measurement 
precision and targeting of items to persons (Pesudovs et al., 2007). Item reduction seeks to 
ensure the unidimensionality of instruments by grouping items into unique constructs. This 
allows the possible summation of related items into latent scores (Streiner et al., 2003; Tennant 
et al., 2004). The following mathematical tools are used for item reduction: Cronbach’s alpha, 
factor analysis and Rasch analysis. These methods indicate the performance of items and guide 
the removal of items that do not fit. Descriptive statistics have also been applied in item 
reduction (Day et al., 2002; Jutai et al., 2003). The commonly used descriptive statistical 
methods are the extent of missing data and the normality of the items. These methods can be 
tested using histogram plots, Kolmogorov-Smirnov, Kurtosis and Skewness tests.  The Cronbach 
alpha assesses the association between each item in each construct with every other item in 
the same construct.  The Cronbach alpha runs from 0 to 1 and the higher the score the higher 
the internal consistency of the set of items. The Cronbach alpha is the same as the average 
correlation between the items in a scale or factor. In the context of this, a very high alpha (>0.9) 
may indicate redundancy. In this regard, the scale may be unidimensional but may have too 
many items representing the same measure. An ideal Cronbach alpha should be between >0.7 
and <0.9 (Pesudvos et al., 2007).  Low reliability has severe implications on the entire 
instrument as the instrument may not correlate with a gold standard instrument or may also 
have implications for the instrument’s convergent and concurrent validity.  
 
It is important to note that Cronbach alpha falls under one of the two categories of tests used 
to determine reliability. The two methods are essentially the single and multiple administration 
techniques. The Cronbach analysis falls under the single administration techniques based on 
the split half or internal consistency tests. The multiple administration involves the test-retest 
method. These methods rely on the Pearson product-moment correlation coefficient, and  
intra-class correlation coefficient (ICC; McDowell and Newell, 1878; Bravo and Potvin, 1991), 
Bland-Altman limits of agreement (Bland and Altman 1986; Bland and Altman 1991) or Kappa 
statistics. The ICC measures the ratio of the between-group variance to the total variance. The 
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Bland-Altman limit of agreement is the range of values over which 95% of the differences 
between the two measures should lie (Bland and Altman 1986; Bland and Altman 1991). The 
Bland-Altman test strength lies in its ability to use a wide range of data as well as its ability to 
detect and manage biases. The Kappa statistics is used when comparing categorical 
measurements. It seeks to demonstrate the level of agreement between two measures using 
the same nominal scale with corrections for likelihoods of chance. The Kappa weighted 
statistics has been designed for ordinal scale variables.  
 
Factor analysis is another statistical tool used to explain variations within a group of items and 
to reduce similar items into factors or groups measuring a similar construct. Through this 
process, unidimensional constructs are identified (McDowell and Newwell, 1987). Factor 
analysis also allows for the rotation of items in order to identify more commonalities between 
items and more factors can be identified through this process. The factors proposed by 
exploratory factor analysis can only be justified by confirmatory factor analysis (Lamoureux et 
al., 2007).  The reduction process can also be used to eliminate items that fail to fit if they 
contribute less than 0.40 to the variation of that factor or redundant if they contribute over 
0.80.  
 
The Rasch analysis is increasingly being used as an item reduction technique (Massof et al., 
2007; Massof et al 2005a, Massof et al., 2005b; Stelmack et al., 2004). The Rasch analysis uses 
modeling and item fit statistics to better guide the identification of unidimensional items or 
factors (Massof, 2002). In the Rasch analysis, a p-value higher than 0.05 suggests a deviation 
from the model and indicates unidimensionality (Lamoureux et al., 2006). Furthermore, the infit 
and outfit statistic is used to identify which item contributed more to the latent score. Rasch 
analysis can also be used to assess the performance of a scale by iteratively removing items.  
Lastly, Rasch analysis can assess the item difficulty to person ability and this can be used to 
remove items from an instrument or factor to ensure the relevance and meaningfulness of the 
items retained. The application of  Rasch analysis can therefore result in the selection of a 
minimum set of items most relevant to a construct or factor. Pesudovs et al. (2007) reiterate 
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the benefits of item removal to include optimum instrument efficiency, shortening of time and 
reducing user/respondent’s burden. Suggestions have been made by Linacre (2007) to guide 
item removal using Rasch analysis: 
1. Infit mean square outside 0.7 to 1.30. 
2. Outfit mean square outside 0.7 to 1.30. 
3. Item which is furthest from the subject mean.  
4. High proportion of missing data (>50%). 
5. Ceiling effect – a high proportion of responses in item and response category (>50%). 
6. Item with markedly different standard deviation of items scores to other items. 
7. Items that do not demonstrate a normal distribution as identified using histogram plots 
and other tests of normality.  
 
2.10 Questionnaires selected for this study 
With the above considerations in mind, this study used the WHOQOL-HIV and the MOS-HIV 
questionnaires. This selection was made from the QOL-HIV instruments available like the AIDS 
health assessment questionnaire (Lubeck & Fries 1997), the HIV/AID-Targeted Quality of Life 
Instrument (HAT-QOL) (Holmes and Shea, 1997), the HIV-QL31 (Lepledge et al., 1997), the 
General Health Assessment (Lenderking et al., 1997) and the Multidimensional Quality of Life 
Questionnaire for HIV/AIDS (Smith et al., 1997). The major criticism with these instruments is 
that they were developed in developed countries and among whites, HIV positive homosexuals 
and a middle to high income group. They may therefore not be suitable for this study’s target 
population (O’Connell, 2003).  
 
The later set of instruments listed above all preceded the WHOQOL-HIV in terms of when they 
were developed. The inadequacies of each of the tools were also considered in the 
development of the WHOQOL-HIV instrument (O’Connell, 2003).  The decision to use the 
WHOQOL-HIV was also in view of its growing global application, particularly across African 
populations. In this regard, the WHOQOL-HIV has been found to be valid and reliable by a study 
conducted in Zambia (Nweemba et al., 2011) while another study conducted in one of the 
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South African ethnic groups (Preez and Peltzer, 2009) had concerns about the reliability of 
some of its domains. Similarly, the MOS-HIV was chosen to validate the WHOQOL-HIV. The 
selection of MOS-HIV was based on the extensive validation and use of its generic version 
across cultural groups and the growing application of the HIV specific version among African 
populations (Babikako et al., 2010; Lara et al., 2006; Taffa et al., 2004; Wu, 1999).   
 
The WHOQOL-HIV was developed out of the WHOQOL-100 following the same process 
(WHOQOL Group, 1995, 1996). It was based on an international collaboration involving 15 
culturally diverse countries and 40 different languages. Qualitative methods were used for item 
selection and this led to the identification of 115 HIV/AIDS specific items. These items were 
added to the 100 items of the WHOQOL-100 and resulted in an initial instrument with 215 
items.  Further trial and testing of these tools saw the reduction of the 215 items into 120 and 
resulted in the WHOQOL-120 HIV. This instrument is further broken down into 29 facets and 6 
domains (Appendix 2.1). The domains are physical, psychological, level of dependence, social 
relationships, environmental and spiritual/religion/personal beliefs. The initial multi-country 
and cross cultural trial of the questionnaire showed an excellent internal consistency with an 
alpha of 0.98. At domain level, the alpha ranged from 0.87 to 0.94.  
 
The Medical Outcome Study HIV Health Survey (MOS-HIV) was mainly introduced to help test 
the validity of the WHOQOL-HIV. The MOS-HIV questions were selected from a pool of existing 
questions that have been extensively tested for use for the Medical Outcome Study (Wu, 1999). 
MOS-HIV has 35 questions assessing 10 main dimensions including key dimensions like physical 
function, social and role function, cognitive function, pain, mental health, energy, health 
distress, quality of life, overall heath and heath transition (Wu et al., 1991).  
 
2.11 Conclusion 
This literature review has among other things shown that HIV and AIDS prevalence in South 
Africa is on the increase but with a declining mortality rate as a result of the improved access to 
antiretroviral treatment and support. This trend, however, increases the burden of care on the 
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health and social support systems. The literature review also showed that this challenge could 
be alleviated by addressing the socio-economic barriers to treatment, support and early 
treatment initiation. Such efforts will minimize the risk of early progression of HIV to AIDS, 
increase the chance of effective immune reconstruction and reduce the risk for virological 
failure and development of drug resistance. With this information, the available information on 
the determinants of disease progression is also important for treatment, care and support 
planning. This chapter showed variations in disease progression based on age, sex, mode of 
infection, genetic predispositions and the environment. The section of this chapter on biological 
markers of disease progression shows the efficacy of CD4 cell count and viral load in monitoring 
disease progression. The importance of using a standardized method of measuring the 
biological markers to ensure a more accurate comparison was also highlighted.  
 
The review also showed the progressive effect of HIV and AIDS on the psychological wellbeing 
of the infected. The review described a process of “achieving a balance” that moves forth and 
back between four main stages including disintegration, re-normalizing, coming to terms and 
creating meaning. Similar to the biological trajectory, the psychological trajectory can be used 
to better plan the care, support and treatment of the infected. This information is also useful in 
understanding and tackling the mediating factors with a view to facilitate quick and effective 
immune reconstruction and recovery.  
 
The importance of patients’ perception and measurement of their level of recovery was 
underscored by this review. The measurement of such constructs presents many complexities 
given its broadness and constitutes the measures of health related quality of life. This 
complexity can however be addressed by developing more focused instruments to measure 
well defined constructs through a rigorous process of collecting the opinions of key 
stakeholders and the statistical evaluation and testing of the information collected.   
 
In the context of this study, people with HIV infections are living longer with the virus due to 
better access to treatment and this shifts the focus of care to the quality of survival of these 
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individuals. It becomes important to measure such constructs through a combination of 
biological and psychological markers as perceived by the participants. This assertion serves to 
guide the responsiveness of support intervention in the context of limited resources. Health 
related quality of life questionnaires will serve this purpose and need to be carefully selected to 
ensure that they meet the needs of the target population, are valid and reliable, efficient and 
easy to use. With this and the issues discussed in the review, this study’s effort to remove items 
from the instruments used should consider the essential techniques required for item reduction 
and removal. This effort should also bear in mind that the very transient and evolving nature of 
HIV and AIDS disease may result in many sub-populations of people living with HIV and AIDS. In 
this regard, any item reduction or removal effort should generate an instrument that 
adequately covers the concerns of all the subsets of people living with HIV and AIDS in the 
different stages of the disease.  
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CHAPTER THREE 
METHODOLOGY 
3.1 Introduction 
This chapter is divided into two parts with each part covering the methodology of Study I and 
Study II respectively. The following subheadings are presented under each part: study design, 
target population, sampling and sampling procedure, instrumentation and data collection 
procedure, selection and training of data collectors, data analysis and ethical considerations.  
 
The decision to divide this chapter into two parts is to allow for clarity given that Study I used a 
qualitative research approach while Study II used a quantitative research approach. The reason 
for separating the two studies is because they have different objectives and use different 
methods and designs in collecting information to answer the main objective of the combined 
study. Study I will involve a qualitative exploration of quality of life in the South African context 
and identify useful elements to develop a valid quality of life tool. Study II uses quantitative 
designs to validate and shorten quality of life tools and measure the change in health related 
quality of life and biomedical markers of HIV over time.  
 
3.2 Part One: Study I:  Identification of factors influencing the HRQOL of PLWH and their 
experiences with care and support services 
 
3.2.1 Study design 
Study I was a qualitative study based on grounded theory. The study used focus group 
discussions to elicit the definitions of health, the perceived factors contributing to the health 
related quality of life (HRQOL) and the general wellbeing of the study participants.  
 
The inclusion of a qualitative research component to this study was driven by the intention to 
generate HRQOL items in the context of the determinants of the local HIV and AIDS epidemic 
and response paradigms and across the variations of cultural definitions of health and 
wellbeing. This effort draws on the qualitative method’s intrinsic flexibility and iterative 
approach to item identification, verification and categorization (Caledron, 2000).  
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It was also envisaged that the inclusion of qualitative methods would help establish the extent 
to which conventional HRQOL assessment tools for people with HIV/AIDS cover the scope of 
HRQOL determinants and definitions as perceived by the different cultural groups in Limpopo 
Province. This effort is premised on the widely described differential values placed on health 
and health care by different socio-cultural groups (Chesney et al., 1982). The proponents of a 
combination of qualitative and quantitative methods emphasize quantitative methods’ 
limitations to adequately incorporate cultural diversities (Giachello, 1996). The findings of 
qualitative methods thus become important in accepting, rejecting or modifying quantitative 
survey tools (Calderon et al., 2000). On the other hand, the subsequent and extensive use of 
quantitative methods in Study II serve to address common concerns relating to the over 
reliance and over interpretation of the findings of qualitative methods like their validity, 
generalisability and reliability (Mays and Pope, 2000).  
 
3.2.2 Target populations  
This study targeted people aged 18 years old and above, living with HIV/AIDS and receiving ART 
in public health facilities in the Limpopo Province. Limpopo is one of South Africa’s nine (9) 
provinces; it is the northernmost province and borders Mozambique, Zimbabwe and Botswana 
from east to west. Limpopo is the fourth most populated province in South Africa with about 
5.3 million inhabitants and constitutes approximately 12% of South Africa’s total population 
(LPG, 2007). This population is distributed across Limpopo’s five districts serviced by close to 
4600 health facilities. The clinic person ratio was 1:10,707 in 2005 with 2.7 clinic visits per 
person in the same year. Limpopo has also been described as the poorest province in South 
Africa with most of its districts falling into the lowest quintile in South Africa (HST, 2007).  
Limpopo is also the third lowest province in terms of access to piped water at 83.6% coverage. 
Government is the major provider of health services in the province as close to 93% of people 
in the province did not have a medical aid scheme in 2007 (HST, 2007). About 19% of its 
antenatal care (ANC) attendees were estimated to be HIV positive in 2007 while about 10.9% of 
its entire population were estimated to be HIV positive in 2008 (HSRC, 2009).  
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3.2.3 Sampling 
Three hospitals that met the study criteria were randomly selected from a list of hospitals in the 
area. Each participating hospital represented each of the three language groups in the province 
which are Sipedi, Xitsonga and Tshivenda. Public health facilities accredited to provide ARV 
were then clustered according to the predominant language group around their respective 
catchment areas. This led to three clusters representing the three predominant language 
groups in the province and a hospital was selected randomly from each cluster. To ensure 
better access to a sufficient number of study participants, only hospitals with a cumulative ARV 
enrolment of over 500 were included in the sample frame.  
 
Following the selection of the study sites, a theoretical sampling method was used to select 
individual participants at the respective study sites. Theoretical sampling is a process that 
combines data collection, coding and analyses with the intention of suggesting the kind of data 
to collect and the target groups for subsequent interviews in an attempt to fully understand 
theories emerging from each completed interview (Glaser and Strauss 1967). Through this 
process, theoretical sampling also helps to identify data categories, their properties and 
interrelationships (Tavakol, 2006).   
 
At this stage of the study, only ambulant people visiting the ARV Clinics within the designated 
study sites (hospitals) were targeted. Study I participants were HIV positive people on ART, 
people of the same language group (Sipedi, Xitsonga and Tshivenda) and who spoke and 
understood the local language. The groups were heterogeneous in terms of the participants’ 
health status, duration on treatment and length of diagnosis of HIV status. The decision to 
assemble heterogeneous groups was in an effort to promote discussion and generate a broader 
range of HRQOL determinants across the various stages of HIV infection/AIDS (Wong, 2008). 
This consideration is also cognizant of the longitudinal nature of this study and hence the need 
to have a more inclusive scope of HRQOL items across the natural history of HIV infection, 
pattern of progression to AIDS or participants’ response to ART. 
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Given the sensitive nature of the research topic, the focus groups were constituted by members 
of an existing HIV/AIDS support group in the three hospitals. An HIV/AIDS support group is a 
group of people living with HIV/AIDS who come together to help each other bear the challenges 
of living with HIV/AIDS by sharing experiences, knowledge and providing  other kinds of support 
that are often non-professional and non-material. Support groups are built on trust, 
understanding and familiarity between members over time. These dynamics hopefully 
encourage honest and spontaneous discussions (Raibee, 2004). In line with the need for 
heterogeneous set of participants, each existing support group was continued by people of 
different ages, sex and treatment and health histories.   
 
Each of the focus groups was constituted by 8 to 12 people. This size was to ensure a 
manageable group that has enough people to generate a wide range of opinions and 
perspectives (Kruger and Casey 2000). To encourage attendance, the list of each focus group 
participants was structured around the support group members’ routine clinic visit dates, so 
that as they came in for their routine clinic visit they could participate in the focus group 
discussions if they were willing. The invitation to participate in the study was made by the 
support group leader and each person could only take part in one focus group discussion in the 
study. 
 
The number of focus group discussions conducted was not predetermined; it was based on the 
emerging information, and continued until no new information was obtained with successive 
interviews. At this point, the data collection and analysis reached its saturation point and 
continuation was unnecessary (Tavakol et al., 2006).  
 
3.2.4 Setting and conducting the discussions 
The focus group discussions were conducted at the health facilities on the day that the 
participants came in for routine services. The discussions were held in adequately spaced 
rooms that provided for comfort, privacy, good ventilation and lighting. Light refreshments (of 
fruit juice and snacks) were provided before the start of the discussion because most of the 
 44
participants may have already been at the health facility on that day for a long time. The 
discussions were facilitated by a moderator and a note taker. The participants and facilitators 
sat in a circle in an effort to create a friendly and non-threatening environment and to allow all 
participants and facilitators to see and hear one another clearly.     
 
The roles of the facilitators in this study are as described by Wong (2008). The moderator was 
mandated to guide the discussion, ensure that the participants were engaged and prevent 
domination by some participants (Smithson 2000). In this study, the note taker documented the 
non-verbal expressions, the moods and other physical gestures. Before the discussion, the note 
taker also made a list of the participants, including their names, age, marital and employment 
status, duration on treatment CD4 counts and viral loads. During the interview, the note taker 
was also responsible for controlling the tape recorder.  
 
Each focus group discussion began with a word of welcome by the moderator. This was 
followed by the introduction of the facilitators, the research study, the intentions and 
procedures for the focus group discussion including the ground rules, expectations, discussion, 
duration and ethical considerations. This was followed by the self introduction by the group 
participants. This activity helped the facilitators to know the participants and served as an ‘ice 
breaker’.  
 
Another key aspect of the preparatory phase was the explanation of the tape recording process 
and assigning identification numbers to participants as a way of ensuring confidentiality by 
masking their identity in the audio tape. This is because participants were expected to 
introduce themselves using the unique numbers allocated to them by the moderator before 
they contributed to the discussions. 
 
3.2.5 Instrumentation and data collection  
Given the intention to collect, code and analyze data, two instruments were used in this study. 
The first focus group discussions were prompted with questions on how the respective 
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participants view their health and common health problems that they encounter (Petersen et 
al, 2005). The interview schedule covered the participants’ ability to carry out activities of daily 
living, including eating and drinking, sleeping, breathing, elimination, movement, 
communication and relationships, sexuality, self care ability, endurance with daily work and 
household responsibilities. The frequency and severity of the concerns raised by the 
participants were further explored. Participants’ obstacles to achieving optimum health and 
coping mechanisms were examined, including the effect of stigma and level of social support on 
participants’ health and ability to seek help. Cultural definitions and quantification of 
participants’ perceptions were also solicited. 
 
The additional questions explored during the first focus group discussions were participants’ 
experience with support services in terms of cost, time and distance.  The services included the 
provision of counseling support and health education, treatment of opportunistic infections, 
nutritional support, disability grant and ART. The participants’ perceived benefits and access to 
services were further explored and ranked. The follow up interviews focused on core themes 
that emerged from the first focus group discussions. This mostly covered the description, 
severity and frequency of occurrence of the themes identified during the first interviews. 
 
3.2.6 Selection and training of facilitators  
Individuals who were native users of the respective languages and fluent in English were 
recruited to participate in the study as facilitators. The facilitators had background training and 
knowledge in health and human research ethics; the conduct of one-on-one interviews and 
focus group discussions; soliciting case study information and HIV/AIDS counseling. Six 
facilitators were involved in the study. Teams of facilitators consisting of a moderator and a 
note taker were sent to each study site.  
 
The three moderators were researchers working at academic institutions with a minimum of 
masters degrees in health related disciplines and with many years of experience in health care 
provision. The three note takers were honours degree holders in clinical psychology, HIV and 
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AIDS counsellors, masters of public health students and currently serving as research-assistants 
at a health research and training centre in Limpopo Province.  
 
As part of the facilitators’ training for this study, they were oriented to the objectives and 
salient components of the study. Mock focus group discussions were conducted to familiarise 
each of the teams with the instruments in the respective languages.  
 
The deployment of the bilingual facilitators to the various sites is due to the fact that the 
researcher does not speak any of the local languages in Limpopo Province. It was also envisaged 
that the use of local facilitators /researchers would facilitate the referral of study participants 
to the available sources of psychological and social support in the area if the need arose during 
the data collection. In addition, the local facilitators were expected to have a better 
understanding of the cultural perspectives of the data collected. This knowledge was essential 
to ensure that the participants were protected during the data collection processes and for a 
better interpretation of the participants’ opinions during the data analysis. 
 
3.2.7 Data analysis  
The grounded theory qualitative data analysis model was used at this stage of the study. 
‘Grounded theory is a qualitative inquiry method that looks systematically at qualitative data 
aiming at the generation of a theory that accounts for a pattern of behaviour that is relevant 
and problematic for those involved’ (Glaser, 2005). Grounded theory uses a model of 
negotiation and renegotiation by means of follow up interviews to better understand human 
phenomena (Tavakol et al., 2006). Through this, grounded theory strives to explain key social 
processes that are grounded in empirical data (Hutchinson, 2001). 
 
Against this background, this study’s data were tape recorded, transcribed verbatim, translated 
into English and analyzed by following the steps recommended by grounded theory. The 
process started with re-reading the field notes and transcripts to fully understand their 
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contents and contexts. This was followed by the coding of the data in an attempt to identify the 
concepts and constructs in the data. 
 
The coding occurred at three levels (Tavakol et al., 2006). Level I coding sought to identify the 
substance of the data as described by the participants’ own words or phrases. These are 
referred to as substantive codes or in vivo codes. The goal at this stage was to identify as many 
codes as possible. Level II coding involved the condensation or collapsing of similar level I codes 
into bigger categories (Hutchinson, 2001). This was followed by the level III coding involving the 
development of theoretical constructs that are high level interpretation of the level two codes 
(Glaser, 1978).  
 
The above step concluded the analysis of the first set of interviews and suggested the kind of 
data that needed to be further collected for the purpose of saturating the data categories and 
identifying core variables. This effort draws on the function of core variables: in accounting for 
some of the variations in a pattern of behaviour; facilitating the integration of other categories 
in the data and generating the grounded theory (Hutchinson, 2001; Mullen & Reynolds, 1978).  
The conclusions reached about the categories and core variables were also based on the 
memos collected during the analysis. The use of memos was based on their function in 
“theorizing write up of ideas about codes and their relationship as they strike the analyst” 
(Glaser 1978). In other words, the memos helped to put data together up to a conceptual level, 
identify properties of each category and suggest hypotheses about linkages and 
interrelationships between categories (Glaser 1978).  
 
The use of multiple data collectors and sites was a way to ensure the trustworthiness of the 
data and results. The study was conducted in multiple sites by different highly trained and 
competent FGD facilitators and this provided an opportunity for checking the credibility of the 
study findings. The use of grounded theory also allows for member checking of data collected 
through follow up interviews used in grounded theory. The data collected was also scrutinized 
 48
independently by the four different researchers, including the student and the three 
supervisors at the time of the data collection. 
 
3.2.8 Ethical considerations 
Efforts were made to protect the rights and dignity of study participants, including their rights 
to confidentiality, anonymity, informed consent and the right to withdraw from the study. This 
information is in the information sheet and consent forms (Appendix 3.1). There was no 
invasive test on the participants as the biomedical information used in the study was obtained 
from medical records of routinely collected patient information. Permission was obtained from 
the Limpopo Provincial Department of Health and Social Development and designated hospital 
authorities. Ethical approval for the study was granted by the University of the Witwatersrand 
Human Research Ethics Committee (HREC). The study was executed in close consultation with 
support groups and organizations of PLWHA, mainly to ensure that study participants were duly 
protected. For easy understanding, the consent forms and information sheet was made 
available in English and the three predominantly spoken languages in the province (Sipedi, 
Xitsonga and Tshivenda) which are the focus of this study. Participants were requested to 
choose the language of preference for the consent forms and information sheets.  
 
Informed consent forms were signed in duplicate; a copy was kept by the researchers while the 
second copy was kept by the respective participant. The invitation to participate in the study 
was made by the support group leader and only those willing to participate availed themselves 
to the study facilitators. This process was aimed at further ensuring participants’ confidentiality 
and autonomy.  
 
The participants’ study records (such as audiotapes, transcripts and interview schedules) are 
being kept by the researcher for a minimum of six years following the study’s completion. In 
line with the agreements with the participants as detailed in the consent forms, the records will 
be kept by the researcher in a safe, suitable, sizeable, durable and locked container. The 
records will be protected from any form of damage, unauthorized use, removal and disclosure 
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of the information they contain (JISC InfoNet, 2007). At the end of the six years storage period, 
the record will be destroyed by the researcher in a manner that continues to protect the 
anonymity and dignity of the participants. 
 
3.3 Part Two: Study II: Description, validation and shortening of the WHOQOL-HIV and 
measurement of changes in CD4 counts, viral load, HRQOL over time 
 
3.3.1 Study design  
A cohort study design was used in Study II. The study cohort was made up of treatment naïve 
HIV positive people who were being initiated to ART. The participants were recruited on their 
first day of treatment initiation and followed up over a twelve month period.  There was no 
selection process used; instead all patients who were ready to commence treatment based on 
the treatment initiation criteria and who may have gone through the treatment readiness 
assessment and training processes were co-opted into the study.  
 
In order to deal with challenges of cohort attrition, the study used the clinic based counsellors 
to follow up on the study cohort during their monthly visits for treatment collection. The clinic 
based counsellors came from community based organisations and with the consent of the 
patient could follow up on them through their community based treatment support networks 
or via telephone calls.  
 
3.3.2 Target population 
All persons aged 18 years and above and living with HIV and AIDS accessing care in public health 
facilities were targeted. The participants were HIV positive, treatment naïve persons and about 
to be initiated to ART. Such people will ideally have a CD4 cell count of < 200 cells/µl, 
presenting with symptoms attributable to or complicated by HIV infection and people being 
initiated to treatment for the first time. The target patient population is consistent with one of 
the categories of the Center for Disease Control and Prevention (CDC) Classification System for 
HIV-Infected Adults and Adolescents. The focus on one category of patients is to facilitate the 
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selection of a highly homogenous population that will serve as a control for itself through 
repeated measurements of the study variables over time. 
 
3.3.3 Sampling criteria and sample size 
The study was located in the original study sites as described in Part A of Study I and 
participants were conveniently selected to participate in the study from the ARV and Wellness 
Clinics of the designated health facilities. The adoption of convenient sampling method in Study 
II is due to the absence of a sampling frame to be used for probability sampling methods. ARV 
clinics do not have a waiting list for treatment initiation. Patients are placed on treatment as 
soon as they meet the requirement for ARV treatment initiation. 
 
 An average of 150 participants were selected at baseline to participate from each of the sites. 
This resulted in at least 450 participants. It was anticipated that 12 items would be retained in 
the index instruments and the WHOQOL-HIV instrument. Between 5 and 10 participants are 
needed to demonstrate levels of variation per variable. This study will therefore require a 
maximum of 120 participants per language. This sampling approach is known as variable 
sampling and its total size is a function of the number of variables (Velicer and Fava, 1998; 
Marascuilo and Levin 1983). It is often used in factor analysis and item reduction; a minimum of 
100 and a maximum of 200 participants is generally recommended when using this approach 
(Comrey, 1973; 1988). The decision to recruit about 450 participants was to cater for attrition 
and accrue statistically adequate numbers of participants to allow for site comparison. Follow-
up through home and hospital visits helped to minimize participant attrition and loss to follow-
up. 
 
3.3.4 Instrumentation  
The instruments used in this study were the WHOQOL-HIV (Appendixes 3.2) and MOS-HIV 
(Appendixes 3.3). The health and demographic data formed part of the instruments used in 
Study II (Appendix 3.4). The participants’ CD4 counts and viral load were also solicited in Study 
II. These clinical measures were collected from patients’ medical records from the routinely 
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collected tests. Using these instruments, data was collected at three points over a period of 12 
months. The baseline data was collected during treatment initiation. Subsequent follow up 
occurred at six and twelve months after the initiation of treatment for each study participant.  
 
The instruments used in this study were all administered in the respective study’s site’s local 
language. With this, the instruments were forward and backward translated by a team of 
professional language speakers and health care workers. The translation instructions provided 
by the instrument developers were followed (Wouter and Marc, 2004). The translated 
instruments were then piloted in each language and further revised by the team as necessary. 
 
3.3.5 Data analysis  
The study data were managed using the Statistical Package for Social Sciences (SPSS) for 
windows. Basic descriptive analysis of the participants’ socio-demographic and quality of life 
measures was done and compared across the three times of data collection (baseline, six and 
12 months). This was followed by internal consistency assessment using Cronbach alpha to 
assess the reliability of the instruments. t-tests and analysis of variance were used to compare 
the average HRQOL subscale and domain scores between times, cultural groups, key 
demographic characteristics and the biological markers. The instrument’s convergent validity 
was tested by comparing WHOQOL-HIV and the MOS-HIV instruments using Pearson’s 
correlation coefficient and the Bland-Altman Limits of Agreement.  The initial plan was to 
reduce the WHOQOL-HIV to two items per domain for each of the six domains to form the new 
shortened version. It was hoped that this process would help retain a minimum of 12 items 
from the long WHOQOL-HIV. The item selection was done using the item-total correlation 
coefficients and the Cronbach alpha if item was deleted. Finally, the number of factors in the 
respective domains was established through principal component analysis.  
 
3.3.6 Ethical considerations 
Efforts were made to protect the rights and dignity of study participants, including their rights 
to confidentiality, anonymity, informed consent and the right to withdraw from the study. This 
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information is detailed in the information sheet and consent forms (Appendix 3.5). There was 
no invasive test on the participants as the biomedical information used in the study was 
obtained from medical records of routinely collected information in patient care. Permission 
was solicited from the Limpopo Provincial Department of Health and Social Development and 
designated hospital authorities (Appendix 3.6). Ethical approval for the study was obtained 
from the University of the Witwatersrand Human Research Ethics Committee (Appendix 3.7). 
The study was executed in close consultation with support groups and organizations of PLWHA, 
mainly to ensure that the study participants were duly protected. For easy understanding, the 
consent forms and information sheets were available in English and the three predominantly 
spoken languages in the province (Sipedi, Xitsonga and Tshivenda) which are the focus of this 
study. Participants were then requested to choose the language of preference for the consent 
forms and information sheets. Informed consents were signed in duplicate. A copy was kept by 
the researcher while the second copy was given to the respective participant. The consent was 
done at the three points of data collection i.e. before every interview conducted in this study. 
To avoid any intrusion or invasion of the privacy of the participants, the interviews were 
conducted by the clinic based lay counselors who already knew the study participants.  
 
The participants’ study records (such as the interview schedules) will be safely kept by the 
researcher for a minimum of six years following the study’s completion. In line with the 
agreements with the participants as detailed in the information sheet and consent forms, the 
records will be kept under a safe, suitable, sizeable, durable and locked container which will be 
kept by the researcher. The records will be protected from any form of damage, unauthorized 
use, removal and disclosure of the information they contain (JISC InfoNet, 2007). At the end of 
the six years storage period, the record will be destroyed by the researcher in a manner that 
continues to protect the anonymity and dignity of the participants. 
 
 
 53 
CHAPTER FOUR  
FINDINGS AND DISCUSSION OF STUDY I: IDENTIFICATION OF FACTORS INFLUENCING THE 
HRQOL OF PLWH AND THEIR EXPERIENCES WITH CARE AND SUPPORT SERVICES 
 
4.1 Introduction 
This chapter presents the findings and discussion of the qualitative aspect of this report. The 
contents of this chapter are structured around the main specific objective of Study I which was 
to identify HRQOL items that can be used to develop an index HRQOL questionnaire. In this 
regard, the results and discussion are presented around the items and determinants of the 
HRQOL of PLWHA identified. The results section hence consists of the items identified and their 
respective literature justification. The result section also attempts to link the various items by 
highlighting the intervening and modifying factors identified by the study and the suggested 
effect of time and treatment on the HRQOL of PLWHA. Following the results, the discussion 
section brings the various items together and highlights the care and support implications of 
items as well as their implications for the survival and overall wellbeing of PLWHA. The 
discussion also presents the factors that impact on the items identified. 
 
4.2 Results  
 A variety of factors were perceived to contribute to the health and wellbeing of the 
participants. Based on the participants’ remarks, these factors tended to impact on their ability 
to carry out routine activities of living and overall health related quality of life. It was also clear 
that while there was often consensus in the groups on the different factors, the perceived 
degree of effect of most of the factors varied. The observed variation is based on the fact that 
the groups were mostly heterogeneous based on the participants’ duration on treatment, age, 
sex, viral burden and length of diagnosis of a positive HIV status. The participants’ duration on 
treatment was often the determinant of concurrence or discordance among the group 
members. Such divisions suggested the alleviation to total absence of some factors with longer 
duration on treatment. This observation reemphasizes the importance of ART.  
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Fourteen core variables were identified and  have been grouped into three main categories 
namely physical, mental and external factors (Table 4.1). The physical factors include the 
differential signs and symptoms of underlining pathological conditions and/or physiological 
imbalances. The mental factors are the different fears, anxieties, concerns and worries 
expressed by the participants as well as the manifestations of such fears and anxieties. The 
external factors are the environmental factors which are often beyond the control of the 
participants and influence their response to health, disease and illness. The 14 core variables 
identified by this study are similar to those identified by the WHO in the WHOQOL-HIV: Users 
Manual (2004) as well as the categories of the MOS SF-36 (Ware & Sherbourne, 1992).  
Similarly, another study conducted in South Africa reported similar core variables as key 
symptoms experienced by PLWHA on ART (Bhengu et al., 2009). Bhengu et al., (2009) also 
found a strong relationship between the intensity of the symptoms and the tolerance of routine 
activities of daily living.  The identification of items was facilitated by open-ended questions 
that required the participants to rank the items based on their perceived severity and 
frequency of occurrence. This question also helped to identify the commonly cited items.      
Table 4.1: Factors perceived to contribute to health and well being 
Main category Factors and core variables  
Physical factors   1. Diarrhoea  
2. Pain 
3. Fatigue 
4. Cough and dyspnea 
5. Insomnia 
Mental factors 6. Body image disturbance  
7. Fear 
8. Perceived psychological effect of AIDS on the family 
9. Disclosure of HIV status 
10. Level of psychological adjustment and acceptance of HIV status 
11. Anger 
External factors  12. Stigma and discrimination 
13. Perceived attitude of health workers 
14. Social support structures and the needs of people living with HIV/AIDS 
 
 55 
While the findings of this study confirm widely documented concerns of people living with HIV 
and AIDS, it further exposes perceived causes of the concerns, how the concerns influence their 
health related quality of life and the coping strategies adopted to alleviate the concerns. These 
additions supplement a body of knowledge that has been mostly informed by quantitative 
research (Bhengu et al., 2009; Rivero-Mendez et al., 2009; Makoae et al., 2005; Shawn et al., 
2005; Holzemer et al. 2001). The findings are important in providing a better understanding and 
helping clinician and programme planners in improving the health related quality of life as 
defined by the participants. This assertion also draws on the new focus on the quality of 
survival of people living with HIV and AIDS as it moves from being a life threatening condition to 
a chronic health problem due to advancements in and better access to ART (Pierret, 2007). The 
results of the study are presented in detail in the following sections. 
 
Through the focus group discussions, different symptoms of pathological conditions or 
physiological imbalances were identified and described in terms of severity, frequency and 
timing of occurrence.  The most commonly cited symptoms were pain, diarrhoea, fatigue, flu 
like symptoms, cough, and insomnia. The reported symptoms varied over time. Based on 
comments of the patients and observations made during the interviews, this study noted four 
key stages defined by the type of symptom manifested and severity of such symptoms. These 
stages and their characteristic symptoms are shown in the table below:  
 
Table 4.2: Common symptoms reported from AIDS through treatment initiation and immune 
reconstruction  
Stage Description Predominant symptom experienced 
1 Pre-treatment stage Pain, diarrhoea, anorexia, dermatological problems, 
cough and fatigue 
2 Treatment initiation stage Pain, diarrhoea, vomiting, stomach cramps, fatigue 
dizziness and nausea 
3 Early treatment stage Pain, diarrhoea, fatigue, insomnia, eating disorders 
4 Treatment maintenance stage Pain 
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The observed variations of predominant symptoms in the above stages is congruent with 
studies that have shown symptom variations throughout the trajectory of HIV disease (Portillo 
et al., 2007; Sukati et al., 2005; Tsai et al., 2002). The stages noted by this study may also be 
attributed to HIV related syndromes, secondary complications, changes in viral burden, immune 
reconstruction effects and the side effects of ART and other medications (O’Brien et al., 2009).  
 
The symptoms listed under each of the respective stages were the predominantly reported 
symptoms under the particular stage and the main health concern for individuals in the 
respective stage. This assertion should be interpreted against the backdrop that this study 
requested its participants to list their priority symptoms based on perceived severity and 
frequency of occurrence. This was done bearing in mind that studies that have explored the 
scope of symptoms experienced by people living with HIV/AIDS (PLWHA) have reported over 60 
different symptoms experienced by PLWHA with each participant reporting an average of about 
15 symptoms (Makoae et al., 2005; Sukati et al., 2005). 
 
4.2.1 Diarrhoea 
In terms of the priority symptoms identified by this study, diarrhoea was ranked very high and 
has been described in similar studies as being one of the most common symptoms of disease 
with AIDS and is associated with decreased quality of life and survival (Henry et al., 1999). 
Diarrhoea is also known to occur in about 50% of PLWHA (Henry et al., 1999). The cause of 
diarrhoea in HIV may be due to known pathogens, side effect of treatments or simply an 
idiopathic HIV associated enteropathy.   
 
In the context of the above, patients in this study were often unable to attribute the diarrhoea 
to any particular cause but emphasized its huge effect on their wellbeing. This can be illustrated 
in the accounts of two participants below:  
 
“With diarrhoea, I do not see a specific thing that causes it because you can take several food, 
then after taking the food you start having diarrhoea and you stop to eat that specific food and 
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eat another type of food then you will experience diarrhoea again, meaning that every food that 
you eat, you will experience diarrhoea, then it means you will stop eating everything”.   
 
“I will talk about myself in relation to diarrhoea.  It will take two weeks for me to have that 
diarrhoea until I feel weak and the ambulance will pick me up to the hospital.  They will put a 
rehydration drip, and then give me Imodium, and then it will stop.  But every month I experience 
diarrhoea”. 
 
Similar to the above, the study by Henry et al. (1999), exploring the effect of chronic diarrhoea 
on quality of life, reported that “chronic diarrhoea can result in a decline in nutritional status 
and subsequent decline in functional status and overall quality of life”.   
 
All the participants reported that the use of Imodium and revision of treatment were the 
common responses by clinicians to the diarrhoea problem. These responses fall short of a best 
result pathway suggested by Jones (1997), consisting of nutritional assessment by a qualified 
dietician, medication review by a pharmacist, appropriate skin care measures and the use of 
Imodium. Following this pathway becomes important given the participants’ concern that the 
diarrhoea may be linked to diet as shown in the statement above and anal pain reported by 
another participant. This suggests the need for professional dietary assessment and skin care 
interventions both of which were not being received by the participants.  
 
4.2.2 Pain 
While diarrhoea was spontaneously reported at the beginning of every interview as the main 
physical symptom experienced, pain was widely reported and in different forms and with 
varying levels of severity.  This finding is in agreement with numerous studies that have 
reported the high prevalence of pain with diverse presentations. The available studies of pain in 
HIV/AIDS have noted it to be significantly associated with psychological and functional 
morbidities (Breitbart et al., 1996; Lebovits et al., 1989; O’Neil and Sherrard 1993; Singer et al., 
1993). In line with earlier studies, this study observed that pain was more common among 
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persons with advanced HIV disease or individuals who have been on treatment for a longer 
time, as suggested in Table 4.2 (Breitbart et al., 1996). In the context of these observations, 
McCormack et al. (1993) reported that 28% of asymptomatic seropositive males, 56% of males 
with AIDS related complex and 80% of males with AIDS reported at least one painful experience 
over a six month period.   
 
The common locations of pain reported by this study’s participants were leg, back and 
abdominal pains. Breathing difficulty due to pain was also reported. This finding agrees with the 
types of pains reported by Hewitt et al. (1997), including headaches, peripheral neuropathy, 
abdominal cramping and rheumatologic conditions and pain tending to be of a chronic nature. 
This study’s participants added that the pain was more severe late at night and in the early 
morning and often affected their sleep and ability to function, including getting up in the 
morning to attend to household responsibilities, taking care of their children or taking their 
medications. For the few who were employed, this affected their ability to work and sometimes 
resulted in absenteeism over long periods. In this regard, some participants expressed that the 
pain they experienced discouraged them from seeking formal employment. These observations 
concur with studies that have demonstrated how the debilitating pain experienced has 
progressively compromised the enjoyment of life by PLWHA (Schofferman and Brody, 1990; 
Breitbart et al., 1998; Singer et al., 1993; McCormack et al., 1993).   
 
The study participants failed to attribute the pain to any particular cause, but the time 
orientation of the pain experience described may guide clinicians in planning effective care 
measures. This information has been lacking before now and may need to be further explored. 
The aetiology of pain in HIV has, however, been reported to vary and may result from the effect 
of HIV on the central or peripheral nervous system, opportunistic infections, the use of ART or 
complications associated with AIDS (Lebovits et al., 1989; Hewitt et al., 1997).  In the context of 
the aetiologies of pain, Abrams et al. (1994) reported that most underlying causes of pain in HIV 
are treatable but often unattended due to inadequate assessment. The observations made 
about pain in this study are typified in statements below: 
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“The problem that I have is with my legs, even now I fell that my legs are painful, even when I 
am sleeping they feel painful” 
 
“My legs trouble me also, when they started they used to be hot underneath and then they 
became too painful to an extent that I had to cook while sitting down. It also became difficult to 
perform house duties, but I just told myself that it will end one day but performing daily 
activities is hell for me” 
 
“My legs are very painful and they become very painful and hot when I step down or walk even 
when I wear shoes, my legs cause problems as they are painful and I can’t walk around without 
wearing shoes. The problem with this is that I have to wash my clothes, fetch water and wood; 
all these tasks are difficult for me” 
 
“In addition to that, what she is experiencing is called pins and nails, which means the pain is 
severe, it’s very severe, you can’t put on your shoes, you can’t walk, it is very severe”. 
 
“For me, when I go to the hospital and  explain that  I have problem with my legs they give me 
pills that I drink but I do not see their help as they do not improve my condition but  it seems as 
if they make me worse or else” 
 
“With me the pills just make me feel better they do not heal the symptoms to an extent that 
they go away”. 
 
“To tell the truth, my painful legs really are stressing me because every day in the morning 
before I wake up I know I will have a problem and I am even scared to climb off the bed. And I 
am even thinking that this problem is caused by the ARV’s because it started immediately after I 
started the ARV”.  
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“I started having severe diarrhoea and I wouldn’t even walk that where I was diagnosed and 
started treatment, but since I started taking treatment the problem that I am having which is 
severe is the deformed jaw and painful legs and also sometimes cough which is not severe after 
taking cough treatment I become too well”. 
 
“I had terrible sores on my back, chest and legs and they were severe and after I have started 
the ARV’s the problems that I have is only the painful legs”. 
 
What is worrying about the last three accounts is that they may suggest treatment induced 
peripheral neuropathy. This assertion may emphasize the findings of Abrams et al. (1994), 
indicating that pains experienced by the participants may be treatable if adequately 
investigated. While it remains beyond the scope of this study to verify the accuracy of the 
accounts of its participants, such observations were always reported to the clinicians 
responsible for the care of the participant to ensure that the issues were further investigated 
and given appropriate clinical attention. 
 
4.2.3 Fatigue  
Fatigue was also widely reported by the participants. Like the pain experiences, fatigue affected 
the ability of the participants to function, including carrying out basic self care and household 
responsibilities and the essential activities of daily living. In the same manner, coping with 
employment was a notable difficulty because the fatigue occurred mostly in the morning and 
with minimal activity. The statements below highlight the nature and effect of fatigue 
experienced by the participants: 
 
“I was doing catering and I had to leave it because when I work I used to feel tired and I do not 
have income any longer” 
 
“I also had the same problem of tiredness and left the job” 
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“I had the same problem also.  I left my job and now I am on computer training and I do not feel 
tired any longer as you always do it while seated.  This illness does not want heavy job” 
 
“Sometimes you are able to do household chores with no problems, but sometimes when you 
wake up you are just tired you won’t do anything until you go to sleep at night” 
 
“We always do household chores but we are not supposed to do them on a daily basis because 
we feel so tired” 
 
“Tiredness makes us not to engage in daily home activities because you find that immediately 
you wake up in the morning, you are already tired” 
    
Similar to the diarrhoea and pain, fatigue has been noted in prior studies as a common problem 
experienced by PLWHA and has been associated with reduced quality of life (Breitbart et al., 
1998).  It has also been described as one of the most frequent and debilitating symptoms of 
HIV/AIDS (Corles et al 2002 Holzemer et al., 1999). Fatigue was notably widespread among the 
study participants. Similarly, other studies have shown that approximately 85% of people living 
with HIV/AIDS experience periodic or persistent tiredness or exhaustion with varying levels of 
severity (Voss, 2005). The effects of fatigue implied in the above statements also agree with its 
definition as “extended perception of tiredness and exhaustion that persist for longer than one 
month, which is not relieved by additional sleep or rest” (Piper, 1998).  
 
Similar to this study’s observation of the effect of fatigue on the participants’ poor tolerance of 
activities of living, Bailey et al., (1995) added that fatigue is one of the major obstacles to 
patients’ adherence to treatment. Poor adherence is known to exacerbate the AIDS epidemic as 
it results in viral resistance, treatment failure and increased morbidity and mortality (Sterling et 
al., 2001; Ostrop et al., 2000).   
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While it was beyond the scope of this study to explore the differences in the level of fatigue by 
sex, other studies have noted that females have reported higher levels of fatigue when 
compared to males (Breitbart et al., 1998).  The higher intensity of fatigue experienced by 
women has been further linked to hormonal effects and their “multi-tasking” life styles. This 
observation presents ripple effects given its timing and the role of women in catering for the 
family, including their male partner who may also be living with HIV/AIDS. This scenario creates 
a vicious circle given its contribution to these same factors which is strongly supported by the 
above statement that “this illness does not want heavy job”. These assertions draw on the 
findings of the same study that noted that women who lived alone experienced less fatigue and 
this has a strong bearing in planning the “rehabilitation”, care and support of women living with 
HIV and AIDS.  
 
 The economic, physical and mental challenges posed by HIV/AIDS are exacerbated by the loss 
of employment, lack of activity and possible isolation resulting from fatigue as shown by this 
study. Similarly, Voss (2005) has attributed depression, lipodystrophy and perceptions of 
physical and mental wellbeing to the reported levels of fatigue.    
 
Winningham et al. (1994) have described a phenomenon known as secondary fatigue which 
results from an individual’s effort to regain vitality by having more rest and instead get more 
fatigued. Other manifestations of secondary fatigue are sleeping difficulty and depressive 
symptoms.  In this regard, most participants reported that they stayed in bed in order to regain 
strength and instead get more fatigued. This is shown by such patients reporting that they 
spent the whole day doing nothing due to the continued fatigue.  
 
4.2.4 Insomnia 
Insomnia was often reported by the participants. The sleeping difficulty experienced by the 
participants was often attributed to the physical pain they experienced, shortness of breath or 
the fears and worries of living with HIV/AIDS. The participants could not associate their sleeping 
difficulty with any factors. These views are expressed in the statements below: 
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“In most cases I do not sleep during the night because I keep thinking about this disease” 
 
“I am having breathing problems especially in the night.  I cannot breath well, I always take a 
mint and put on my nose so that I can be able to sleep. This makes us scared because when we 
are sleeping, we are afraid that we might end up dead, as I have already told you that I have 
difficulty in breathing during the night” 
 
“I am currently trying to ascertain what is causing these after effects  because I don’t have a 
problem with the ARV’s ,but ever since I started taking the ARV’s insomnia has been a problem, 
it’s starting now because I used to sleep peacefully before but for the last four months I have 
sleep difficulties” 
 
“When my sleeping problem started I explained to the doctor who prescribed certain pills is just 
that I don’t remember their name but they gave me sleep but I complained it’s only that they 
made me subdued because they will make me feel tired instead of giving me sleep, so they gave 
me another type which did not treat me well, so now when I feel sleepless I just wake up and 
sweep”. 
 
“I experience the dizziness while I am asleep” 
 
“Like other people I will get inside the blanket with the aim of sleeping but nothing will happen, 
it  will be 09 pm,10,11,12,01am,2,3,then I will sleep at around 4 am” 
 
“I also had a problem with sleep, I went to the hospital and they gave me some blue pills. The 
problem with these blue pills is that maybe if I drink them at seven o’clock I will remain seated 
at the place that I took them. People will come with pillows without my awareness and I will 
wake up in the morning, so I think these pills are good because if I drink them early I won’t even 
see ‘Generations”(others laugh). The reason why I stopped using them is because when I am 
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sleeping I don’t hear anything so things will happen around eight and nine that I will not be 
aware of. The other problem was that my husband usually calls around nine and by that time I 
am already dead so he will end up talking to the children but I explained to him that I am on 
medication. So that is why I stopped taking the pills, they appear to be blue on the inside, they 
are very strong” 
 
“when I go inside the house it will be hot and I will just sit until 4 am. That is when I will feel 
sleepy and at four is my time to wake up and cook for my lunchbox but in the afternoon I will 
not feel the need to sleep, I will just feel tired and have a headache” 
 
“I also have a problem with sleeping, I would sleep at around eight but when it is around twelve 
I will wake up and not sleep, I will not sleep for the whole night, I will be walking around and 
sitting, the others will just look at me sitting alone(laughter),and it does not end” 
 
“The issue of sleep is interesting because since the insomnia started the hours that I sleep is only 
four, strictly four, after that at eleven o’clock I will be wide awake so it is somehow helpful 
because I will wake up and do some work or watch some stories on channel E. There are some 
nice pictures that I can see. When I get tired of watching TV I will go and take the broom and 
sweep which is why my place is very clean. So my wife started to complain saying that’ people 
will say that you are a wizard’ I asked her what I am supposed to do if I am feeling sleepless, she 
said I must stay inside the house and not go out during the night (he laughs) The issue of staying 
inside the house is not ok with me because I like to keep busy, there is no other way” 
 
“When I wake up I will not feel sleepy or tired at all but I don’t sleep, I explained my problem to 
the doctor who gave me pills that I should drink at night but even after drinking the pills there 
has not been any improvement as I still experience the problem. As a result I stopped using the 
pills. Sometimes I will walk around the house during the night so are people not going to say 
that I am a witch? Anyway I will walk, when I get tired I will sit down and fall asleep at 05:am” 
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The above remarks all bear the hallmarks of insomnia which has been defined as 
“unsatisfactory duration of efficient or quality sleep that is experienced three or more nights 
per week” (Morin, 1993). In the same context, Luce and Segal (1969) have classified insomnia 
into three types namely: problems with falling asleep, problems with staying asleep and 
problems with early waking. These problems are common in HIV/AIDS and have been described 
as a frequent and bothersome symptom of HIV infection and are known to impact on the 
quality of life of people living with HIV/AIDS (Cohen et al., 1996). Insomnia has also been 
associated with chronic fatigue, social and physical functioning and eventual loss of 
employment (Darko et al., 1995). This association was strongly suggested in the presentation of 
fatigue as a symptom earlier in this report.  
 
Similar to the above remarks of the participants, Lashley (1999) reported that the lack of sleep 
may have resulted from other symptoms of HIV/AIDS like pain, cough, dyspnea, night sweats, 
anxiety, fear and depression. In the same way, insomnia is a known side effect of some 
antiretroviral drugs (Chohan, 1999).  
 
4.2.5 Body image disturbance 
Body image disturbances resulting from treatment induced lipodystrophy was another problem 
among the study participants. In this regard, different studies have found strong correlations 
between the severity of lipodystrophy and the level of dissatisfaction with body image 
(Burgoyne et al., 2005). The participants unanimously agreed that the changes in body shape 
resulted from the treatment that they were receiving. In the same context, other studies have 
noted that lipodystrophy impacts negatively on health related quality of life, erodes self-
esteem, decreases desirability and attractiveness, impairs social functioning and potentially 
results in anxiety and depression (Collins et al., 2000). Some statements depicting participants’ 
experience with lipodystrophy are as follows:   
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“These tablets affect the looks of these women, they misshape them because even when they 
are dressed they do not look good.  Their buttocks are squeezed inside and they are having big 
tummies” 
 
“We are surprised what is happening because since we took treatment our tummies are big and 
we do not know what the problem is.  Always, even if you do not know that this person is on 
ARV’s, you will see her having big tummies and squeezed-in buttocks” 
 
“She is telling the truth.  Our buttocks seem as if we were beaten with a plank and our sizes 
have been reduced.  Even our faces become too small” 
 
“This is a side effect of the treatment because even men develop breasts and these treatments 
also make our veins to protrude” 
 
The above morphological changes are in consonance with the findings of similar studies 
(Mutimura et al., 2007; Saint-Marc et al., 1999; Carr et al., 1998). These studies have reported 
peripheral fat loss of the face, buttocks and limbs as well as the accumulation of fat in the 
abdomen, breast and dorso-cervical spine. These changes have been viewed as hallmarks of 
people on treatment and they develop stigmatizing features (Guaraldi eta al., 2008). This 
situation may lead to forced disclosure of HIV status and increases the fear of side effects 
related to antiretroviral therapy (Power et al., 2003).  
 
It was also noted that despite these morphological changes and concerns, the patients had no 
problem continuing with treatment given the expressed benefits which they experienced 
outweighed the side effects. Martinez et al. (2001), however observed that depression resulting 
from body image problems may lead to poor adherence to treatment.  
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4.2.6 Disclosure of HIV status 
Disclosure rate among the study participants was high mostly because the study participants 
consisted of members of support groups of people living with HIV/AIDS. This means that all the 
members of the groups would have disclosed their status to health workers and group 
members at least. The participants clearly underscored the benefit of disclosing their HIV by 
comparing the life before and after disclosure. In terms of the radius of disclosure, the 
participants were more likely to disclose to their immediate family members and health service 
provider. This observation mainly suggests the perceived importance of such people.  Some of 
the remarks that support these observations are presented below: 
 
“You get support from family members and community if you have disclosed your status, then 
they will take care of you by buying fruits and vegetables.  But if you did not disclose, no one will 
take you serious when you tell them that you are sick” 
 
“If you have disclosed to your family, they are the first ones to see you when you have problems 
because they are checking on you on daily basis and they are able to help you quickly” 
 
“When you arrive at a clinic and you do not disclose, they do not help you in totality, but if you 
disclose, they are really helpful, still some nurses never help” 
 
“We sometimes access services because when you complain about the diarrhoea they will tell 
you to do rehydration solution and drink, and when you report to them that you have cough 
they will tell you to take a lemon until you disclose your status is then that they will help you in 
totality meaning if you do not disclose you will not receive the correct help” 
 
“The difference is that when a person talks they are setting themselves free from self 
stigmatization which is more dangerous than being stigmatized by others, so by talking you set 
yourself free which also boosts the body’s defence, even when they talk or laugh the person will 
not be affected but the one who did not disclose will have a problem because when people talk 
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you will think that they are talking about you, that is the difference. When you talk you are free 
just like me. People can say whatever I don’t mind”. 
 
“Always when I wake up and I don’t feel well, I tell my children who will then help me with all 
house chores for that day and I will rest.  Even the community is supporting me because I have 
disclosed my status to them” 
 
“Even the community is supporting me because when I am not well I tell them and they will 
come and help me with my household activities” 
 
Similar to this study’s findings, disclosure of HIV status has been repeatedly described by other  
studies as an essential element in the prevention, treatment, care and support of people living 
with HIV/AIDS (Ncama, 2007; WHO, 2004). In further agreement with this study, other studies 
have reported that people who do not disclose their HIV status deprive themselves of family 
and social support and burden themselves with the guilt and secrecy of non-disclosure (Ncame, 
2007; Norman et al, 2005). Paxton (2002) has added that the suppression of one’s feeling 
results in stress which affects physical health and wellbeing. Furthermore, inverse correlations 
between HIV related worries, depression and disclosure have been reported (Derlega et al., 
2004).  
 
The high family support noted in this study was also reported by Norman et al., (2005). In 
agreement with the study findings, Simoni et al., (1995) did demonstrate that people living with  
essential social support experienced better psychological wellbeing when compared to those 
without such support. This point goes further to implicate the inverse relationship between the 
number of people disclosed to and psychological wellbeing and this may explain the variations 
in the health status of study participants based on their implied radius of disclosure. This 
observation is in agreement with studies that have reported that people who have disclosed, 
experience better health with optimum immune and autonomic nervous system functions 
(Pennebaker et al., 1990). In the same context, other studies have found that satisfaction with 
 69 
social support following disclosure buffers the effect of HIV related physical symptoms on 
depressive symptomatology (Hays et al., 1993).  
 
The findings of this study suggest the participants’ initial reluctance to disclose their HIV status. 
This phenomenon was also noted by Norman et al., (2005), adding that disclosure is not an 
event but a process. The reluctance to disclose one’s HIV status has been widely documented 
and is often attributed to the fears of loss of economic support, abandonment, blame, physical 
and emotional abuse, disruption of family relationships, discrimination and other forms of 
reprisal following HIV status disclosure (WHO, 2004; Rothenberg et al., 1995).   
 
4.2.7 Fear 
The study participants expressed different fears. The most common fears were the fear of 
disclosure of HIV status and the anticipated stigma, fear of HIV/AIDS related illnesses and the 
fear of dying. While this was the case, most of the study participants had gone beyond the 
expressed fear with the help of the support group, particularly the fear of disclosure.  They 
added that the fear of falling sick and dying was a source of stress and depression. The remarks 
below reflect the participants’ feeling with regard to their fears: 
 
“I also feel that I do not have a problem, I used to fear people, the problem I had was at home I 
had a problem with how I was going to tell my parents but I told myself that it is not fair that 
the support group know about my status but my parents do not so I ended up telling them, now 
things are in order as they have accepted my status” 
 
“In the beginning it was difficult for me to accept my status because I got tested after my 
husband passed away, so because I saw how he suffered I had fear that I will experience the 
same things and pain that he suffered, that is why it was difficult to accept but at the present 
moment, I am good I have accepted my status” 
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“I will start with the headache.  It is caused by thinking a lot about this illness, meaning you are 
always in fear that you will die.  Then you are always stressed” 
 
“The other thing is that people perceive HIV as a threatening disease and this makes me feel 
depressed and fearful because people who are not infected treat us somehow” 
 
“The community is not accepting us and I have fear of going out and this makes me feel sad 
always”.  
 
In the context of the above remarks, many studies have noted that the level of fear experienced 
by people living with HIV/AIDS causes distress, impacts on the health related quality of life and 
affects life satisfaction (Makoae et al., 2005; Hudson et al., 2004). Similarly, Doyal and Anderson 
(2005) observed the “complex feelings” that emanate from fear, uncertainty and depression. 
They added that this feeling was often the result of the insecurities of the limited predictability 
of the daily health outcome of living with HIV and AIDS. The fear of stigma is commonly 
reported in similar studies (Green and Sobo, 2000). Such studies further reported that the fear 
of stigma was often over estimated. This agrees with this study’s finding given the general 
acceptance and support that the study participants received from their family following the 
disclosure of their HIV status.  
 
Similar to other studies, the fear experienced by the participants of this study can be related to 
the stage of the disease, length of time since diagnosis and treatment initiation and ultimately 
the level of acceptance of their HIV status. In this regard, the expressed fears are likely to lessen 
over time (Ickovics et al., 2001).  
  
4.2.8 Level of psychological adjustment and acceptance of HIV status 
This study noted the participants’ initial negative reactions to a HIV positive result. Such 
reactions included the loss of the will to live, depression, social and emotional distress. These 
reactions usually take a long time (which often ran into years) to resolve. The participants 
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however, underscored the importance of nurses, social workers, counsellors and support 
groups in accepting their HIV status and resolving the negative reactions.  
 
The period prior to the acceptance of the participants’ HIV positive status was also marked by 
poor use and access to social and health services (largely due to the associated non-disclosure 
of HIV status) and the loss of the will to live. On the other hand, the participants’ acceptance of 
their HIV status provides the energy to live and more aggressively to respond to the various 
health and social challenges of living with HIV/AIDS. Below are some of the comments of the 
participants on their psychological adjustment and acceptance of their HIV status  
 
“I decided to get tested for HIV but after knowing my status it was difficult to accept and it took 
two years of not telling anyone, at the hospital nurses introduced me to support group team 
leader who gave us a speech to motivate me and after that I disclosed my status to my mother 
and started the ARV treatment” 
 
“I got tested in 2001, February, I was pregnant but there was no problem. It took me a long time 
to accept it but now I am coping” 
 
 “I am coping because I have I accepted by status and I do not care about what people say” 
 
“I have just accepted myself that I will live with this virus because I have realised that if I do not 
accept, I will have a problem” 
 
“I have accepted myself that I am living with this virus and I am eating nutritious food to keep 
me healthy” 
 
“I have painful legs and I came to the clinic nurses at the clinic helped me because they advised 
me not to work too hard and I am not stressed because I have accepted my virus and all my 
illnesses and I told myself I will live with this” 
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“I cope because I have told myself that I must accept my illness and I know that here on earth, if 
you do not accept your illness, you won’t live long” 
 
“With me, also, I have accepted my illness so that I have peace with myself” 
 
“All these services are useful like for example, counselling, where you find that pre-counselling is 
done before testing HIV and if the results come positive, you find that you are able to accept 
your status and ongoing counselling helps you to live with your virus and cope throughout with 
your disease process”  
 
“I am coping because I have I accepted by status and I do not care about what people say” 
 
“The problem is stigma and this ARV cannot work if you are not accepting the status the 
medicines can only work if you are accepting” 
 
The initial negative psychological responses to HIV diagnosis are common and well documented 
(Coward, 1994). Furthermore, the noted psychological adjustment to a positive HIV diagnosis 
has been noted to be critical in developing effective coping strategies (Farber et al., 2010). The 
development of personal meaning of being HIV positive was noted in the study at the point of 
acceptance of the virus as part of their lives.  
 
Similarly, personal meaning is increasingly being recognized as important in adjusting or coping 
with traumatic events and life threatening illnesses including HIV/AIDS (Janoff-Bulman and 
Yopyk, 2004).  Personal meaning is broadly defined as “foundational beliefs that lend a sense of 
explanatory coherence, goal-directed purpose and emotional value to one’s life” (Wong, 1998). 
This definition involves the explanation that one has over a personal impact or important life 
events like living with HIV/AIDS (Park and Folkman, 1997). In similar studies, participants have 
for instance, described HIV/AIDS as a “challenge to be met” or “a source of personal growth” 
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(Moskowitz et al., 2005; Schwartzbege, 1993). This kind of confrontation has been positively 
associated with clinical benefits (Gifford et al., 1998; Lutgendorf et al., 1998). In the context of 
this knowledge, the study participants who reported accepting their status and the willingness 
to “live with their virus” often reported an improved wellbeing.  
 
Similar to this study, social support and encouragement such as that received from health 
workers have been shown  to be useful in improving psychological adjustment and coping 
(Heckam, 2003). Beyond the benefits of social support in ensuring psychological adjustment 
and coping, the continuous coping will require active efforts to address the stressors through 
processes that have been described as process or emotion focused coping (Gore-Felton et al., 
2006).  This kind of effort can be seen in the study participants’ acceptance of their situation 
and resolve to respond positively in dealing with the challenges of being HIV positive.  
 
4.2.9 Anger 
Anger was a common theme among some group members. The anger was often uncontrollable 
and expressed towards people around the participants, such as family and work mates. The 
expressed anger was often attributed to the antiretroviral treatment by the participants. Most 
of the comments suggest that the anger stage was often after the initiation of treatment during 
a period that is still characterized by various opportunistic infections and AIDS defining 
conditions. The described pattern of anger may suggest some level of transient frustration 
given that it was hardly reported by participants who had been on treatment for longer periods. 
Some of the remarks of the participants characterizing the anger they experienced are 
presented below: 
 
“I was angry about the disease and this makes me to shout at my children all the time” 
 
“Eh, the other thing that was bothering me is short temper, I got irritated very quickly and I was 
also very aggressive and couldn’t appreciate anything, even at home I did not appreciate my 
wife, there was loss of sexual appetite and loss of sleep i.e. I would wake up at night and 
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struggle to sleep again. I also had problem with allergy, especially meat, even at the present 
moment I use only yellow and white meat because red meat made me to scratch my body all 
over. I used to have an unpleasant smell that will not go away no matter how much I bath ,at 
that time I even lost my weight, but since  ARV’s there is improvement” 
 
 “I have a problem of short-temper; I live with my mother and I always have a short-temper 
towards her and it affects our relationship most especially that she is old and sick” 
 
“It affects us at work because you are short-tempered to everybody and they move away from 
you” 
 
“The steps that I have taken is that I told people I am working with that when I am short-
tempered they must not take me serious because I am sick, I am on ARV’s.  They are the ones 
who make me to be short-tempered” 
 
“ People will always avoid you because you are short-tempered as they don’t know that you are 
sick, and this affects your interpersonal relationship with everybody” 
 
“I always avoid being with people as I am short-tempered” 
 
“I was short tempered and having sores in my body especially at the back but after starting with 
the ARV treatment but now I am coping very well” 
 
“I am agreeing to what others are saying because after taking ARV I was short tempered and 
cannot walk properly” 
 
Other research studies have reported similar anger among persons living with HIV/AIDS 
(Kalichman and Sikkema, 1994). The anger in HIV/AIDS has often been attributed to recent HIV 
positive diagnosis, social rejection, shame and self devaluation (Holland and Tross, 1985). This 
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theory may not apply to the study participants who often have known their diagnosis for a very 
long time. The remarks of the participants suggested that close family members were very likely 
to accept and support HIV positive family members who disclosed their HIV status. 
 
Instead, the finding of this study may be better explained by other established causes like 
frustrations, uncertainties and a sense of the uncontrollability of HIV disease (Dilley et al., 
1985).  
 
4.2.10 Stigma and discrimination 
HIV related stigma and discrimination was widely reported by the study participants. The 
stigmatising experiences were often described as distressing, dehumanising and resulted in 
social dysfunction, isolation and loss of the means of economic livelihood.  
 
The stigma experienced was often attributed to ignorance about the modes of HIV transmission 
and fear of infection. The participants also reported that their family members (particularly 
children) were also being stigmatized by neighbours and people in their communities. The 
common places where the stigma occurred were at public events like funerals, parties, 
churches, clinics and schools. It was also noted that psychological adjustment and acceptance 
of HIV status helped the participants to better cope and positively respond to the acts of 
stigma. Below are some remarks from the participants indicating their experiences with stigma: 
 
“Other people do not consider us as people.  They think we must be taken to our own place 
where all HIV/AIDS infected people will stay” 
 
“Stigmatization is a lot because they think that even when they touch us, they will be infected.  
That is why they do not want to move next to us” 
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“They think we have been infected by HIV/AIDS through sexual intercourse.  They do not know 
that there is a lot of mode of transmission like through blood transfusion.  They usually think we 
were running around” 
 
“They just think we are dying by looking at us” 
 
“The first place that they discriminate us is in the weddings and funerals when we are supposed 
to take knives to chop vegetables because they do not want us to touch those.  They will always 
say we must wash dishes while we are scared to touch cold water as we catch flu easily.  If you 
can happen to cook, they will throw away your food.  The second place is at the clinics.  Other 
nurses seem not to attend HIV courses because when you enter the consulting room, they will 
open windows and stay a distance from you” 
 
“At school they call our children with names like your mom is positive and she going to die you 
will be left alone” 
 
“At church because if you disclose your status to the pastor he will use you as an example like 
you see she is HIV and she is still breathing it means HIV does not kill and after church people 
will be talking about you and next Sunday they don’t want to sit next to you” 
 
“People do not take us serious and always belittle you when you talk.  We always just conform 
to everything that they do to us” 
 
“Yes my neighbour said I must not pass next to their house because am HIV. (They all laugh)This 
is serious am not joking” 
 
“People in my village said we have many people who are infected and they trying to depress me 
by saying this painful words and some said am a professor of HIV” 
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“Yes, we are discriminated at church, e.g. shaking hands, washing hands in the same basin and 
sharing same glass” 
 
“Yes, there is discrimination in soccer teams e.g. they burn the t-shirt of the other player after 
knowing that he is HIV positive”  
 
“When we attend parties they really do not want us to prepare food” 
 
“I always do not touch the pots when I am attending funerals and parties” 
 
“I do not care what they say about me the bottom line is that I have accepted my virus” 
 
“Hmm, with the issue of employment we have to work but you still find that there is no place in 
which we can work because of our status. Even if we try to sell no one will come and buy and 
also when we want to work at parties or funerals as a lady you will be told to leave everything 
and to sit down so I end up telling myself that I will just sit down because I cannot force things 
and I will not kill myself because of that. I will continue living, it is just that I will be living in pain. 
It is very difficult because I have children whom I must help and also buy food for, so what will I 
use to buy as I don’t have money and I am not getting any employment, there is no one who will 
give me money, so I find life very difficult” 
 
Stigmatization has been defined as a process of devaluing individuals characterized by 
discounting, discrediting, tainting, labeling and prejudice (Thomas, 2006; Goffman, 1963). These 
attributes can be observed in the above accounts of the study participants. Prior work on 
stigma has also described three forms of stigma: (i) self stigma, manifesting as self blame and 
self deprecation; (ii) perceived stigma, formed from the fear of being stigmatized if they 
disclose their HIV status; and (iii) enacted stigma, resulting from actual discrimination due to 
the perceived or confirmed HIV status of the person being stigmatized (Bond et al., 2002). With 
these definitions, this study noted mostly enacted stigma. 
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The above occurrence is despite the fact that HIV related stigma remains a major obstacle to 
effective prevention and management of HIV (Parker and Aggleton, 2003). This fact also takes 
into consideration that poor physical health has been associated with lower levels of quality of 
life (Vassend and Esklid, 1998) and depression (Schmitz and Crystal, 2000).  
 
Based on the reports of the study participants, the common places (like churches, funerals and 
other community events) where stigmatization was more likely to occur confirms the 
description of stigma as a social construct emanating from social, cultural, historical and 
situational factors (Liamputtong et al., 2009). In further agreement with similar studies, stigma 
was also due to public perception that HIV infection was a result of immorality, deviant 
behaviours and actions that are incongruent with socially accepted norms (Deng et al., 2007).  
 
The participants who seem to have coped with responding to stigma were often as a result of 
their acceptance of their HIV status, and this has often occurred through the help of support 
groups and health care workers. This observation is in agreement with the findings of 
Liamputtong et al. (2009). They noted that people find different strategies to counteract the 
effects of stigmatization and that joining support groups was one  such strategy.  
 
4.2.11 Perceived attitude of heath workers 
The participants mostly highlighted the good support they received from nurses and other 
health workers. These included quality health services and personalised attention, disclosure, 
counseling and support.  Most of the participants also added that the quality of service and 
support received varied between nurses. With this, the participants indicated that they avoided 
consulting the health care workers who were less supportive. There were only a few reports of 
stigmatization and discrimination by health workers.  
 
 79 
“In our hospital we have ARV clinic.  Some nurses in that clinic do not take of us in a positive 
way.  They treat us badly even if we are not feeling well.  I even confronted some of them and 
we have solved the issue” 
 
“When you arrive at a clinic and you do not disclose, they do not help you in totality, but if you 
disclose, they are really helpful.  But some don’t, as nurses are not the same” 
 
“The nurses at the clinics really assist us as they always sent home based carers to come and 
check on how we are coping with our home chores” 
 
“The other problem is when we come to support groups, some of us are sick so the nurses will be 
showing other people, it will be better if the government could arrange that we meet elsewhere 
but not here in this stand so that we can feel free” 
 
The mostly good nursing support as reported by this study has been attributed by the 
participants of other studies to better quality of life as it reportedly diminished loneliness and 
improves the sense of acceptance (Ragsdale et al., 1992). This observation is also in agreement 
with the findings of this study that psychological adjustment to living with HIV/AIDS and 
acceptance of positive HIV status were often facilitated by health care workers. The study by 
Kermode (1995) also noted psychological support as the most important nursing action 
received by participants. On the other hand, the rejection of health workers by patients as a 
result of insecurity and lack of confidence as noted by this study has also been previously 
reported (Weitz 1990).  
 
4.2.12 Support structures and needs of people living with HIV/AIDS 
The common sources of support cited by the study participants were the family, support groups 
of people living with HIV/AIDS, counsellors and nurses. The participants added that the support 
received from these groups provided a sense of acceptance and cushioned against the 
psychological demands of living with HIV/AIDS. It was also unanimously agreed that the 
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disclosure of HIV status was essential to obtaining full support from the different sources 
mentioned. The commonly cited family members who provided support were siblings, parents 
and children. The family members mostly donated food and provided support by helping with 
household responsibilities. There were mixed responses on the role of religious groups. Noting 
disclosure to religious leaders often resulted in the involuntary disclosure to church 
congregations and this often exposed the participants to acts of stigma and discrimination from 
members of the church.  
 
Participants also highlighted the financial burden of living with AIDS which is compounded by 
their often inability to work as a result of their poor health condition. They added that the 
temporary disability grant provided to them was inadequate and often discontinued 
prematurely (that is, before they get well enough to go back to work/begin to earn a living 
again). The participants, however, praised the health services that they were receiving noting 
that they were easily accessible and often met their needs. The counselling and ART services 
were mostly praised.  
 
The findings of this study largely highlight the role of social support systems (including the 
family, health care workers and support groups) in alleviating the impacts of HIV/AIDS on the 
individual.  
 
The study participants further noted that grant services needed to be improved in terms of 
access, duration and that the major problems they had was securing housing and education for 
their children. The issues relating to social support can be noted in the comments below: 
 
“TLC, support groups and family members help me to cope with the disease” 
 
“The support that I get is from this support group because when I have problems, I share with 
them and they give me advices” 
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“We get the support from this support group and nurses in the clinics” 
 
“The support we get from our family members is very useful because if they do not support us 
we will have a serious depression and things will not go well at home. For  example my child 
knows my status so other children fought with him but he told them my dad is better because he 
knows his status what about your dad? So it is nice to get family support” 
 
“My family members are very supportive and sometimes they buy fruits for me and give money 
to support myself” 
 
“Support from family members and community you get it if you have disclosed your status, then 
they will take care of you by buying fruits and vegetables.  But if you did not disclose, no one will 
take you serious when you tell them that you are sick” 
 
“Our family members help us through out because they will even remind you when it is time to 
take treatment and also with household chores like doing washing.  Financially they can’t 
because they do not have money themselves” 
 
“They support with food, clothes and other things the family members do help.  They have even 
taken my own child to take care of” 
 
“Family members do assist a lot except where money is involved as they themselves do not have 
it.  My brothers do help me a lot” 
 
“I always get support from the support group because we share ideas, but our support group is 
no longer active.  My brothers support me” 
 
“The support the government is offering these days is useless because they give us a grant for 
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“The problem with money is there just like we mentioned in the beginning, money is needed, 
and especially when you are unemployed it is difficult to get the variety of food that is needed. It 
is not easy if the government is not helping us. It is difficult because these doctors will tell us 
that we did not qualify to get the grant money. There was a certain lady who died because she 
used to receive the money and they stopped it so she could not take care of herself, it is very 
bad” 
 
Person 1: “The 1
st
 one is the issue of government considering taking our children to 
tertiary institution after matric because we do not have money to afford tertiary 
institution more so they have taken the grant away” 
 
Person 2: “The 2
nd
 most important I think we should be considered first when they 
allocate RDP houses” 
 
Person 3: “The social grant is the 3
rd
 one and it should be more than the aged pension 
grant so that when you have a family you are able to meet the needs because you 
are unable to work. We also have a problem with RDP houses  and food parcels 
because ward counselors are the ones who allocate these houses and they do 
canvass for elections with them and people in need do not get them. They must be 
taken away from the ward counsellors” 
 
Person 4:  “The most difficult thing to get is the RDP houses” 
 
Person 5:  “The service that we easily get are ARV’s and social grants” 
 
Person 6: “I want to oppose that we get grants easily because some people get them 
earlier and some don’t” 
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Person 7:  “If it was me, I will rank them like this; the most easy to get are counselling, 
ARV’s, grant and the most difficult to get are the RDP houses and followed by 
tertiary education for our children” 
 
Person 8: “The most challenge that we face is that when you are supposed to get an 
RDP house, after you have filled the necessary forms, then Ward Councilors gives 
the houses to people who did not even fill the forms.  There is a lot of 
discrimination”  
 
4.3 Discussion 
This study identified factors that contribute to the HRQOL of PLWHA and the interrelationship 
between the factors as perceived by the study participants. The study focused on the factors 
that tended to most frequently and more severely compromise the HRQOL of PLWHA. This is on 
the basis that such information will inform the prioritization of the needs of PLWHA and the 
planning and management of appropriate care and support services. In the same context and in 
line with the objectives of this study, the identified factors were grouped into three categories 
(the physical, mental and external factors). The categorization was based on the level of 
occurrence of the factors. The physical factors were the physically observable manifestations of 
the disease; the mental factors were manifestations of HIV/AIDS and the responses to such 
manifestations and occurred in the mental/psychological domain; and the external factors were 
social elements impacting on the participants’ response to the disease and health outcomes. 
 
The above finding agrees with early research done by Murdaugh (1998), indicating that the 
HRQOL of PLWHA is dependent on physical elements, emotional factors, spiritual components, 
relationship with others and financial aspects. In further agreement with Murdaugh (1998), this 
study noted that HRQOL is a function of the interplay and balancing of all the factors involved. 
In a similar effort, Ferrans (1996) has described categories of determinants of HRQOL like the 
physical, psychological/spiritual, social, economic and family domains.  
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In this study, there was however less spiritual connection with the participants’ level of 
resilience to the disease and a wider scope of social support elements for PLWHA. This may be 
attributed to better survival of PLWHA with the advent of ART, improved government support 
for PLWHA and their better acceptance and support from family members and health workers. 
This is the case for South Africa given its comprehensive ART programme and the provision of 
support grants during specific stages of HIV/AIDS related diseases.  
 
The multifactorial nature of HRQOL determinants among PLWHA and their interrelatedness is 
again emphasized by the many studies that suggested the need for comprehensive treatment 
strategies that concurrently offer a combination of services like physical and mental 
rehabilitation and other support services (Handford et al., 2006). This is apparent in this study 
with the various physical and mental manifestations of HIV/AIDS aggravating each other’s effect 
and thus creating a complex web of vicious circles. For instance, fatigue will perpetuate fatigue, 
poor adherence to treatment, poor health outcomes, job loss, weight loss, body image 
disturbance, social isolation, fear and worry, stigma (self, perceived and enacted) and vice 
versa. 
 
In line with the above, South Africa has a comprehensive HIV/AIDS strategy that seeks to guide 
the provision of the multidimensional responses needed to address the needs of PLWHA. The 
participants of this study mostly praised the role of health services in the provision of ART, 
treatment of opportunistic infections and counselling services. Despite this, the accounts of the 
study participants raise questions about quality and comprehensiveness of the services offered. 
This can be seen in the very symptomatic management of the physical manifestations of 
HIV/AIDS and treatment side effect which were less holistic, not adequately multi-disciplinary in 
their approach and with little patient involvement. In the same context, social support services 
were noted to be less laudable by the participants. This is despite government’s heavy spending 
on disability grants and other support initiatives for PLWHA. The participants noted that the 
HIV/AIDS support grant was difficult to access and was based on their CD4 count which they 
reported was often not a reflection of their ability to earn a living. Even if the CD4 counts can be 
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used as a reliable proxy for HRQOL and ability to earn a living, loss of means of livelihood, assets 
and economic security were common prior to most marginal recovery. With this, socio-
economic rehabilitation and reintegration was a major challenge for the study participants. In 
response, there were reports of people defaulting treatment in order to maintain a low CD4 
count and high viral load and retain the support grant or get pregnant in order to secure the 
child support grant. The scale or authenticity of this report was beyond the scope of this study 
but presents an immense public health concern and needs to be further explored.  
 
Furthermore, the many limitations of the studies that have explored the possibility of using 
biological markers as proxy for HRQOL further implicates the current dependence on CD4 
counts and viral load as measures of HRQOL (Campsmith et al., 2003; Call et al., 2000). In 
addition, the discrimination of the eligibility of PLWHA to receive the support grant is also 
based on the subjective assessment of clinicians and thus raising ethical questions given the 
unreliability of such subjective assessments.  
 
The participants remarked that the identified factors (Table 4.1) affected the ability to perform 
basic activities of living or remaining employed in their jobs. This finding is in agreement with 
other studies that have found strong associations between symptoms and role function 
(Hudson et al., 2004). In the same context, most of the participants were unemployed and 
often struggled with performing household functions like cooking, caring for their children and 
household cleaning and washing. In this regard, the ability to carry out such specific 
responsibilities should constitute the measurement of HRQOL. This is given the definition of 
HRQOL as “an individual’s perceptions of their position in life in the context of the culture and 
value systems in which they live and in relation to their goals, expectations, standards and 
concerns” (WHO, 1993). The use of such measures is currently missing in most HIV specific 
HRQOL assessment instruments and may be useful in the South African context.  
 
This study’s emphasis on symptoms as the main determinants of HRQOL concurs with studies 
that have demonstrated that an individual’s symptom status is the best predictor of their 
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HRQOL (Sousa et al., 1999). In addition, the symptom status of an individual and its impact on 
HRQOL is influenced by personal, intervening and modifying factors (Figure 4.1). These 
suppositions agree with Wilson and Cleary’s (1995) Measures of Patient Outcome in a Health-
Related Quality of Life Conceptual Model. In all, the interrelatedness between the various 
factors (Figure 4.1) identified by this study replicates the propositions of the HRQOL conceptual 
model (Wilson and Cleary, 1995) that incorporates physiological variables, symptom status and 
environmental, individual and nonmedical characteristics.     
      
Stigma tended to be the main intervening factor influencing participants’ response to the 
manifestation of HIV/AIDS in terms of seeking help or accessing the available support 
resources. The types of stigma reported were mostly perceived and enacted. In this regard, 
Zhou (2007) suggests that “stigma is not only the internalization of the AIDS stigma but also an 
effect of their interaction with others or actual experience with public attitude through which 
AIDS-related social standards are manifested”. This was demonstrated in this study by the 
reported high rate of family acceptance of relatives that are HIV infected despite their fear of 
rejection. On the other hand, PLWHA were often not accepted or discriminated at the 
community level. This occurrence may be linked to the continued fear of the virus in 
communities as known HIV-infected persons were often not allowed to get involved in 
community cooking activities or using shared cooking or eating utensils at public events. This 
assertion is supported by the findings of Aggleton and Parker (2002,) indicating that stigma are 
often driven by the fear of being infected by the virus. These trends discourage PLWHA from 
disclosing their HIV status and thus deprive themselves of the support of their family members 
and other support networks. This fear also prevents the use of health and social support 
services for fear of being identified as HIV positive and thus discriminated against. These 
behaviours aggravate the manifestations of the virus in the absence or poor use of the 
appropriate treatment and support services.  
 
Some participants displayed some inherent ability to better respond to stigma and 
discrimination while the support groups have helped most of their members to respond better 
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to stigma and discrimination. The value of support groups has been reported by Liamputtong et 
al. (2009). In another study, Lyttelton et al., (2007) described support groups as “panacea of 
stigma and alienation”. This point emphasizes the importance of support groups in helping 
PLWH to respond appropriately to acts of stigma. 
 
The individuals who were less affected by the fear of stigma and discrimination tended to be 
people with better education and with middle to high economic standing. Similar to other 
studies, this study also noted that the fear of stigma diminishes the level of perceived support 
and often results in psychological distress and social isolation (Mak et al., 2007).  This scenario 
presents implications for the adherence to ART and is more likely to result in poor adherence to 
treatment (Mannheimer et al., 2005). In agreement with Thomas (2006), people’s ability to deal 
effectively with stigma either in the home or community affects their wellbeing, HRQOL and 
survival. This will in turn affect the ability to work and thus brings about significant economic 
hardship which perpetuates an already bad situation (UN, 2005).      
 
It is however important to note that the high rate of acceptance and support of family 
members who are HIV positive observed in this study marks a shift from studies that have 
mostly reported a breakdown in family cohesion and social support network and increased 
intra-household tension as a result of an infected member (Thomas, 2006).  Furthermore, Li et 
al., (2009) have found significant associations between the disclosure of HIV status to family 
members, family function and the quality of life of PLWHA. Family support is known to help 
improve the HRQOL of PLWHA as it helps improve their mental health and reduce psychological 
distress (Yen et al., 2004; Murphy et al., 2002; Lang 2000). Like this study findings, Chandra et 
al., (2003) itemized the family support resources to include information about treatment 
options, financial assistance, care in sickness, sharing feelings and reassurance that one is loved 
and valued. These factors have been noted to help buffer the effects of HIV related physical 
symptoms on depressive symptomatology (Hays et al., 1992). This is in consonance with the 
reports of the study participants who noted how they coped better with support from family, 
health workers and support group after disclosure.  
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The above points emphasize the importance of family and social support in responding to the 
manifestations and demands of living positively with HIV/AIDS. Despite these benefits, almost 
all the study participants indicated an initial reluctance to disclose their HIV status. In the past 
PLWHA have been known to be discriminated against, abandoned, abused and marginalized by 
their families and communities and the fear of these possible negative outcomes often 
discourages disclosure (Medly et al., 2004). 
 
The high rate of HIV infection in South Africa together with improved survival of the HIV-
infected due to advances in ART, better information on HIV prevention and care strategies and 
improved government support programmes may be responsible for the observed better 
acceptance of PLWHA by their family members and the more subtle discrimination at the 
community level. This  assertion is on the basis that the fear of the virus and concerns about the 
burden of caring for PLWHA are among the major drivers of discrimination, rejection and 
stigmatisation of PLWHA and are ameliorated by the current state of the epidemic and its 
response programmes (Liamputtong et al., 2009; Li et al., 2008; Lyttleton, 2004).  
 
The study participants also reported how their quality of life improved as the modifying factors 
increased over time (Figure 4.1). The time it takes to achieve the balancing effect of the 
modifying factors could not be established by this study but each of the modifying factors could 
be facilitated through appropriate interventions in order to ensure better quality of survival in 
the shortest possible time. This proposition is supported by Murdaugh’s (1998) pathway to 
psychological adjustment among PLWHA. Murdaugh’s (1998) pathway moves through four 
stages: disintegration (or mourning loss), re-normalizing, coming to terms and creating 
meaning.  
 
In line with the above pathway, this study adds that PLWHA can move forwards and backwards 
along the stages depending on the state of equilibrium created by the balancing of intervening 
and modifying factors. Key among the factors are (1) increasing knowledge about the disease as 
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a way to gain better control of the related symptoms and reduce the anxiety and 
unpredictability of living with the virus and (2) social support from various networks to provide 
psychological and financial resilience that buffers some of the negative effects of the mental, 
physical and external determinants of HRQOL (Table 4.1). Similar to other studies, this study 
also noted that the psychologically well adjusted participants seem to have come to terms with 
“their virus” and created new meanings of living with it as a coping mechanism and tended to 
have higher life satisfaction (Faber et al., 2010).  
 
In all, the findings of this study highlight the combination of factors that influence quality of life 
of people living with HIV/AIDS. This study further proposes possible relationships between the 
various factors as shown in Figure 4.1 below.  
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Time 
HIV infection and AIDS 
Common manifestations of HIV/AIDS: diarrhoea, pain, fatigue, insomnia, fear/worry, anger, weight 
loss and morphological changes 
 
HIV/AIDS related intervening factors: stigma and discrimination, 
economic implications and costs, poor/absence of social support, 
poor/non-use of HIV/AIDS related treatments  
People affected by the intervening 
factors  
Effects of intervening factors: 
Social isolation, poor adherence 
to treatment, poor utilization of 
HIV support services, job loss and 
economic hardship, body image 
disturbance, poor coping ability 
Poor HRQOL 
Improved HRQOL 
Modifying factors: 
- Knowledge about living positively with 
HIV/AIDS 
- Disclosure of HIV status    
- Acceptance of HIV status   
- Psychological adjustment 
- Adherence to treatment 
- Psychosocial support from family, 
support group and health workers  
 
People not/marginally affected 
by the intervening factors  
Better HRQOL 
 
 
Figure 4.1: Factors affecting the HRQOL of PLWHA 
 
In conclusion, the identified items are similar to those contained in the WHOQOL-HIV and MOS-
HIV instruments. With this finding, it became unnecessary to develop a new instrument 
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because the items identified have been covered by existing instruments. This was apparent 
through a direct matching of the subscales of the existing instruments with the items identified 
by this study’s participants. With this, Part B of Study I became unnecessary. The removal of 
items from the existing instruments envisaged in Study II remains important to promote the 
efficiency and convenience of their use without compromising their validity.   
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CHAPTER FIVE 
FINDINGS AND DISCUSSION OF STUDY II: DESCRIPTION, VALIDATION AND SHORTENING OF 
THE WHOQOL-HIV AND MEASUREMENT OF CHANGES IN CD4 COUNTS, VIRAL LOAD, HRQOL 
OVER TIME 
 
5.1 Introduction 
This section of the study followed up a group of treatment naïve PLWHA from their time of 
treatment initiation over a twelve month period. The same group of participants was 
repeatedly interviewed at six monthly intervals (that is, baseline, six and twelve months 
respectively). This intention was, however, challenged by the logistical issues of conducting this 
research without disrupting the participants’ use of health services.  The pressure presented by 
this challenge made it difficult to keep accurate records of patient unique numbers on the 
questionnaires. This information gap made it difficult to accurately link the participants over 
time and hence limited the analysis in terms of linking the participants for a longitudinal 
analysis.  
 
In view of this, the results presented in this chapter at best represent three different cohorts of 
PLWHA defined by their duration on treatment despite the fact that the same group of 
individuals was interviewed repeatedly. Efforts were, however, made by this analysis to avoid 
double counting or record duplication by the splitting of the database and results according to 
the time of data collection/duration on treatment. This measure was mainly aimed at ensuring 
that the study objective of monitoring the pattern of change over time is achieved (with regards 
to the HRQOL and biomedical markers). 
 
Despite the challenge, and in order to maximize the opportunity that it presents, aggregate 
analyses of all the interviews conducted (regardless of time of interview) was also performed 
and mostly presented as appendixes to the study findings. These additional analyses were to 
augment the results of the changes observed over time.  The interpretation of the aggregate 
analyses should be viewed against the backdrop that this study reported very high reliability 
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scores and that the biomedical and HRQOL indicators of the participants was also subject to 
change over time. This assertion is given the assumed bio-psychosocial trajectory of HIV and 
AIDS (Gurunathan et al., 2009; Murdaugh, 1998). With this, each interview conducted at the 
different time points will measure different degrees of biomedical and HRQOL outcomes even if 
they are from the same group of individuals. It is hence hoped that the aggregate analyses will 
not directly translate to duplication of records if it is interpreted correctly.   
 
With the above, this chapter presents the findings and discussion of Study II. The chapter is 
structured around the objectives of Study II which are to describe the quality of life of people 
living with HIV and AIDS; and establish the relationship between the biological markers and 
HRQOL measures and assess their change over time and finally to validate and shorten the 
WHOQOL-HIV instrument.  
 
In line with the first objective, the results section describes the HRQOL of PLWHA in Limpopo 
Province. This description is mostly done along demographic characteristics and over time. In 
order to do this, the results section starts by providing demographic characteristics of the study 
participants at baseline and dropout rate over time, followed by a description of the level of 
reliability of the HRQOL instrument used in the study.  
 
With the second objective, the relationships between the biological markers and HRQOL 
measures and their change over time were assessed and presented using Spearman correlation 
coefficient. The t-tests and ANOVA were further used to compare HRQOL scores across the 
different levels of the biological marker. For instance, the mean HRQOL scores were compared 
between people with suppressed viral load and those with unsuppressed viral load over time.  
 
The third objective was omitted because an index instrument was not developed at the end of 
Study I. This was based on the conclusion that such an instrument will be unwarranted as its 
proposed items and domains are catered for by the WHOQOL-HIV instrument. 
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The fourth objective of validating the WHOQOL-HIV was achieved by using Pearson correlations 
and Limits of Agreement Plots to assess and present the convergent and discriminant validities 
of the WHOQOL-HIV instrument. The MOS-HIV instrument was used in this section to validate 
the measures provided by the WHOQOL-HIV instrument. The construct validities of each of the 
six domains were assessed using the rotated component matrix tables of the principal 
component analysis.  
 
The fifth objective of item removal/shortening was done at each of the three times of data 
collection using the item-total correlation and Cronbach’s Alpha if item is deleted.    
 
The discussion section of this chapter followed the outline of the result as guided by the above 
objectives of Study II.  
 
For reference and clearer understanding of the results, the list of the WHOQOL-HIV instrument 
domains and their respective subscales can be found in Appendix 2.1. 
 
5.2 Results  
 
THE DESCRIPTION OF THE HEALTH RELATED QUALITY OF LIFE OF PEOPLE LIVING WITH HIV 
AND AIDS IN LIMPOPO PROVINCE  
  
5.2.1: Demographic characteristics of study participants 
The demographic characteristics of the participants at baseline are presented in Table 5.1. 
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Table 5.1: Socio-demographic characteristics of study participants at baseline  
Characteristics  Pedi (n = 159) Venda (n = 155) Tsonga (n = 158) 
Sex n (%)    
Male 60 (37.7) 68 (43.9) 52 (33.1) 
Female 99 (62.3) 87 (56.1) 105 (66.9) 
Age group (years) n (%)   
18 – 25 15 (9.4) 11 (7.1) 5 (3.2) 
26 – 35 55 (34.6) 44 (28.6) 46 (29.9) 
36 – 45 52 (32.7) 56 (36.4) 63 (40.9) 
46 + 37 (23.3) 43 (27.9) 40 (26.0) 
Marital status n (%)   
Married 51 (34.0) 78 (56.6) 67 (45.3) 
Never married 85 (56.7) 21 (13.6) 50 (33.8) 
Divorced 4 (2.7) 18 (11.7) 6 (4.1) 
Separated 7 (4.7) 23 (14.9) 10 (6.8) 
Widowed 3 (2.0) 14 (9.1) 15 (10.1) 
Children n (%)    
No 29 (19.1) 19 (12.9) 15 (10.8) 
Yes 123 (80.9) 128 (87.1) 124 (89.2) 
Education n (%)    
No education 25 (19.2) 27 (18.2) 48 (38.4) 
Primary 70 (53.8) 65 (43.9) 37 (29.6) 
Matric 29 (22.3) 44 (29.7) 36 (28.8) 
Tertiary 6 (4.6) 12 (8.1) 4 (3.2) 
Employment n (%)    
No 141 (89.2) 135 (87.7) 135 (90.6) 
Yes 17 (10.8) 19 (12.3) 14 (9.4) 
Support group n (%)   
No 24 (47.1%) 128 (89.5) 126 (89.4) 
Yes  27 (52.9%) 15 (10.5) 15 (10.6) 
 
The study cohort was drawn from three sites with each site, representing each of the target 
ethnic groups. The availability of biomedical patient data in each site was dependent on the 
site’s policy on the timing of CD4 cell count and viral load testing. This means that some sites 
did not have the CD4 and viral load tests done at baseline and instead, relied on previous tests 
and presenting cardinal signs and symptoms of AIDS. Based on this, there were no baseline data 
 96 
for the Tsonga site and no six months data for the Venda site. Participants were, however, 
identified to participate at baseline in the Tsonga site even if there were no data for them. 
 
Four hundred and seventy two participants were drawn from the three sites to participate in 
the study. The study cohort at baseline was mostly constituted by females, persons over 35 
years old, married with children and unemployed. At baseline the ages of all the study 
participants ranged from 20 to 71 with an average age of 40.5 (s.d. = 9.90). The majority of the 
cohort had children, with each having an average of 3 children (s.d. = 1.71). The participants 
had disclosed their HIV status to an average of three people (s.d. = 2.32). The average 
household income was R565.98 (s.d. = R775.80).  
 
This distribution of participants by ethnic group / study site and over time is illustrated in Figure 
5.1 while the distribution of participants’ demographic characteristics at baseline only is shown 
in Table 5.1. Given that same participants were followed from the day of treatment initiation to 
the 12
th
 month (end of the follow up), the demographic characteristics varied over time due to 
deaths, loss to follow up and down referral of patients to feeder clinics outside the study sites 
for continued care. There was, however, no mechanism to establish the cause of patient 
attrition given that the study was conducted in very busy outpatient facilities in regional and 
super-speciality hospitals. The attrition pattern of participants due to the factors listed can be 
seen in the Figure 5.1 below. 
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Baseline   Pedi =159   Venda = 155   Tsonga = 158 
              
              
              
Six months    
Pedi = 133 
(16.4%*) 
  
Venda = 128 
(17.4%*) 
  
Tsonga = 121 
(23.4%*) 
              
              
              
Twelve months    
Pedi = 133 
(16.4%*) 
  
Venda = 94 
(39.4%*) 
  
Tsonga = 107 
(32.3%*) 
* : Percentage dropout after baseline  
Figure 5.1: Distribution of study participants by ethnic group and over the twelve months follow 
up period 
472 treatment naïve PLWHA recruited at baseline 
  
From Figure 5.1 above, the lower dropout rated noted in the Pedi site in comparison to the 
Venda and Tsonga sites may be due to the fact that the Pedi site is a super-speciality hospital 
located in a high density area and in close proximity to its catchment population, unlike the 
other two sites which are regional hospitals in rural areas and servicing a widely dispersed 
catchment population.    
 
The proportion of all participants joining support groups significantly increased with time (χ
2 
= 
66.78; p = .000; n = 765); 22% of the participants at baseline were in support groups, 33% and 
57% of the participants were in support groups at six and twelve months, respectively. This was 
also the case for the proportion of people reporting CD4 count increase over time. All the 
participants CD4 cell counts were below 500 cells/µl at baseline while 5% and 15% of the 
participants had greater than 500 cells/µl at six and twelve months, respectively. While almost 
half of the participants still had a CD4 cell count of < 200 cells/µl at six months, about two-
thirds of the participants had CD4 cell count of between 200 cells/µl and 500 cells/µl at twelve 
months (χ
2 
= 336.71; p = .000; n = 882). The exact median CD4 cell counts at the different time 
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points are presented later in this chapter in Figure 5.2. Similar to the observed changes in CD4 
cell count, the proportion of people with suppressed viral load consistently increased with time 
(χ
2 
= 80.60; p = .000; n = 560). The proportion of participants with unsuppressed viral load 
reduced with time, giving  87%, 44% and 21% at baseline, six and twelve months, respectively.  
 
5.2.2: Reliability of the WHOQOL-HIV 
Table 5.2 shows the reliability values for each of the WHOQOL-HIV domains. The alpha scores 
presented in Table 5.2 are the aggregate scores over time and in all three languages.  
 
Table 5.2: Reliability analysis for the WHOQOL HIV domains 
Domain    Cronbach’s  alpha 
Physical  .92 
Psychological   .86 
Level of Independence   .89 
Social Relationship   .76 
Environmental   .89 
Spirituality/Religion/Personal Belief (SRPB)    .94 
Overall quality of life and general health perceptions  .81 
 
This study used the WHOQOL-HIV to measure the HRQOL of PLWHA in the three languages. The 
respective domains had very high combined reliability scores ranging from .79 with social 
relationship to .94 with the Spirituality/Religion/Personal Belief (SRPB) domain (Table 5.2). The 
overall quality of life and general health perception also has a high reliability (.81). Two 
subscales from the 29 subscales of the WHOQOL-HIV had low Cronbach’s alpha scores 
(Appendix 5.1). The two subscales were physical environment and sexual activity at .43 and .53, 
respectively. In the 29 subscales, the highest reliabilities were recorded for death and dying and 
work capacity with Cronbach alphas of .96 each.  
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5.2.3 The health related quality of life of people living with HIV and AIDS in Limpopo Province 
5.2.3.1 Health related quality of life score of the study cohort 
 Table 5.3 below shows mean HRQOL scores in the ethnic groups and over time. The study’s inability to obtain baseline data in the 
Tsonga site and six months data in the Venda site is shown by the respective blank spaces in the table. 
 
Table 5.3: Mean WHOQOL-HIV domain scores by ethnic group and over time  
 Baseline Six  Months Twelve  Months 
N Mean SD F p 
value 
n Mean SD F  p 
value 
N Mean SD F p 
value 
Physical Domain  
Pedi 144 10.47 1.72 12.59 .00 129 10.88 1.31 297.2 .00 126 9.93 1.13 294.11 .00 
Venda 145 9.32 3.49   - - -   91 11.10 2.24   
Tsonga - - -   109 15.46 2.66   94 16.06 2.37   
Psychological Domain 
Pedi 142 12.36 2.07 11.25 .00 129 12.78 1.60 53.21 .00 130 13.23 1.45 10.98 .00 
Venda 139 11.38 2.77   - - -   91 13.36 2.48   
Tsonga - - -   106 14.58 2.19   87 14.45 2.04   
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Table 5.3 (continued): Mean WHOQOL-HIV domain scores by ethnic group and over time  
 Baseline Six  Months Twelve  Months 
N Mean SD F p 
value 
n Mean SD F  p 
value 
N Mean SD F p 
value 
Level of Independence Domain 
Pedi 138 10.54 1.35 102.2 .00 131 10.76 1.24 61.81 .00 128 9.66 .715 187.15 .00 
Venda 146 7.95 2.71   - - -   92 11.48 1.80   
Tsonga - - -   109 12.85 2.74   93 14.14 2.42   
Social Relationships Domain 
Pedi 141 11.60 1.33 7.072 .01 129 12.33 1.59 136.9
5 
.00 131 11.29 1.15 140.32 .00 
Venda 142 12.18 2.21   - - -   90 13.78 2.04   
Tsonga - - -   114 15.17 2.18   91 15.42 2.38   
Environment Domain 
Pedi 130 11.45 1.05 1.39 .24 123 12.99 .86 17.12 .00 132 13.77 .94 5.37 .00 
Venda 136 11.19 2.25   - - -   89 13.03 1.83   
Tsonga - - -   106 13.91 2.27   90 13.54 2.21   
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Table 5.3 above shows marked significant differences in quality of life scores between the three 
ethnic groups. Over time, the Tsongas consistently reported higher domain scores when 
compared to the scores of the Vendas and the Pedis. At baseline, the Pedis reported higher 
average domain scores when compared to the averaged scores of the Vendas. With the 
exception of the environmental domain, the observed differences between the Pedis and the 
Vendas at baseline were mostly significant.   
 
On face value, the Tsongas and the Pedis had lower domain scores at twelve months in 
comparison to their domain scores at six months in some of the domains. In this regard, the 
Tsongas had lower average scores with the environmental and psychological domains at twelve 
months in comparison to the average score at six months. The Pedis, on the other hand, had 
lower average scores with the physical, level of dependence and social relationship domains at 
twelve months in comparison to the average score at six months. In general, the mean-
differences between the average quality of life domain scores at six and twelve months were 
often small in comparison to the mean-differences between baseline and six and twelve 
months, respectively. The highest quality of life average domain score reported by the Tsongas 
was 16.06 (under physical domain at twelve months); for Vendas, it was 13.78 (under social 
relationship at twelve months); and for the Pedis it was 13.77 (under environmental domain at 
twelve months). A post hoc test comparing the three groups showed that differences observed 
between the three groups as shown in Table 5.3 were all significantly different (p = 0.00). 
 
The above result was augmented by aggregate analyses of all the interviews conducted and is 
presented in Appendix 5.2. The analyses show significant differences in average scores of the 
ethnic groups in all 29 subscales and six domains (Appendix 5.2). Similarly, the Tsonga group 
consistently had higher HRQOL mean scores in almost all the 29 subscales and six domains of 
the WHOQOL-HIV. The mean difference between the Tsonga group and the other  two groups 
was also very wide.  Across the subscales, all the ethnic groups had the lowest scores with the 
subscales “dependence on treatment” and “financial resources”. This observation is expected 
to be consistent in all the comparisons to follow.  
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The aggregate analysis in Appendix 5.2 further shows that when comparing the Pedi and Venda 
groups, the quality of life mean scores were in most cases higher among the Pedis. The few 
instances when the mean score was higher among the Venda group when compared to the Pedi 
group were with positive feelings, dependence on medication, social support, sexual activity, 
home environment, overall quality of life and general health perception and social support. The 
post hoc text in Appendix 5.3 further showed that the observed differences in mean HRQOL 
scores between the Pedi and Venda groups were often not statistically significant. Appendix 5.3 
also shows that the differences observed between the Tsonga groups and each of the other two 
groups differed significantly in all subscales and domains.  
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5.2.3.2 Differences in quality of life scores by demographic characteristics  
 Table 5.4 below presents the HRQOL by sex and over time. 
 
Table 5.4: Mean WHOQOL-HIV domain scores by sex and over time 
 Baseline Six  Months Twelve  Months 
N Mean SD F p 
value 
n Mean SD F p 
value. 
n Mean SD F p 
value 
Physical Domain  
Male  118 9.87 2.69 .014 .90 76 12.88 3.44 .10 .75 109 12.17 3.30 .04 .85 
Female  171 9.91 2.89   162 13.02 2.88   201 12.09 3.25   
Psychological Domain 
Male  115 12.33 2.40 6.49 .01 77 13.80 2.311 1.13 .29 110 13.57 2.06 .06 .81 
Female  166 11.57 2.50   158 13.49 1.971   197 13.63 2.02   
Level of Independence Domain 
Male  121 8.73 2.54 7.76 .01 80 11.61 2.47 .21 .65 109 11.45 2.41 .15 .70 
Female  163 9.56 2.44   160 11.76 2.23   204 11.56 2.58   
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Table 5.4 (continued): Mean WHOQOL-HIV domain scores by sex and over time 
 Baseline Six  Months Twelve  Months 
N Mean SD F p 
value 
n Mean SD F p 
value 
n Mean SD F p 
value 
Social Relationships Domain 
Male  116 12.12 1.60 3.08 .08 79 13.87 2.67 .97 .33 112 13.36 2.62 .67 .41 
Female  167 11.73 2.0   164 13.55 2.20   199 13.11 2.49   
Environment Domain 
Male  111 11.64 1.62 6.37 .01 77 13.71 1.68 3.54 .06 109 13.51 1.53 .03 .87 
Female  155 11.09 1.84   152 13.26 1.73   202 13.48 1.76   
Spirituality/Religion/ Personal Beliefs Domain 
Male  54 9.24 2.97 .13 .72 81 14.41 3.12 .00 1.00 73 13.58 3.12 .01 .92 
Female  96 9.42 2.81   162 14.40 3.26   156 13.62 3.35   
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Table 5.4 above shows the differences in quality of life domain scores when comparing males 
and females. The differences between males and females were mostly not significant at six and 
twelve months. The observed significant differences were at baseline and males had 
significantly higher scores with psychological and environmental domains. Females had 
significantly higher average score in the level of dependence domain. There was no significant 
difference between males and females in the physical domain, social relationship domain and 
the spirituality/religion/personal belief (SRPB) domain at six months. 
 
On face value, males consistently had higher quality of life scores at six months when compared 
to their quality of life scores at twelve months. On the other hand, females recorded improved 
average quality of life domain scores in the psychological domain and environmental domains. 
Generally, the mean-differences between the six and twelve month scores were small in both 
males and females when comparing the average scores at six and 12 months  with the average 
scores at baseline. The highest average domain scores for the males and females were under 
the SRPB and psychological domains at six months while their lowest scores were in the level of 
dependence domain at baseline.  
 
An aggregate analysis of all the interviews conducted showed significant differences in average 
WHOQOL-HIV scores in seven out of the 35 subscales and domains of the WHOQOL-HIV. Males 
recoded significantly higher scores in three out of the seven components. The four subscales 
where males had higher mean scores were thinking, learning, memory and concentration (p = 
.01); home environment (p = 00.); and opportunity for acquiring new information and skills (p = 
.04). The females scored higher mean scores with activities of living (p = .03); dependence on 
medication or treatment (p = .04); work capacity (p = .01); and level of independence (p = .00). 
Both groups had notably lower mean scores with dependence on medication or treatment 
while the highest scores were reported for opportunity to acquire new information and skills. 
These findings are similar to the findings of the time specific analysis as the listed subscales 
constitutes the domains where such differences was observed earlier.  
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The table below shows the quality of life domain scores by marital status and over time. Three categories of marital status are 
considered as shown in the table. People not currently in a marriage are grouped together as divorced/separated/widowed. 
 
Table 5.5: Mean WHOQOL-HIV domain scores by marital status and over time 
 Baseline Six  Months Twelve  Months 
n Mean SD F p 
value 
n Mean SD F p 
value 
n Mean SD F  p 
value 
Physical Domain  (CD4 cell counts in cells/µl) 
Married 119 9.66 2.85 2.98 .05 93 13.28 3.19 22.32 .00 126 12.48 3.27 2.599 .07 
Never married 99 10.42 2.42   99 11.77 2.55   95 11.49 2.95   
Divorced/Separat
ed/Widowed 
63 9.44 3.24 
  
38 15.29 2.49 
  
89 12.24 3.45   
Psychological Domain 
Married 113 11.76 2.64 1.21 .29 94 13.79 2.25 3.98 .02 123 13.66 2.12 1.505 .22 
Never married 96 12.21 2.22   99 13.24 1.86   97 13.81 2.00   
Divorced/Separat
ed/Widowed 
63 11.66 2.60   34 14.31 1.90   87 13.31 1.91   
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Table 5.5 (continued): Mean WHOQOL-HIV domain scores by marital status and over time 
 Baseline Six  Months Twelve  Months 
n Mean SD F p 
value 
n Mean SD F p 
value 
n Mean SD F  p 
value 
Level of Independence Domain 
Married 120 8.95 2.76 6.28 .00 94 11.99 2.26 5.58 .00 126 11.78 2.53 1.217 .29 
Never married 91 9.93 1.78   103 11.25 2.08   96 11.39 2.19   
Divorced/Separat
ed/Widowed 
64 8.63 2.79   35 12.60 2.60   90 11.28 2.78   
Social Relationships Domain 
Married 115 11.88 2.08 .02 .98 93 14.18 2.32 17.07 .00 121 13.78 2.61 5.599 .00 
Never married 98 11.93 1.41   103 12.76 2.16   100 12.97 2.45   
Divorced/Separat
ed/Widowed 
62 11.88 2.07   38 14.91 2.10   90 12.68 2.41   
Environment Domain 
Married 112 11.31 1.94 .01 .98 87 13.39 1.72 6.57 .00 123 13.48 1.63 .140 .86 
Never married 91 11.30 1.37   99 13.19 1.37   99 13.45 2.08   
Divorced/Separat
ed/Widowed 
57 11.34 2.07   34 14.38 2.25   88 13.57 1.18   
Spirituality/Religion/ Personal Beliefs Domain 
Married 50 9.22 3.04 .18 .83 95 14.68 3.04 11.53 .00 71 14.41 3.28 4.160 .01 
Never married 79 9.49 2.90   100 13.43 3.09   74 13.68 3.01   
Divorced/Separat
ed/Widowed 
14 9.64 2.62   39 16.10 2.96   84 12.90 3.38   
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Table 5.5 above shows that the quality of life increased after treatment initiation. Regardless of 
marital status, the participants tended to have higher quality of life domain score at six and 
twelve months when compared to the baseline domain scores. On face value, scores 
sometimes declined at twelve months. Significant differences based on marital status were 
noted under the baseline level of dependence, social relationship and environmental domains 
and under the social relationship and SRPB domains at twelve months. In this regard, married 
people reported higher quality of life in comparison to the other two categories in instances 
where there were significant differences in domain scores at twelve months. All the quality of 
life domains at six months showed significant differences by marital status. Divorced/separated 
/widowed participants consistently had the highest quality of life domain scores followed by 
those who were  married  at six months. The highest scores were recorded for people who 
were divorced/separated /widowed at six months under the physical and SRPB domains, 
respectively 
 
The aggregate analysis of all the interviews shown in Appendix 5.4 indicates that many of the 
domains and subscales differed significantly by marital status.  People who were 
divorced/separated/widowed mostly recorded significantly higher mean scores in seven out of 
the twelve subscales and domains where the subscales and domain differed significantly.   
People who had never married had significantly higher scores with positive feelings and 
transport subscales while married people had significantly higher scores with sexual activity and 
social relationships subscales. The participants reported the lowest scores with financial 
resources and the highest scores with SRPB. Despite the reported difference in Appendix 5.4, 
Appendix 5.5 shows that differences between married and people who had never married was 
often not significantly different. Appendix 5.5 also shows the higher mean scores reported by 
persons who were divorced/separated/widowed often significantly differed from the mean 
scores of the other two groups (married and never married). In this regard, the findings of this 
aggregate analysis are also similar to the findings of the time specific analysis. 
 
 109 
The WHOQOL-HIV domain scores are presented in Table 5.6 below showing a distribution of the scores across people with and 
without children. The presentation also displays the respective domain scores at different points in time. 
 
Table 5.6: Mean WHOQOL-HIV domain scores by people with and without children and over time 
 Baseline Six  Months Twelve  Months 
n Mean SD F  p 
value 
n Mean SD F p 
value 
n Mean SD F p 
value 
Physical Domain  
With 233 10.08 2.86 3.48 .06 168 13.43 3.21 22.17 .00 217 12.87 3.42 52.03 .00 
Without 45 9.22 2.59   56 11.30 1.82   85 10.08 1.55   
Psychological Domain 
With 224 12.04 2.44 1.69 .20 162 13.87 2.10 10.44 .00 211 13.77 2.13 4.61 .03 
Without 46 11.51 2.70   59 12.88 1.75   89 13.22 1.80   
Level of Independence Domain 
With 229 9.24 2.52 .40 .53 166 12.07 2.30 19.79 .00 216 12.11 2.62 53.50 .00 
Without 44 8.98 2.61   60 10.62 1.74   88 9.97 1.30   
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Table 5.6 (continued): Mean WHOQOL-HIV domain scores by people with and without children and over time 
 Baseline Six  Months Twelve  Months 
N Mean SD F  p 
value 
n Mean SD F p 
value 
n Mean SD F p 
value 
Social Relationships Domain 
With 233 11.99 1.85 2.34 .13 171 13.90 2.34 16.11 .00 215 13.84 2.56 55.37 .00 
Without  42 11.52 1.72   57 12.53 1.92   89 11.66 1.63   
Environment Domain 
With 219 11.36 1.75 .25 .62 163 13.52 1.84 2.46 .12 214 13.45 1.87 .36 .55 
Without 40 11.51 1.61   57 13.11 1.19   88 13.58 1.21   
Spirituality/Religion/ Personal Beliefs Domain 
With  117 9.43 2.88 .03 .86 169 14.63 3.29 9.09 .00 145 14.68 3.24 58.41 .00 
Without  26 9.54 2.98   60 13.22 2.55   78 11.58 2.09   
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Table 5.6 shows that people with and without children had no significant differences at 
baseline. With the exception of the environmental domain, there were significant differences 
between their quality of life scores at six and twelve months. People with children consistently 
had significantly higher quality of life average domain scores when compared to people without 
children. The mean-differences in scores between  six and twelve months were small when 
compared to their difference with  baseline scores. For people with children, the highest scores 
were recorded under the spirituality domain followed by the social relationship domain. The 
highest score for those without children was recorded under the environmental domain. The 
lowest score for people with children was under level of dependence at baseline while for 
people without children it was the physical domain at baseline.  
 
The aggregate analysis presented in Appendix 5.6 similarly showed that people with children 
consistently had higher scores in all the subscales and domains where there was significant 
difference between both groups. When compared to other demographic characteristics 
discussed earlier, more subscales and domains differed significantly when comparing the scores 
of participants with or without children. Like most other characteristics, mean scores in both 
groups was lowest with financial resources and highest with opportunity for acquiring new 
information and skill subscales. From the result, there was significant difference between both 
groups in all the six main domains except the environmental domain.  
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 Table 5.7 below shows differences in HRQOL domain scores by employment status.   
 
Table 5.7: Mean WHOQOL-HIV domain by employment status and over time  
 Baseline Six  Months Twelve  Months 
n Mean SD F p 
value 
n Mean SD F p 
value 
n Mean SD F p 
value 
Physical Domain  
Employed  31 9.06 2.44 3.04 .08 10 16.00 3.86 10.25 .00 31 13.77 3.36 9.40 .00 
Unemployed  257 9.99 2.84   208 12.88 2.96   271 11.91 3.19   
Psychological Domain 
Employed  29 11.61 2.31 .38 .54 8 14.70 2.53 2.07 .15 32 14.65 2.16 10.10 .00 
Unemployed  251 11.91 2.51   206 13.62 2.07   267 13.47 1.97   
Level of Independence Domain 
Employed  32 8.88 2.74 .59 .44 10 13.60 3.10 7.02 .01 29 13.14 2.57 13.87 .00 
Unemployed  251 9.24 2.49   209 11.63 2.25   275 11.35 2.44   
Social Relationships Domain 
Employed  29 12.16 1.44 .70 .41 10 15.03 2.24 3.44 .07 31 15.08 2.56 20.24 .00 
Unemployed  253 11.86 1.89   214 13.63 2.32   272 12.99 2.43   
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Table 5.7 (continued): Mean WHOQOL-HIV domain by employment status and over time  
 Baseline Six  Months Twelve  Months 
n Mean SD F p 
value 
n Mean SD F p 
value 
n Mean SD F p 
value 
Environment Domain 
Employed  29 11.74 2.40 1.83 .18 9 13.72 1.79 .29 .59 29 14.38 1.98 9.16 .00 
Unemployed  236 11.27 1.68   203 13.40 1.72   273 13.39 1.64   
Spirituality/Religion/ Personal Beliefs Domain 
Employed  16 8.88 3.52 .55 .46 10 15.80 2.94 1.90 .17 18 16.00 3.51 10.44 .00 
Unemployed  133 9.44 2.78   212 14.39 3.19   203 13.44 3.19   
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Table 5.7 shows that employed people had lower average domain scores when compared to 
the unemployed at baseline even if the differences were not significant.  This pattern changed 
at six and twelve months with the employed people having higher quality of life scores at both 
times. Relative to the other demographic characteristics, employed people seem to have a 
much higher average score when compared to unemployed people. The highest average score 
among the employed people was 16.00 under the physical domain at six months and SRPB 
domain at 12 months. The highest quality of life scores for unemployed people were 13.62 
under the psychological domain at six months and 14.39 under the SRPB domain at six months. 
The lowest score for employed people was 8.88 under level of dependence at baseline and 9.24 
for  unemployed under level of dependence at baseline.    
 
Table 5.8 below presents the aggregate analysis of the HRQOL scores of only subscales and 
domains where there were significant differences between employed and unemployed people. 
In other words, the table does not include subscales and domains where there was no 
significant difference between both groups. 
 
Table 5.8: Aggregate analysis of the mean WHOQOL-HIV subscale and domain scores showing 
significant difference by employment status 
 N Mean SD T p value 
Energy and fatigue Yes 76 2.91 2.239 .03 
No 771 2.73   
Negative feelings Yes 75 3.25 2.362 .02 
No 771 2.95   
Dependence on medication or 
treatments 
Yes 76 1.95 2.758 .00 
No 768 1.70   
Social support Yes 75 3.25 2.310 .02 
No 775 2.99   
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Table 5.8 (continued): Aggregate analysis of the mean WHOQOL-HIV subscale and domain 
scores showing significant difference by employment status 
 N Mean SD T p value 
Sexual activity Yes 75 3.11 3.511 .00 
No 768 2.77   
Financial resources Yes 75 2.33 6.962 .00 
No 768 1.58   
Social Relationships Yes 70 13.86 3.641 .00 
No 739 12.79 3.405 .00 
 
The findings of the aggregate analysis shown in Table 5.8 above indicate that employed and 
unemployed people in the study differed in term of energy and fatigue, negative feelings, 
dependence on medication and treatments, social support, sexual activity, financial resources 
and social relationships. The reported means and t-test all show that employed people had 
significantly better quality of life in all the subscales and domains where significant differences 
were reported. While the table does not show all the subscales, on face value, the participants 
scores was lowest under dependence on medication or treatment and highest with social 
support subscales.  
 116 
 Table 5.9 below presents the quality of life domain scores by support group membership 
 
Table 5.9: Mean WHOQOL-HIV domain scores by support group membership and over time  
 
 Baseline Six  Months Twelve  Months 
n Mean SD F p 
value 
n Mean SD F p 
value 
n Mean SD F p 
value 
Physical Domain  
Member  38 10.55 2.28 3.61 .06 76 12.13 2.44 8.94 .00 170 11.11 2.58 44.39 .00 
Nonmember  143 9.44 3.41   151 13.40 3.28   127 13.47 3.54   
Psychological Domain 
Member  33 11.52 1.90 .02 .88 78 13.45 1.93 .76 .37 171 13.38 1.70 5.37 .02 
Nonmember  142 11.44 2.68   146 13.70 2.21   123 13.94 2.39   
Level of Independence Domain 
Member  38 10.16 1.52 17.62 .00 77 11.17 2.06 6.56 .01 171 10.64 2.05 54.02 .00 
Nonmember  139 8.19 2.77   153 11.99 2.41   128 12.63 2.63   
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Table 5.9 (continued): Mean WHOQOL-HIV domain scores by support group membership and over time  
 Baseline Six  Months Twelve  Months 
n Mean SD F p 
value 
n Mean SD F p 
value 
n Mean SD F p 
value 
Social Relationships Domain 
Member  34 11.75 1.63 1.04 .31 77 12.93 2.00 13.61 .00 174 12.35 2.10 46.69 .00 
Nonmember  140 12.15 2.13   156 14.10 2.43   124 14.23 2.63   
Environment Domain 
Member  36 10.71 1.16 2.93 .10 76 13.16 1.37 3.17 .08 176 13.65 1.20 3.81 .05 
Nonmember  134 11.35 2.18   145 13.59 1.89   120 13.26 2.17   
Spirituality/Religion/ Personal Beliefs Domain 
Member  25 7.80 1.26 1.72 .20 79 13.66 3.13 6.95 .01 147 12.48 2.85 59.26 .00 
Nonmember  23 8.74 3.33   154 14.82 3.23   77 15.64 3.01   
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Table 5.9 shows that non members of support groups reported better quality of life in all the 
domains and consistently over time. On face value, people in support groups mostly reported 
lower average quality of life scores at twelve months when compared to their quality of life 
scores at six months while people not in support groups were more likely to have higher quality 
of life scores at twelve months when compared to their scores at six months. With the 
exception of the level of dependence domain at baseline, people not in support groups 
consistently had higher quality of life scores in instances where average scores between groups 
were significantly different. This was particularly the case at twelve months except for the 
environmental domain where there was no significant difference between both groups at 
twelve months. The highest average score among people not in support groups was 14.23 
under the social relationship domain at twelve months and 15.64 under SRPB domain at twelve 
months. The lowest average score for people not in support groups was with level of 
dependence at baseline (8.19) while among people in support groups the lowest score was 
10.16 under the level of dependence domain at baseline. 
 
The aggregate analysis presented in Appendix 5.7 further indicates that many of the subscales 
and domains differed by the participants support group membership status. The aggregate 
analysis showed a slightly different trend in the pattern of difference in average scores reported 
by people in support groups and those not in support groups. Participants belonging to support 
groups reported significantly higher quality of life in some subscales and domain while the 
participants who did not belong to support groups had significantly higher quality of life scores 
in other instances. With regards to symptoms (p = 00.), pain and discomfort (p = .01) and 
energy and fatigue (p = .00), those not in support group reported a better quality of life while 
those in support group reported better quality of life on the subscale “overall quality of life” 
and general health perception” (p = .01). Another observation was that the participants in 
support groups had significantly high positive feeling score (p = .02) while the participants not 
in support groups had significantly lower negative feelings score (p = .00) and more social 
support (p = .00) and financial resources (p = .00).  
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The aggregate analysis in Appendix 5.7 further showed that people in support groups also had 
better self esteem (p = .02), body image appearance (p = .)02, opportunity to learn (p = .00), 
health care (p = .00) and environmental (p = .01) and psychological domain scores (p = .00). On 
the other hand, the same group had significantly less dependence on medication and 
treatments (p = .00), personal relationships (p = .00), social support (p = .00), sexual activity 00, 
financial resources (p = .00), social relationships (p = .00) and SRPB 00.  
 
THE RELATIONSHIP BETWEEN CHANGES IN CD4 COUNT, VIRAL BURDEN AND HRQOL OVER 
TIME  
 
5.2.4: Relationship between the biological markers HIV and AIDS and the HRQOL measure 
and their change over time 
5.2.4.1 Change in biological markers over time  
Figure 5.2 below shows the median CD4 cell count and viral load over time.  
 
 120 
Figure 5.2 shows a marked decline in viral load six months after treatment initiation and a 
further reduction at 12 months. Similarly, the CD4 cell count increased over time. The lines for 
the viral load and CD4 cell counts both tended to plateau after six months with little changes at 
12 months.    
 
5.2.4.2 Change in HRQOL measures over time  
Table 5.10 presents the average quality of life scores across the three points of data collection. 
Unlike the earlier tables, Table 5.10 is independent of demographic characteristics. Instead, it 
shows the pattern of change in each of domain scores over time.  
 
Table 5.10: Comparison of the average WHOQOL-HIV domain scores at the three interview 
times  
WHOQOL-HIV scales and 
domains  
Interview 
time 
n Mean SD F Sig. 
Physical Baseline 289 9.90 2.806 73.702 .000 
6 months 238 12.97 3.065   
12 months 311 12.13 3.260   
Psychological Baseline 281 11.88 2.484 56.359 .000 
6 months 235 13.59 2.089   
12 months 308 13.61 2.031   
Level of Independence Baseline 284 9.20 2.515 89.789 .000 
6 months 240 11.71 2.305   
12 months 313 11.52 2.519   
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Table 5.10 (continued): Comparison of the average WHOQOL-HIV domain scores at the three 
interview times  
WHOQOL-HIV scales and 
domains  
Interview 
time 
n Mean SD F Sig. 
Social Relationships Baseline 283 11.89 1.850 44.426 .000 
6 months 243 13.66 2.360   
12 months 312 13.21 2.543   
Environment Baseline 266 11.32 1.769 137.594 .000 
6 months 229 13.41 1.725   
12 months 311 13.49 1.681   
Spirituality/Religion/ Personal 
Beliefs 
Baseline 150 9.35 2.859 128.508 .000 
6 months 243 14.40 3.207   
12 months 230 13.63 3.281   
 
The mean scores for all quality of life scales and domains differed significantly over time. With 
the exception of the environmental domain, the mean scores tended to be higher at six months 
when compared to the mean scores at baseline and twelve months (Table 5.10). Six and twelve 
month scores had marked mean differences when compared to the baseline mean scores, 
respectively. As usual, the lowest means at baseline, six and twelve months were reported for 
financial resources while the highest mean scores were reported under the health care and 
opportunity for new information and skills domains. In both subscales, there was a significant 
and progressive increase with time. 
 
Appendix 5.8, however, shows that the observed higher mean score at six months was not 
always significantly different from the mean scores at twelve months. For instance, the means 
at six and twelve months were not significantly different in terms of level of dependence (p = 
.38), environmental (p = .61) and psychological (p = 90.) domains. 
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5.2.4.3 Correlation and comparison of CD4 cell count, viral load and the HRQOL measures 
The table below shows the correlation between the six quality of life domains and CD4 and viral load categories respectively, across 
the three points of data collection 
 
Table 5.11: Correlation coefficients of CD4 cell count level, viral suppressions status and the WHO-QOL domains  
  
Baseline Six  Months Twelve  Months 
CD4 cell 
count 
grouping 
Viral load 
suppression 
status 
CD4 cell 
count 
grouping 
Viral load 
suppression 
status 
CD4 cell 
count 
grouping 
Viral load 
suppression 
status 
Physical Coefficient -0.04 -0.21 .15
*
 0.12 -0.01 -0.12 
Sig. (2-tailed) 0.53 0.16 0.02 0.10 0.83 0.05 
n 279 48 237 204 302 270 
Psychological Coefficient 0.03 -0.07 .17
**
 0.02 0.08 -.17
**
 
Sig. (2-tailed) 0.62 0.66 0.01 0.74 0.15 0.01 
n 272 44 234 203 299 269 
Level of 
Independence 
Coefficient -0.02 -.31
*
 0.04 0.09 0.00 -0.08 
Sig. (2-tailed) 0.77 0.04 0.54 0.21 0.98 0.17 
n 275 46 239 207 304 273 
 
 
 
 
 123 
Table 5.11 (continued): Correlation coefficients of CD4 cell count level, viral suppressions status and the WHO-QOL domains  
  
Baseline Six  Months Twelve  Months 
CD4 cell 
count 
grouping 
Viral load 
suppression 
status 
CD4 cell 
count 
grouping 
Viral load 
suppression 
status 
CD4 cell 
count 
grouping 
Viral load 
suppression 
status 
Social 
Relationships 
Coefficient 0.06 0.23 -0.02 0.08 -0.07 -0.06 
Sig. (2-tailed) 0.36 0.12 0.73 0.23 0.23 0.34 
n 275 47 242 209 303 273 
Environment Coefficient 0.02 .40
**
 0.13 0.04 0.07 0.01 
Sig. (2-tailed) 0.82 0.01 0.06 0.63 0.21 0.86 
n 257 43 228 196 302 272 
Spirituality/Religi
on/ Personal 
Beliefs 
Coefficient -0.11 . 0.07 0.05 -0.11 -0.01 
Sig. (2-tailed) 0.18 . 0.25 0.47 0.10 0.93 
n 146 0.00 242 207 228 220 
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For better clinical and statistical judgment, the viral load and CD4 cell count were grouped into 
categories. The viral load was classed as suppressed and unsuppressed by using 400 copies/ml 
as a cut-off point (DOH, 2003). The CD4 cell counts were, however, grouped into four (0 – 200 
cell/µl; 201 – 349 cell/µl; 350 – 500 cell/µl; >500 cell/µl) (Peltzer et al., 2008). The correlation of 
these categories of biological markers with WHOQOL-HIV domains are shown in Table 5.11 
which shows two notably low  associations between viral load and level of dependence and 
environmental domains respectively at baseline. All the other correlations at the different times 
showed no associations.   
 
Table 5.12 shows the aggregate analysis correlating the biomedical markers with HRQOL 
indicators.  
 
Table 5.12: Aggregate Correlation coefficients of CD4 cell count level, viral suppressions 
status and the WHO-QOL domains  
 CD4 cell count grouping:  Viral load suppression status 
 N r p N r p 
Physical 818 .20
*
 .00 522 -.08 .08 
Psychological 805 .26
*
 .00 516 -.13
*
 .00 
Level of Independence 818 .20
*
 .00 526 -.10
*
 .02 
Social Relationships 820 .11
*
 .00 529 .03 .52 
Environment 787 .37
*
 .00 511 -.04 .34 
Spirituality/Religion/ 
Personal Beliefs 
616 .21
*
 .00 427 .04 .37 
 
The above table shows a slightly different pattern with CD4 cell count categories tending to 
correlate more with WHOQOL domains. The highest correlation coefficient observed was for 
the environment (r = .37, p = .000) and psychological domains (r = .26, p = .000). Despite this, all 
the correlations were too low to suggest any association (Sim and Wright, 2000). 
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Table 5.13 shows the average domain scores by viral load suppression status across the three data collection times 
 
Table 5.13:  WHOQOL-HIV domains scores by viral load suppression status over time  
 Baseline Six  Months Twelve  Months 
n Mean SD t p 
value 
N Mean SD t p 
value 
n Mean SD T p 
value 
Physical Domain  
Suppressed   7 11.71 4.15 1.36 .18 113 12.21 2.81 -1.69 .09 212 12.39 3.37 1.76 .08 
Unsuppressed   41 9.41 4.14   91 12.90 2.99   58 11.52 3.18   
Psychological Domain 
Suppressed   5 12.64 2.22 .44 .66 118 13.40 1.88 -.35 .73 215 13.87 1.97 2.60 .01 
Unsuppressed   39 12.02 3.05   85 13.50 2.20   54 13.10 1.91   
Level of Independence Domain 
Suppressed   7 10.14 2.27 1.88 .07 117 11.42 2.03 -1.31 .19 218 11.68 2.64 1.60 .11 
Unsuppressed   39 7.67 3.33   90 11.81 2.26   55 11.05 2.31   
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Table 5.13 (continued):  WHOQOL-HIV domains scores by viral load suppression status over time  
 Baseline Six  Months Twelve  Months 
N Mean SD t p 
value 
N Mean SD t p 
value 
n Mean SD T p 
value 
Social Relationships Domain 
Suppressed   7 11.61 2.45 1.74 .09 120 13.35 2.38 -.93 .35 215 13.25 2.63 .84 .40 
Unsuppressed   40 13.07 2.00   89 13.65 2.18   58 12.93 2.53   
Environment Domain 
Suppressed   5 9.70 1.82 2.86 .00 113 13.15 1.43 -1.19 .27 213 13.54 1.69 -.17 .87 
Unsuppressed   38 12.43 2.03   83 13.42 1.63   59 13.58 1.41   
Spirituality/Religion/ Personal Beliefs Domain 
Suppressed        120 13.92 3.15 -.84 .40 174 13.59 3.24 .04 .97 
Unsuppressed        87 14.29 3.08   46 13.57 3.64   
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Like all the earlier analyses, Table 5.13 shows that the quality of life improved following 
treatment initiation. In other words, the quality of life at six and 12 months were higher than 
the quality of life at baseline among people with suppressed and unsuppressed viral load.  On 
face value, people with suppressed viral load had a higher quality of life at twelve months in 
comparison to their reported quality of life at six months in all the six domains except the SRPB 
domain. Conversely, the mean quality of life of people with unsuppressed viral load tended to 
be lower at twelve months when compared to their score at six months. Despite this, significant 
differences in the quality of life score between people with suppressed and unsuppressed viral 
load were noted in two instances. People with suppressed viral load had higher environmental 
domain score at baseline and a higher psychological domain score at twelve months. The 
highest domain score was also noted among people with suppressed viral load under the 
psychological domain at twelve months. On the other hand, people with unsuppressed viral 
load reported the lowest quality of live domain average score under level of dependence at 
baseline.  
 
 Table 5.14 below shows results of the aggregate analysis of the average quality of life scores by 
viral load suppression status. 
Table 5.14:  Comparison of the aggregate average WHOQOL-HIV domains cores by viral load 
suppression status  
 Viral load 
suppression 
status 
N Mean SD T p-value  
Physical Suppressed 332 12.31 3.200 1.931 .05 
Unsuppressed 190 11.73 3.577 1.873  
Psychological Suppressed 338 13.69 1.952 3.250 .00 
Unsuppressed 178 13.05 2.389 3.055  
Level of 
Independence 
Suppressed 342 11.56 2.451 3.512 .00 
Unsuppressed 184 10.71 2.994 3.309  
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Table 5.14 (continued):  Comparison of the aggregate average WHOQOL-HIV domains cores 
by viral load suppression status  
 Viral load 
suppression 
status 
N Mean SD T p-value  
Social 
Relationships 
Suppressed 342 13.25 2.550 -.220 .83 
Unsuppressed 187 13.30 2.273 -.228  
Environment Suppressed 331 13.35 1.678 .553 .58 
Unsuppressed 180 13.26 1.702 .550  
Spirituality/Religi
on/ Personal 
Beliefs 
Suppressed 294 13.72 3.205 -.937 .35 
Unsuppressed 133 14.04 3.288 -.928  
(Suppressed viral load below 400 copies/ml; unsuppressed above 400 copies/ml)   
 
The aggregate analysis in table 5.14 shows that the domain mean scores of the suppressed and 
unsuppressed participants differed significantly in two out of the six domains. The two domains 
were the psychological and level of dependence domains. With the exception of the SRPB 
domain, participants with suppressed viral loads had higher quality of life scores in the 
remaining five domains.  The mean scores on level of dependence were relatively lower than 
the mean scores in the other five domains (Table 5.14). The highest mean scores were reported 
for the SRPB domain. Both the specific time and aggregate analyses show significant differences 
in the psychological domain.  
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Table 5.15 shows the average domain scores by CD4 cell count categories across the three data collection times 
 
Table 5.15:  WHOQOL-HIV domains scores by CD4 count level over time  
 Baseline Six  Months Twelve  Months 
n Mean SD F p 
value 
n Mean SD F p 
value 
n Mean SD F p 
value 
Physical Domain  (CD4 cell counts in cells/µl) 
0 - 200  254 9.95 2.87 .65 .52 105 12.60 2.95 2.65 .05 58 12.34 3.24 2.53 .06 
201 - 349  23 9.43 2.40   84 12.83 2.91   97 12.53 3.54   
350 - 500  2 11.50 4.95   37 14.08 3.48   101 11.52 2.99   
> 500      11 14.00 3.29   46 12.89 3.07   
Psychological Domain 
0 - 200  247 11.92 2.53 .14 .86 101 13.30 2.20 2.50 .06 55 13.57 2.54 3.81 .01 
201 - 349  23 12.17 1.94   84 13.57 2.03   98 13.53 1.91   
350 - 500  2 12.40 2.82   39 14.01 1.90   100 13.44 1.82   
> 500      10 14.88 1.65   46 14.57 1.75   
Level of Independence Domain 
0 - 200  251 9.21 2.55 .05 .94 100 11.69 2.11 1.94 .12 56 11.77 2.85 2.54 .06 
201 - 349  22 9.05 2.17   86 11.35 2.27
0 
  99 11.71 2.69   
350 - 500  2 9.50 3.54   42 12.14 2.71   102 11.04 2.22   
> 500      11 12.73 2.24   47 12.15 2.38   
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Table 5.15 (continued):  WHOQOL-HIV domains scores by CD4 count level over time  
 Baseline Six  Months Twelve  Months 
n Mean SD F p 
value 
n Mean SD F p 
value 
n Mean SD F p 
value 
Social Relationships Domain 
0 - 200  251 11.89 1.86 .30 .74 102 13.79 2.24 .84 .47 55 13.55 2.50 3.44 .01 
201 - 349  22 12.15 1.50   86 13.34 2.41   101 13.54 2.70   
350 - 500  2 12.50 2.48   42 13.94 2.49   102 12.61 2.45   
> 500      12 13.48 2.39   45 13.74 2.35   
Environment Domain 
0 - 200  234 11.37 1.80 .21 .81 96 13.33 1.57 .85 .46 57 13.45 1.76 .87 .46 
201 - 349  21 11.60 1.05   83 13.33 1.94   97 13.43 1.60   
350 - 500  2 11.00 3.54   39 13.81 1.66   101 13.54 1.67   
> 500      10 13.25 1.44   47 13.88 1.65   
Spirituality/Religion/ Personal Beliefs Domain 
0 - 200  129 9.45 2.90 2.27 .13 102 14.33 3.11 1.30 .27 38 14.34 3.50 5.37 .00 
201 - 349  17 8.35 2.15   87 14.05 3.38   74 14.22 3.22   
350 - 500       41 14.88 2.84   86 12.58 2.98   
> 500      12 15.67 3.77   30 14.53 3.26   
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Table 5.15 shows an increase in the quality of life with treatment even among people who had 
low CD4 cell counts at six and twelve months. On face value, the mean domain scores were 
lower at 12 months in all the CD4 cell count categories of the physical domain when compared 
to their mean scores at six months.  Some CD4 cell count categories of the other five domains 
had higher mean scores at twelve months while others had lower scores when compared to 
their scores at six months. The significant differences in the mean scores of the various 
categories were only observed at 12 months  in the  psychological, social relationship and the 
SRPB domains. In these three domains, people with CD4 cell counts of over 500 cell/µl 
consistently had higher mean domain scores.  The highest score was also reported under the 
psychological domain at six months (14.88) while the lowest score was reported under level of 
dependence domain at baseline (9.05).   
 
 Table 5.16 below shows the aggregate comparison of the quality of life domain scores by CD4 
cell count categories. 
Table 5.16:  Comparison of the average WHOQOL-HIV domains scores by CD4 count level 
  n Mean  SD F p value. 
Physical  0 - 200 cells/µl 417 10.95 3.193 14.406 .000 
201 - 349 
cells/µl 
204 12.30 3.329 
  
350 - 500 
cells/µl 
140 12.20 3.320 
  
> 500 cells/µl 57 13.11 3.115   
Psychological  0 - 200 cells/µl 403 12.49 2.555 21.570 .000 
201 - 349 
cells/µl 
205 13.40 2.001 
  
350 - 500 
cells/µl 
141 13.58 1.860 
  
> 500 cells/µl 56 14.63 1.724   
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Table 5.16 (continued):  Comparison of the average WHOQOL-HIV domains scores by CD4 
count level 
  n Mean  SD F p value. 
Level of Independence  0 - 200 cells/µl 407 10.17 2.772 17.863 .000 
201 - 349 
cells/µl 
207 11.28 2.582 
  
350 - 500 
cells/µl 
146 11.34 2.425 
  
> 500 cells/µl 58 12.26 2.344   
Social Relationships  = 
820) 
0 - 200 cells/µl 408 12.59 2.233 6.671 .000 
201 - 349 
cells/µl 
209 13.31 2.506 
  
350 - 500 
cells/µl 
146 12.99 2.517 
  
> 500 cells/µl 57 13.69 2.341   
Environment  0 - 200 cells/µl 387 12.16 1.993 31.496 .000 
201 - 349 
cells/µl 
201 13.19 1.787 
  
350 - 500 
cells/µl 
142 13.58 1.708 
  
> 500 cells/µl 57 13.77 1.618   
Spirituality/Religion/ 
Personal Beliefs  
0 - 200 cells/µl 269 11.99 3.912 12.182 .000 
201 - 349 
cells/µl 
178 13.57 3.626 
  
350 - 500 
cells/µl 
127 13.32 3.119 
  
> 500 cells/µl 42 14.86 3.404   
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The aggregate analysis as presented in Table 5.15 also indicates that the average scores 
reported under each of the CD4 cell count categories tended to be higher in the psychology 
domain and lowest in the level of dependence domain. The lowest mean scores were under 
CD4 cell count of 0 – 200 cell/µl in the level of dependence (10.17) and physical (10.95) 
domains. On the other hand, the highest mean scores were noted under CD4 cell count of > 500 
cell/µl under the psychology (14.63) and SRPB domains (14.86). On face value there was almost 
a chronological increase in the mean quality of life score with increase in CD4 cell count 
category in all the domains.  
 
The post hoc test of the aggregate analysis as presented in Appendix 5.9 further shows the 
differences in the mean scores within the respective domains of the CD4 cell counts categories. 
The quality of life score tended to increase with increases in the CD4 cell count category. The 
differences between consecutive categories were mostly significant. There was, however, no 
clear and consistent pattern of difference between the scores under the 201 – 349 cells/µl and 
the 349 – 500 cells/µl categories in all the six domains. However, the differences observed 
between the two categories were not all significant. The mean scores recoded for 0 – 200 
cell/µl under all the six domains were consistently significantly lower than all the other 
categories and had notably higher mean difference with all the categories.  
 
VALIDATION THE WHOQOL-HIV IN THE PREDOMINANTLY SPOKEN LOCAL LANGUAGES IN 
LIMPOPO PROVINCE WHICH ARE NORTHERN SOTHO, TSHIVENDA AND XITSONGA 
 
5.2.5 Validation of the WHOQOL-HIV instrument  
5.2.5.1 Convergent and discriminant validity 
Table 5.17 shows the correlations between the domains and scales of the MOS-HIV and 
WHOQOL-HIV.  
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Figure 5.17 shows the correlation coefficients of the domains of the WHOQOL-HIV and MOS-HIV instruments  
Table 5.17: Correlation coefficients of WHOQOL-HIV and MOS-HIV domains  
WHOQOL-HIV Domains  MOS-HIV Domains 
Name Phy Psych LoD SR Env SRPB  GHP PF RF SF CF Pain  MH E/F HD QoL HT 
Phy 1.00                  
Psych .65
*
 1.00                 
LoD .78
*
 .59
*
 1.00                
SR .66
*
 .56
*
 .58
*
 1.00               
Env .50
*
 .71
*
 .45
*
 .54
*
 1.00              
SRPB .67
*
 .62
*
 .57
*
 .64
*
 .59
*
 1.00             
GHP -.42
*
 -.23
*
 -.44
*
 -.15
*
 -.05 .01  1.00           
PF .56
*
 .52
*
 .53
*
 .33
*
 .45
*
 .39
*
  -.24
*
 1.00          
RF .48
*
 .42
*
 .55
*
 .33
*
 .24
*
 .13
*
  -.46
*
 .51
*
 1.00         
SF .60
*
 .48
*
 .51
*
 .45
*
 .36
*
 .64
*
  -.06 .57
*
 .32
*
 1.00        
CF .63
*
 .48
*
 .53
*
 .49
*
 .41
*
 .56
*
  -.05 .55
*
 .30
*
 .68
*
 1.00       
Pain -.70
*
 -.56
*
 -.70
*
 -.46
*
 -.43
*
 -.50
*
  .42
*
 -.57
*
 -.49
*
 -.52
*
 -.52
*
 1.00      
MH .57
*
 .40
*
 .45
*
 .44
*
 .39
*
 .57
*
  .06 .46
*
 .18
*
 .69
*
 .75
*
 -.468
*
 1.00     
E/F .14
*
 .030 -.01 .18
*
 .06 .48
*
  .37
*
 .06 -.16
*
 .39
*
 .43
*
 .002 .5
*
 1.00    
HD .67
*
 .49
*
 .53
*
 .47
*
 .43
*
 .62
*
  -.13
*
 .55
*
 .27
*
 .67
*
 .78
*
 -.545
*
 .75
*
 .41
*
 1.00   
QoL -.52
*
 -.36
*
 -.58
*
 -.30
*
 -.21
*
 -.05  .61
*
 -.33
*
 -.51
*
 -.19
*
 -.20
*
 .539
*
 -.08
*
 .31
*
 -.26
*
 1.00  
HT -.64
*
 -.43
*
 -.60
*
 -.44
*
 -.24
*
 -.32
*
  .56
*
 -.39
*
 -.50
*
 -.36
*
 -.38
*
 .61
*
 -.28
*
 .13
*
 -.43
*
 .71
*
 1.00 
Green coded figures: WHOQOL vs WHOQOL; Red coded figures: WHOQOL vs MOS-HIV; Blue coded figures: MOS-HIV vs MOS-HIV; 
Phy: physical; Psych: psychological; LoD: level of dependence; SR: social relationships; Env: environmental; SRPB: spirituality / 
religion / personal belief; GHP: general health perception; PF: physical functioning; RF: role functioning; SF: social functioning; CF: 
cognitive functioning; MH: mental health; E/F: energy/fatigue; HD: health distress; QOL: quality of life; HT: health transition s    
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The range of association between the WHOQOL-HIV domains ranged from 0.45 to 0.78 (p = 
0.000). The strength of associations are from moderate to high. The highest correlation 
between WHOQOL-HIV domains and MOS-HIV scales was between the physical domain and the 
pain scale (0.70) followed by the level of dependence domain and the pain scale (0.70). A very 
poor correlation was found between the SRPB domain and the role functioning scale (0.13) 
followed by the physical domain and the energy/fatigue scale (0.14). In terms of the 
convergence of the WHOQOL-HIV and the MOS-HIV, the correlation of similar measures is as 
follows: physical domain and the physical function was 0.56; social relationship and social 
function was 0.45 and psychological domain and mental health was  0.40.  
 
Table 5.17 also shows that there was no correlation between the energy/fatigue scale and the 
psychological, level of dependence and the environmental domains. In the correlation between 
the WHOQOL-HIV domains, the highest correlations were shown between the physical and the 
level of dependence domains (0.78; p = 0.00). On the other hand, the lowest correlation was 
between the environment and the level of dependence domains (0.45; p = 0.00). 
 
Figure 5.3 further shows the confidence intervals of the difference between the scores on the 
respective scales. In all instances, the difference between the upper and lower limit was usually 
less than 1.  
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WHOQOL vs MOS-HIV scale Observations Mean 95% CI 
Pain - Pain 862 3.14 3.36 - 2.92 
Physical - Physical functioning 824 2.48 2.70 - 2.26 
Social relationship - Social 
functioning 
823 9.34 9.50 - 9.19 
Psychology - Mental health 777 4.36 4.70 - 4.02 
Overall QOL - QOL 865 0.83 0.92 - 0.74 
Figure 5.3: Bland-Altman Plots on similar measures in the WHOQOL-HIV and MOS-HIV 
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Top left graph: pain (WHOQOL-HIV) and pain (MOS-HIV); top centre graph: physical domain  
(WHOQOL-HIV) and physical function (MOS-HIV); top right graph: social relationship (WHOQOL-
HIV) and social function (MOS-HIV); bottom left graph: psychological domain (WHOQOL-HIV) 
and mental health (MOS-HIV); bottom right graph: overall quality of life and general health 
perception (WHOQOL-HIV) and quality of life (MOS-HIV).      
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5.2.5.2 Construct validity  
5.2.5.2.1 Physical domain 
The physical domain has 16 items with mean scores per item ranging from 3.97 (s.d. = +1.27) 
with the item “how much do any sleep problems worry you” to 2.92 (s.d. = +.99) with the item 
“Do you have enough energy for everyday life”.  The factor analysis showed two factors with 
eigenvalues greater than 1.0. The two factors identified had a cumulative variance of about 
65.2% even though the first factor contributed about 55.8% of the combined variance. The item 
with the highest loading in the first factor was “to what extent do you feel that physical pain 
prevents you from doing what you need to do?” at .814 and the highest loading in the second 
factor was “how satisfied are you with your sleep” at .843 (Table 5.18). Three items had a 
loading of less than .4 in the first factor. These three items had better loading in the second 
factor.  
 
Table 5.18: Rotated component matrix for the physical domain items 
Item 1
st
 factor 2
nd
 Factor 
To what extent do you feel that (physical) pain prevents you 
from doing what you need to do? 
.814  
How much are you bothered by fatigue? .813  
Do you worry about your pain or discomfort? .806  
To what extent are you bothered by fears of developing any 
physical problem? 
.802  
How much are bothered by any unpleasant by any physical 
problems related to your HIV infection? 
.791  
How difficult is it for you to handle any pain or discomfort?  .788  
How easily do you get tired? .773  
Do you have any difficulties with sleeping? .764  
To what extent do you fear possible future (physical) pain? .742  
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To what extent do you feel any unpleasant physical problems 
prevent you from doing things that are important to you? 
.630  
How satisfied are you with your sleep?  .843 
How satisfied are you with the energy that you have?  .824 
How well do you sleep?  .756 
How often do you suffer ( physical) pain? .438 .618 
Do you have enough for everyday life? -.460 -.587 
How much do any sleep problems worry you?  .495 
 
5.2.5.2.2 Psychological domain  
The psychological domain has 20 items with mean scores ranging from 2.68 (s.d. = 1.22) with 
the item “do you generally feel content?” to 4.09 (s.d. = .869) with “how satisfied are you with 
your ability to learn new information”. The analysis showed that five factors had eigenvalues of 
over 1.0. The five factors had a combined variance of 67.9%. The first factor alone had a 
variance of about 32.6%. The item with the highest loading, the first factor was “how satisfied 
are you with your ability to make decisions?” (.789) and the highest loading in the second factor 
was “how much do any feeing of depression bother you?” (.908). In the third factor, the highest 
loading was with the item “how positive do you feel about the future?” and in the fourth factor 
it was “do you feel inhibited by your looks?” (.716). In the last factor, the highest loading was 
with the item “are you able to accept your bodily appearance?” (.781). The component matrix 
can be found in Table 5.19. Items with loading of less than .4 are not represented under the 
respective factors. 
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Table 5.19: Rotated component matrix for psychological domain items 
 Factor 
 1
st
 2
nd
 3
rd
 4
th
 5
th
 
How satisfied are you with your ability to make 
decisions? 
.789     
How satisfied are you with your abilities? .788     
How satisfied are you with your ability to learn new 
information? 
.787     
How satisfied are you with yourself? .749     
How satisfied are you with the way your body looks? .588   .448  
How would you rate your memory? .458     
How much do any feelings of depression bother you?  .908    
How much do any feelings of sadness or depression 
interfere with your everyday functioning? 
 .900    
How worried do you feel?  .844    
How often do you have negative feelings, such as blue 
mood, despair, anxiety, depression? 
 .661    
How positive do you feel about the future?   .783   
How much do you value yourself?   .776   
How much do you enjoy life?   .692   
How much confidence do you have in yourself?   .674   
How well are you able to concentrate   .550   
How much do you experience positive feelings in your 
life? 
  .504  .504 
Do you feel inhibited by your looks?    .716  
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Is there any part of your appearance which makes you 
feel uncomfortable? 
   .692  
Are you able to accept your bodily appearance?     .781 
Do you generally feel content?     -.706 
 
5.2.5.2.3 Level of dependence domain  
The level of dependence domain has 16 items with mean scores ranging from “how dependent 
are you on medications?” at 1.56 (s.d. = .80) to “how well are you able to get around?” at 3.78 
(s.d. = .98). Three factors had eigenvalues greater than 1.0. The three factors contributed about 
66.6% to the observed variation and the first factor alone contributed about 43.0%. The highest 
loading in the first factor was “how satisfied are you with your capacity to work” at .884 (Table 
5.20). The highest loading in the second factor was with “how much do you need any medical 
treatment to function in your daily life” (.819) and the highest loading in the third factor was 
with “how much do any difficulties in your mobility bother you?” (.901). Further information is 
provided in Table 5.20 below. 
 
Table 5.20: Rotated component matrix for level of dependence domain items 
 Factor  
 1
st
 2
nd
 3
rd
  
How satisfied are you with your capacity to work? .884   
How would you rate your ability to work? .865   
Do you feel you are able to carry out your duties? .859   
Are you able to work? .857   
How satisfied are you with your ability to perform your daily living 
activities? 
.789   
To what extent are you able to carry out your daily activities? .720   
How well are you able to get around? .705   
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How satisfied are you with your ability to move around? .600   
How much are you bothered by any limitations in performing 
everyday living activities? 
.514 .423 .485 
To what extent do you have difficulty in performing your routine 
activities? 
.448  .422 
How much do you need any medical treatment to function in your 
daily life? 
 .819  
How much do you need any medication to function in your daily 
life? 
 .816  
To what extent does your quality of life depend on the use of 
medical substances? 
 .787  
How dependent are you on medications?  .478  
How much do any difficulties in mobility bother you?   .901 
To what extent do any difficulties in movement affect your way of 
life? 
  .899 
 
5.2.5.2.4 Social relationship domain 
The social relationship domain has 16 items with average scores ranging from 2.17 (s.d. = 1.21) 
with “how well are your sexual needs fulfilled?” to 4.34 (s.d. = .95) with “how often do you feel 
you are discriminated against because of your health condition?”. Four factors had eigenvalues 
greater than 1.0. The four factors contributed about 62.7% to the observed variation while the 
first factor alone contributed about 27.7%. The highest loading in the first factor was with the 
item “do you feel happy about your relationship with your family members?” at .795 (Table 
5.21). The second factor’s highest loading was with the item “how would you rate your sex 
life?” at .853, the third factor’s highest loading was with “to what extent can you count on your 
friends when you need them?” at .865 and the highest loading in the fourth item was with “how 
much do you feel alienated from those around you?” at .758.  
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Table 5.21: Rotated component matrix for the social relationship domain items 
 Factor 
 1 2 3 4 
Do you feel happy about your relationship with your 
family members? 
.795    
How satisfied are you with the support you get from your 
family? 
.784    
How satisfied are you with your ability to provide for or 
support others? 
.760    
To what extent do you feel accepted by the people you 
know? 
.744    
To what extent do you feel accepted by your community? .693    
Do you get the kind of support from others that you 
need? 
.610    
How alone do you feel in your life? .507   .434 
How would you rate your sex life?  .853   
How satisfied are you with your sex life?  .804   
How satisfied are you with your personal relationships?  .651 .421  
How well are your sexual needs fulfilled?  .646   
To what extent can you count on your friends when you 
need them? 
  .865  
How satisfied are you with the support you get from your 
friends? 
 .404 .739  
How much do you feel alienated from those around you?    .758 
Are you bothered by any difficulties in your sex life?    .753 
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How often do you feel you are discriminated against 
because of your health condition? 
    
 
5.2.5.2.5 Environmental domain 
The environmental domain has 32 items with average scores ranging from 1.71 (s.d. 1.10) with 
the item “have you enough money to meet your needs?” to 4.20 (s.d. = 1.13) with “how concern 
are you with the noise in the area where you live in?”. Six factors had eigenvalues greater than 
1.0. The highest loading in the first factor was “how satisfied are you with opportunities to learn 
new information?” (.817), the highest loading in the second factor was “how much do you like 
where you live?” (.786) and the highest loading in the third factor was “to what extent do you 
have problems with transport?” (Table5.22). In the fourth factor, the highest loading was 
observed with “do you have financial difficulties?” (.875); in the fifth factor the highest loading 
was with “How satisfied are you with your physical environment (e.g. pollution, climate, noise, 
attractiveness?” (.637) and in the sixth factor, the highest loading was observed under the item 
“to what extent do you have opportunities for leisure activities?” (.565). All six factors 
contributed about 61.88% to the observed variation with the first factor only contributing 
about 29.00%.  
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Table 5.22: Rotated component for the environmental domain items 
 Factor 
 1
st
 2
nd
 3
rd
 4
th
 5
th
 6
th
 
How satisfied are you with your opportunities to learn 
new information? 
.817      
How satisfied are you with your opportunities for 
acquiring new skills? 
.807      
How satisfied are you with your physical safety and 
security? 
.715      
How satisfied are you with the way you spend your spare 
time? 
.713      
How satisfied are you with your access to health 
services? 
.671  .417    
How satisfied are you with the social care services? .664      
How satisfied are you with the conditions of your living 
place? 
.636 .412     
How satisfied are you with the climate of the place 
where  you live? 
.611      
How would you rate the quality of social services 
available to you? 
.527      
How much are you able to relax and enjoy yourself? .416      
How much do you like it where you live?  .786     
How comfortable is the place where you live?  .785     
Do you feel you are living in a safe and secure 
environment? 
 .707     
How much do you enjoy your free time?  .622     
How safe do you feel in your daily life? .419 .617     
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How healthy is your physical environment?  .587     
To what extent do you have problems with transport?   .823    
How much do difficulties with transport restrict your life?   .787    
To what extent do you have adequate means of 
transport? 
  .671    
How easily are you able to get good medical care?   .616    
How satisfied are you with your transport?   .570    
To what extent do you have opportunities for acquiring 
the information that you feel you need? 
  .467   .404 
Have available to you is the information that you need in 
your day-to-day life? 
  .466   .456 
Do you have financial difficulties?    .875   
How much do you worry about money?    .868   
Have you enough money to meet your needs?    .756   
How satisfied are you with your financial situation?    .676   
How satisfied are you with your physical environment 
(e.g. pollution, climate, noise, attractiveness)? 
    .637  
How much do you worry about your safety and security?     .604  
How concerned are you with the noise in the area you 
live in? 
     -.582 
To what extent do you have the opportunities for leisure 
activities? 
    .510 .565 
To what degree does the quality of your home meet your 
needs? 
 .404    .454 
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 5.2.5.2.6 Spirituality/religion/personal belief (SRPB) domain 
The SRPB domain has 15 items and the mean scores on the items ranged from 2.61 (s.d. = 1.24) 
with the item “to what extent do any feelings you are suffering from a fate or destiny that 
bothers you?” to 4.05 (s.d. = .84) with the item “do your personal belief give meaning to your 
life?”. Two factors had eigenvalues greater than 1.0. The two factors contributed about 70% to 
the observed variations with the first factor alone contributing about 57%. The highest loading 
in the first factor was by the item “how concerned are you about how you will die?” (.904) while 
the highest item in the second factor was “to what extent do your personal beliefs give you the 
strength to face difficulties?” at .838 (Table 5.23).   
 
Table 5.23: Rotated component matrix for the spirituality/religion/personal belief domain 
items 
 Factor 
 1
st
 2
nd
 
How concerned are you about how where you will die? .904  
How bothered are you by the thought of not being able to die the 
way you would want to? 
.896  
How much do you blame yourself for your HIV infection? .887  
How guilty do you feel about being HIV positive? .875  
To what extent are you concerned about how people will remember 
you when you are dead? 
.872  
How much do you worry about death? .868  
How much preoccupied are you about suffering before dying? .852  
To what extent are you concerned about your HIV status breaking 
your family line and your future generations? 
.847  
To what extent are you bothered by people blaming you for your 
HIV status? 
.847  
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To what extent do you feel guilty when you need the help and care 
of others? 
.816  
How much do you fear the future? .755  
To what extent do any feelings you are suffering from fate or 
destiny bother you? 
.627  
To what extent do your personal beliefs give you the strength to 
face difficulties? 
 .838 
To what extent do your personal beliefs help you to understand 
difficulties in life? 
 .811 
Do your personal beliefs give meaning to your life?  .691 
 
THE DEVELOPMENT OF A SHORTER VERSION OF THE WHOQOL-HIV THAT ADEQUATELY 
REPLICATES THE DOMAINS OF THE LONG VERSIONS OF THE WHOQOL-HIV THROUGH ITEM 
REMOVAL TECHNIQUES 
 
5.2.6 Shortening of the WHOQOL-HIV instrument  
Item analysis was done by calculating the corrected item – total correlation and Cronbach’s 
Alpha if item deleted. Given the transient nature of the HIV and AIDS, the analysis was done by 
duration on treatment which has been shown to be linked to wellbeing in terms of immune 
reconstruction.  With this, the analysis was done separately for baseline, six and 12 months 
respectively, for each of the six domains. The result of the analysis can be found in Appendixes 
5.10 to 5.15. The results consistently showed that the items that had higher correlation with 
the rest of the items in each of the respective domains varied with time. The best two items in 
terms of the correlation coefficients were in some instances common across the three 
measurement times. Extracts of the best two items with the highest corrected item – total 
correlation coefficient are presented in Table 5.24.  
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Bearing in mind that each domain is made up of many subscales, it was notable that the best 
two items under each domain were more likely to come from specific subscales. This was often 
the case for the six and 12 months analysis, respectively. The items (questions) may not be the 
same but fell under the same subscale in the respective domains.  
 
For instance, under the physical domain, the best two items for the baseline analysis were from 
the sleep and pain subscales, six months best two were from fatigue while the 12 months best 
two were from fatigue and pain, respectively. The item “how bothered are you by fatigue” was 
common at six and 12 months.  Under the psychological domain, the best two items for the 
baseline analysis were from self esteem and negative feeling, the six months best two items fell 
under body image and self esteem while the 12 months best two items fell under body image 
and negative feeling. The item “how much do any negative feeling of sadness or depression 
interfere with your everyday functioning” featured in baseline and 12 months while the item 
“how satisfied are you with the way your body looks” featured in the six and 12 months 
analyses. 
 
In the level of dependence domain, the best two items were from the work subscale at baseline 
and at six and 12 months the best items were from the work and activity of daily living 
subscales respectively. The item “how would you rate your ability to work” was common to the 
baseline and 12 months analyses. 
 
Under the social relationship domain, the item “how satisfied are you with your personal 
relationship” featured in all three analyses (baseline, six and 12 months). In addition, an item 
from sex featured at baseline, an item from inclusion featured at six months while an item from 
support featured at 12 months. In the environmental domain, all three analyses had different 
items from the environmental subscale, the baseline data had an item from information, the six 
month analysis had a item from the leisure subscale while the 12 months analysis had an item 
from the safety subscale. Lastly, SRPB domain had best two items falling under the death 
subscale for the baseline and six months analysis respectively, even if the items were not 
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always the same, but the item “how bothered are you by the thoughts of not being able to die 
the way you would want to”. On the other hand the 12 month analysis under the SRPB domain 
had its best two items from the forgiveness and future subscales.  
 
Table 5.24: Items with the highest corrected item – total correlation coefficient by WHOQOL-
HIV domain and time of interview/duration on treatment  
Physical domain  
 Baseline  
 To what extent do you feel that (physical) pain prevents you from doing what you need to 
do? 
 Do you have any difficulties with sleeping? 
 6 months  
 How much are you bothered by fatigue? 
 How easily do you get tired? 
 12 months  
 How much are you bothered by fatigue? 
 Do you worry about your pain or discomfort? 
Psychological domain  
 Baseline  
 How much do you value yourself? 
 How much do any feelings of sadness or depression interfere with your everyday 
functioning? 
 6 months  
 How satisfied are you with the way your body looks? 
 How satisfied are you with yourself? 
 12 months  
 How satisfied are you with the way your body looks? 
 How much do any feelings of sadness or depression interfere with your everyday 
functioning? 
Level of dependence domain  
 Baseline  
 Are you able to work? 
 How would you rate your ability to work? 
 6 months  
 How satisfied are you with your capacity to work? 
 Do you feel able to carry out your duties? 
 12 months  
 How would you rate your ability to work? 
 Do you feel able to carry out your duties? 
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Table 5.24 (continued): Items with the highest corrected item – total correlation coefficient 
by WHOQOL-HIV domain and time of interview/duration on treatment 
Social relationship domain  
 Baseline  
 How satisfied are you with your sex life? 
 How satisfied are you with your personal relationships? 
 6 months  
 How satisfied are you with your personal relationships? 
 To what extent do you feel accepted by the people you know? 
 12 months  
 How satisfied are you with the support you get from your friends? 
 How satisfied are you with your personal relationships? 
Environmental domain  
 Baseline  
 How comfortable is the place where you live? 
 How satisfied are you with your opportunities to learn new information? 
 6 months  
 How satisfied are you with the conditions of your living place? 
 How satisfied are you with the way you spend your spare time? 
 12 months  
 Do you feel you are living in a safe and secure environment? 
 How healthy is your physical environment? 
SRPB domain  
 Baseline  
 How bothered are you by the thought of not being able to die the way you would want to? 
 How concerned are you about how where you will die? 
 6 months  
 How much do you worry about death? 
 How bothered are you by the thought of not being able to die the way you would want to? 
 12 months  
 How guilty do you feel about being HIV positive? 
 To what extent are you concerned about how people will remember you when you are 
dead? 
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5.3 Discussion  
5.3.1 The health related quality of life of people living with HIV and AIDS in Limpopo Province 
This chapter started by describing the socio-demographic characteristics of this study’s 
participants given that an individual’s perceived quality of life is determined by their socio-
cultural and demographic characteristics (Spring et al., 2005; WHO, 1983). This assertion was 
demonstrated in this study through the observed differences in the participants’ quality of life 
based on their socio-cultural and demographic characteristics. Most of the participants were 
females who were married with children and unemployed. This trend was observed in Table 
5.1. 
 
The above group does not only characterize the typical AIDS survivals on treatment but also 
reflects a group that may be socio-economically less able to cope with living with the virus 
(Venter et al., 2009). In terms of the disease prevalence, females  are at a higher risk of HIV 
infection when compared to males (UNAIDS, 2004). Some of this higher risk can be linked to the 
biological make up of women. The vulnerability of females to HIV and AIDS is also linked to their 
reduced power in relationships given their gender-linked socio-cultural and economic 
dependence on their male partners. This also means that they have less access to household 
and community resources which may include HIV and AIDS treatment and related social 
support services (Taylor, 1996). This phenomenon is expected to be exacerbated by the high 
poverty and unemployment noted by this study. Research studies have for instance noted that 
food insecurity and hunger is higher among HIV positive individuals. One study noted that this 
risk was 17 times more among PLWH when compared to the general population (Normen et al., 
2005;) Poverty is also known to be a major obstacle to treatment and care (Simwaka et al., 
2006). The effect of unemployment and poverty may be perpetuated by the need for frequent 
and repeated visits to health facilities for treatment and care. This trend has implications for 
the affordability of other household necessities like food, water, electricity, education and 
clothing (Collins et al., 2007).  This creates a vicious cycle and has implications for health, 
wellbeing, quality of life and survival of people living with AIDS. Tables 5.4 and 5.5 show the 
differences between the quality of life of males and females and support the proposition that 
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males performed better in terms of financial resources and the psychological domain 
components.  
 
In the context of the above, there were notable significant differences in the perceived health 
related quality of life of employed and unemployed people as illustrated in Tables 5.7 and 5.8. 
This study showed that unemployed people perceived themselves to be having less social 
support and fewer social relationships. This observation is despite their benefits in the face of 
unemployment.  This study also noted that negative feeling was reported to be more profound 
among the unemployed. This observation is equally worrying given its role in psychological 
adjustment, acceptance of the virus, use of health and social services and improved chance of 
recovery. The deleterious effect of negative feeling has been underscored by the finding of 
Study I and the theoretical model on “achieving a balance” in HIV and AIDS by Murdaugh 
(1998).  
 
Various analyses in this study also suggest strong links between the environmental domain and 
its financial resource subscale and the biological markers of HIV and AIDS. Similarly, 
unemployed people perceived themselves to be worse in terms of their “dependence on 
medication or treatment”. This may translate to mean that unemployed people are more likely 
to have undesirable health outcomes. This assertion is in consonance with the suggestions that 
greater burden of AIDS symptoms are experienced by economically more disadvantaged 
groups. As well, this study finding indicates that unemployed people had significantly lower 
scores in subscales that fall under the physical domain (Makoae, 2005). In this regard, Ruutel et 
al. (2009) have described employment status as one of the most influential contributors to 
HRQOL while Worthington and Krentz (2005) noted that employment and higher income are 
related to better quality of life among PLWH. Ruutel et al., (2009) added that employment does 
not only provide financial resources but also a source of structure, social support, role identity 
and meaning.  
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The study also showed that females were more likely to report better perceptions of “level of 
dependence”, “work capacity” and ‘activity of daily living”. These elements may be reflective of 
better health and activity tolerance among females when compared to males. This finding is in 
agreement with the findings of the original instrument validation study by the WHOQOL-HIV 
Group (2004). In the same context, the study’s data showed that females were more likely to 
have a suppressed viral load and CD4 count greater than 500 cells/µl over time when compared 
to males. This finding agrees with studies that have shown greater benefits of ART over time in 
females when compared to males (Moore et al., 2001).  Other studies have further shown that 
females are more likely to have a lower viral load when the CD4 cell count was greater than 350 
cells/µl (Donnelly et al., 2005).  
 
Many of the health related quality of life subscales and domains varied significantly by marital 
status. These differences are presented in Table 5.5 and Appendix 5.4. These differences were 
inconsistent but highlight the fundamental contribution of the presence or absence of a partner 
in shaping the quality of life of people living with HIV and AIDS. The married participants had 
significantly higher average scores on social support, financial resources and social 
relationships. These observations are in consonance with the findings of Jatoi et al (2007) that 
have linked marriage with longer and better quality of life (Rohrbaugh et al., 2005; Gore et al., 
2006).  This phenomenon has also been associated with the fact that marriage may provide 
better social support and financial resource needed to better access the relevant health service 
(Denberg et al., 2005; Iwashyna and Christakis, 2003). All the other instances where 
divorced/separated/widowed women may have performed better than married women may be 
linked to their autonomy and ability to cater for themselves. 
 
Based on the observed differences in quality of life domain and subscale scores by support 
group membership seen in Table 5.9 and Appendix 5.7, it may be concluded that support 
groups attracted people with lower financial standing and with less social support and 
relationships. The tendency of support groups to attract people requiring more professional 
attention and support have also been noted by a similar study (Buck et al., 1999). The finding of 
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this study and the reviewed literature further suggest that such people (with lower financial 
standing and with less social support) are more likely to be in a poorer state of health and 
experience more HIV related symptoms. The ability of support groups to attract such people is 
important given its established gains for such individuals.  In line with the findings of Study I, 
other studies have shown that support groups help to reduce isolation and improve quality of 
life (Crook et al., 2005). Support group service should hence form part of the essential services 
for people living with HIV and AIDS given the chronic nature of the disease and their many 
unmet needs. The findings of this study suggest that support groups help to facilitate 
psychological adjustment to the disease. This observation is premised on the fact that the 
aggregated analysis in Appendix 5.7 showed that people in support groups had significantly 
higher scores of self-esteem, body image, psychological standing and positive feeling scores 
when compared to those people not in support groups.  
 
Similarly, other studies have demonstrated that support groups help deal with the 
manifestations of poor adjustment such persistent denial and behavioral disengagement that 
avoid dealing with change (Tunner-Cobb et al., 2002). Poor coping and adjustment have been 
linked by other studies to immunological deterioration (Freeman, 2004). This is important as 
support groups could help augment the negative effect of the observed lower scores on the 
symptoms and financial resources subscales among its members. This assertion is based on the 
fact that these factors are known predictors of poor quality of life and poor immunity (Preeze 
and Peltzer, 2009).  
 
In agreement with the literature review section of this report, the above variations in HRQOL 
based on socio-demographic characteristics further demonstrate the complexity of defining 
quality of life (Tyrrell et al., 2005; Kimmel, 2000; Ferrans and Power, 1992). This variation was 
again seen in the differences observed between the three cultural groups. While it is beyond 
the scope of this study to describe the reason for such cultural variations, other studies have 
among other factors attributed the observed differences to societal attitudes and inherent 
outlooks and expectations in respective cultures (Buck et al., 1999). In the same context, such 
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cultural differences in disease expression have been documented and described by Guillemin et 
al. (1993).  Buck et al., (1999) add that different cultural groups may not give the same 
weighting to certain health related parameters. In this regard, Dodrill et al., (1984) suggest that 
some cultural groups have lesser likelihood of acknowledging the presence of psychosocial 
problems. The knowledge of this variation is important in planning care and support that is 
meaningful and responsive to the needs of recipients based on their expectations. Hence, 
achieving one of the cardinal objectives of quality of life assessment of allowing individuals to 
gauge their health will not be achieved if cultural interpretations of such assessments are not 
considered.  
 
5.3.2 Relationship between the biological markers HIV and AIDS and the HRQOL measure and 
their change over time  
The correlation was weak between CD4 counts and the overall quality of life domains. Similarly, 
viral load suppression status (Tables 5.11 and 5.12) had very low correlation coefficients with 
overall quality of life.  Despite this, the findings corroborate the outcomes of studies that have 
shown that the economic standing and psychological state of an individual impact on their 
immune status and HIV disease progression (Freeman, 2004). Another study conducted among 
another cultural group in South Africa reported similar correlations between quality of life 
domains and CD4 cell counts (Venter et al., 2009). Jia et al., (2007) further demonstrated a 
significant positive longitudinal association between CD4 cell count and emotional status of 
people living with HIV and AIDS. The reported correlations were, however, too low for quality 
of life measures to become direct predictors of CD4 cell count and viral load. This observation 
may be linked to the highly subjective nature of the quality of life measure and the many socio-
cultural and demographic factors that influence their variation. Such variations may be 
profound even in the most homogenous populations given the expected differences based on 
age, sex, religious beliefs, ethnic group, marital status, economic standing and the extent of 
social support and access to treatment and other health services. This assertion draws on the 
finding of this and other studies that have shown marked differences based on these variables 
(Preez and Peltzer., 2009; Peltzer and Phaswana-Mafuya, 2008; WHOQOL-HIV Group, 2004). 
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The study by Venter et al., (2009) for instance, showed marked differences in correlation 
coefficient across the various quality of life domains and CD4 cell count by simply splitting their 
study population by sex. The general prominence of the psychological, environmental and level 
of dependence domains noted in this and related studies may require a further analysis to 
explore the link between the individual items on scales and the biological markers (CD4 cell 
count and viral load).  
 
The study also noted marked differences in quality of life between the baseline and the other 
points of data collection following treatment initiation. This finding agrees with studies that 
have shown such improvements in the perceived quality of life over time (Saunders and 
Burgonye, 2002; Solomon et al., 2009). This observation highlights the benefits of treatment in 
improving the health and health related quality of life of people living with HIV and AIDS. 
Similarly, other studies  have demonstrated significant improvements in the quality of life of 
people with advanced HIV following treatment initiation (Nieuwkerk et al., 2001; Cohen et al., 
1998). Furthermore, this study found that the quality of life of people with low CD4 cell counts 
and unsupressed viral load also increased with treatment initiation. There was no significant 
difference between the six and 12 month scores in three domains (psychological, level of 
dependence and the environmental domains). This may suggests that the study cohort did not 
improve in these domains between the
 
sixth and 12
th
 month post treatment initiation or the 
improvements were too negligible for the participants to notice when compared to the 
improvement they may have noted in the first six months. The participants however, had a 
significantly higher score in the physical, social relationships and the SRPB domains at six 
months when compared to their score at 12 months. This finding agrees with the findings of 
Solomon et al. (2009) which showed high improvements in the quality of life in the first six 
months and this improvement diminished over time. This observation should be read against 
the backdrop of the subjective nature of the assessment and the marked improvement in 
clinical symptoms at six months and stabilization over the following six months.  
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5.3.3: Validation and shortening of the WHOQOL-HIV instrument  
All the six WHOQOL-HIV domains reported very high reliabilities even though two (physical 
environment and sexual activity) of their 29 subscales reported relatively low Cronbach’s Alpha. 
The reliability values noted in this study are similar to those found in the original field test of 
the WHOQOL-HIV instrument (WHOQOL-HIV Group, 2003). The original field study also 
reported some relatively low Cronbach’s Alpha in specific subscales in the environmental and 
SRPB domains.  
 
Bearing in mind the high reliability noted in the respective domains, the factor analysis showed 
that each domain had multiple dimensions. This finding is in line with the original instrument 
design as each domain is made up of multiple subscales or facets (WHOQOL – HIV Group, 2004, 
2003). The factors identified in this study almost replicate those suggested in the original 
instrument.  
 
Convergent validity of this instrument was established by comparing the upper and lower 
confidence limits of the differences in scores of similar domains and subscales of the WHOQOL-
HIV instrument and the MOS-HIV instrument (Figure 5.3). This comparison is clinical rather than 
statistical and is based on the Bland-Altman Limits of Agreement (Bland and Altman, 1986, 
1991). The plots generally showed agreements between both instruments with differences in 
confidence interval of less than 1.0 in the various domains. Furthermore, Pearson Correlations 
of the similar domain and items (in the MOS-HIV and WHOQOL-HIV) in Table 5.17 showed 
moderate correlations between the respective subscales/domain. This indicates that the 
measures are related but each instrument still has its unique value over the other. The review 
by Pesudovs et al., (2007) indicates that moderate correlations (>.3 and <.9) should be ideal for 
any meaningful convergent validity. 
 
The literature review of this report underscored the importance of considering target 
population characteristics in instrument development and selection. This consideration was 
apparent in this study as efforts to reduce the items through item-total correlation did not yield 
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similar results at the three times of data collection. This assertion supports the finding of Study I 
which indicated that the clinical concerns and psychosocial needs of people living with HIV and 
AIDS vary greatly with time and treatment. A similar study for instance showed that the same 
quality of life instrument cannot be used for individuals with glaucoma and those with low 
vision (Lamoureux et al., 2007). Given the very transient nature of HIV and AIDS symptoms 
across the different biological (Gurunathan et al., 2009) and psychological (Murdaugh, 1998) 
stages of the disease, an instrument that considers all the stages in item selection will be most 
appropriate. This is against the consideration that an instrument that specifically targets newly 
diagnosed individuals with no symptoms may not be suitable for individuals with AIDS. 
 
In all, this section of the study was able to describe the HRQOL of PLWH in Limpopo Province 
over time and noted the weak to no association between HRQOL indicators and the biomedical 
markers of HIV/AIDS. The study mostly underscores the multiple factors that affect the natural 
history of HIV/AIDS. Some of such factors are time, treatment and the socio-demographic 
characteristics of the individual. This proposition is also predicated on the observation that an 
individual’s perceived quality of life and wellbeing is also defined by their cultural and religious 
beliefs and will hence vary by cultural groups. With all the variations observed in the study, 
including the differences in the findings of the time specific and aggregate analyses, one can say 
that PLWH are highly heterogeneous and should only be grouped together with caution in 
research studies and intervention programmes. This observation made it impossible to create a 
universal and shorter HRQOL instrument from the existing WHOQOL-HIV instruments.         
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CHAPTER SIX 
CONCLUSIONS AND RECOMMENDATIONS  
6.1 Conclusions  
The main objective of this study was firstly to explore the HRQOL and the experiences of PLWH 
in seeking care and support services and secondly, to validate the ability of the WHOQOL-HIV 
instrument to measure the health related quality of life of PLWH among the three cultural 
groups in Limpopo Province over time. With this objective, the study followed various research 
methods with literature support leading to key qualitative and quantitative findings. Following 
this process, the conclusions below can be jointly made about the qualitative and quantitative 
components of this study.  
 
There are a variety of factors that impact on the HRQOL of PLWH in Limpopo Province. These 
factors can be categorized as physical, mental and external. The physical factors are the 
biological problems; the mental factors include the psychological problems, fears and concerns; 
and the external factors are environmental issues that are largely beyond the control of the 
individual. The extent to which the factors affect quality of life is predicated by their frequency 
of occurrence and severity, which is in turn, dependent on the individual’s duration on 
treatment, membership of a HIV support group, disclosure of their HIV status as well as their 
socio-demographic and economic standing. In this regard, individuals who are on treatment for 
a longer time have disclosed their HIV status (to at least their family members), and belong to a 
support group.  Individuals with better socio-demographic and economic status are more likely 
to have a better quality of life and better ability to live with the virus. 
 
Among other things, the above proposition highlights the benefit of ART and support groups as 
they help to restore health and hope to individuals who often get despondent about life, 
survival and the future following a positive HIV diagnosis and AIDS. On a positive note, the 
participants of this study had good access to health service, particularly ART, but deplored the 
quality of social support services such as disability grants and access to housing.  
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ART was generally rated and notably useful in improving the quality of life of the participants, 
including those who maintained an unsuppressed viral load and with low CD4 cell counts over 
time. Most patients indicated that they will continue to adhere to treatment despite its 
associated morphological changes and other side effects. This position was also confirmed by 
the quantitative study, with the generally improved quality of life and immune reconstruction 
following treatment initiation.   
 
A notable obstacle to commencing treatment and the utilization of support services were late 
HIV diagnosis and the nondisclosure of HIV status. On this premise, the study participants often 
recounted how their lives changed for the best following their serostatus disclosure. This study 
noted that none and late disclosure of HIV status was often driven by the fear of rejection and 
reprisal from their families and the community.  
 
The above fear was mostly untrue particularly at family level, with family members accepting 
and supporting HIV positive family members. In most cases, the family turned out to be the 
strongest source of financial and psychological support for the participants. Health care workers 
also provide similar kinds of support to known PLWH. Elements of stigma still exist at 
community level and are driven by fear of HIV infection. The common places where PLWH get 
stigmatized are socio-cultural and religious gatherings like funerals, weddings and churches.  
 
In the same context, social support from family members, HIV support groups and health 
workers tended to facilitate psychological adjustment to living with the virus and creating new 
personal meaning of living with HIV and AIDS. Psychosocial support does not only buffer the 
effect of the physical factors but also alleviates some of the devastating fears of living with the 
virus. It provides hope for the future and reasons to live.    
 
Psychological adjustment to living with the virus has positive consequences for the use of 
health and social support services and the optimization of health and recovery.  
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While diarrhoea, pain and fatigue were the most commonly cited physical problems, the study 
noted that all the 14 core factors affecting the quality of life of PLWH are interlinked in a vicious 
circle where one factor perpetuates the effect of another factor. For instance, fatigue will result 
in insomnia and vice versa. The link between these factors has the propensity to negatively 
trigger all the other factors identified by this study. This point emphasizes the benefits of the 
comprehensive management of HIV/AIDS and that suboptimal management of any of the 
factors has a strong negative bearing on the other factors.  
 
Furthermore, the observed improvement in HRQOL and biomedical markers over time may 
largely be attributed to the cumulative effect of treatment and recovery through the gradual 
immune reconstruction process, but psychological adjustment through the passage of time is 
equally important. In this regard, efforts to facilitate the treatment and rehabilitation of the 
physical, mental and external domains are essential given the strong interplay between them.          
 
It was also not surprising that financial worry ranked among the highest concern of PLWH in 
both the qualitative and quantitative studies. This assertion should be read against the 
backdrop that the debilitating effect of AIDS often leads to job loss and the liquidation of other 
forms of financial security.  In this regard, the reported needs of PLWH anchor on financial 
insecurity including matters of housing and tertiary education for children and aggravated by 
the poor and limited access to the disability grant.  
 
What is clear from the qualitative and quantitative studies is that recovery from AIDS to living 
as normally as possible with the virus is achievable if all modifying factors are harnessed. This 
process can be further improved by programmes that facilitate socio-economic rehabilitation. 
This proposition is further supported by the marked differences in the quality of life and the 
extent of immune reconstruction of people with and without formal employment and how 
social isolation perpetuates poor quality of life and recovery. 
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This study also predominantly showed weak to no association between the biomedical markers 
of HIV/AIDS and the HRQOL indicators. The biomedical markers are therefore not accurate 
predictors of the HRQOL of an individual. In this regard, an individual may experience significant 
improvement in their biological markers but still be unfit to cope with living as normally as 
possible, including earning a living.  While the quantitative study showed significant 
improvements in HRQOL over time, the mean differences between the six and 12 months were 
often very small and not significant.   
 
The two paragraphs above discourage reliance on CD4 cell count and viral load as valid criteria 
for eligibility for disability grants and reemphasize the need for further socio-economic 
rehabilitation and support of PLWH following immune reconstruction. 
 
Much value was placed on physical symptoms as determinants of quality of life. A HRQOL 
instrument that is mostly constituted by measures of AIDS specific symptoms may provide a 
better link between HRQOL and the biomedical markers. This assertion may contradict the 
notion that HRQOL is multifaceted but should be read against the backdrop that the 
determinants of HRQOL among PLWH are interlinked and interrelated. This suggestion is 
further supported by the high correlations between the various domains of the WHOQOL-HIV 
instrument. This point does not undermine the value of a multifaceted instrument as it provides 
a detailed and holistic overview of the impact of HIV/AIDS on the individual. However, a 
symptom centered instrument exploring the frequency and severity of incidences can be used 
to form a brief and concise instrument that can be used routinely to predict the state of the 
other dimensions of quality of life and biomedical markers and thus make recommendations in 
routine care of PLWH.  
 
Despite the above suggestion, the WHOQOL-HIV instrument was noted to be reliable and valid 
in measuring the HRQOL in the three languages. The study also showed the multidimensional 
nature of the instrument. This point corroborates the multiple determinants of quality of life 
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identified in the qualitative study and the socio-economic and demographic variations within 
each category of determinants.  
 
The shortening of the WHOQOL-HIV is highly discouraged by this study. This is based on the fact 
that PLWH are highly heterogeneous given the bio-psychosocial trajectory of the disease which 
can be cyclic depending on the balance between the modifying and intervening factors. A 
simple analogy to this is that the needs and concerns of a newly HIV infected and undiagnosed 
individual are different from those of a person with full blown AIDS who is not on treatment as 
well as  those of a psychologically well adjusted individual on treatment with stable biological 
markers of HIV. This position is well supported by the findings of the qualitative and 
quantitative components of this study.  
 
In all, ethnicity was a major determinant of quality of life with significant variations observed 
along its divide. This observation underscores the role of the socio-demographic characteristics 
of an individual in shaping their perceived position in life in relation to their goals, expectations, 
standards and concerns.   
  
6.2 Recommendations  
In view of the study findings and conclusions of the qualitative and quantitative components of 
this study, the following recommendations are proposed: 
- Multidisciplinary teams should be constituted and actively involved in care, treatment 
and support of all PLWH to ensure that appropriate attention is given to the physical, 
mental and external factors affecting the quality of life. 
- Community awareness focusing on how to live with HIV/AIDS and/or individuals with 
HIV/AIDS is needed to address the issues of stigma that mostly stem from the fear of 
infection. Such programmes should target religious and cultural leaders and groups, 
given that a lot of the stigmatization was noted to occur mostly at these places.  
- Tools to profile the physical, mental and external needs of PLWH should be developed 
and used given variations in such needs across the different categories of PLWH.   
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- PLWH and their family members should be educated about basic self care and self help 
measures to deal with the common signs and symptoms of HIV/AIDS like pain, 
diarrhoea, fatigue, cough, dermatological problems and insomnia 
- The above recommendation should include non-pharmacological approaches like 
hygiene practices, dietary adjustments that are feasible, appropriate exercise 
programmes, relaxation techniques and other plausible indigenous approaches. These 
will help limit undue reliance on medications and their consequences and hopefully 
increase self determination and self care. 
- Factors to promote psychological adjustment (like disclosure of HIV status, family 
support, support group membership) should be facilitated given their importance in 
determining the natural history of the disease, use of health and social support services, 
recovery and the quality of survival of PLWH.         
- CD4 cell count and viral load should not be used as a measure of the overall wellness of 
people living with HIV/AIDS. 
- CD4 cell count and viral load should not be used as eligibility criteria for accessing 
disability grants  
- There is a need to explore ways of developing a brief and universal quality of life tool 
that replicates the existing quality of life tools and correlates with biomedical markers of 
HIV/AIDS. A symptom focused tool that measures the severity and frequency of 
commonly HIV/AIDS related symptoms may serve this purpose.  
- Programmes to help PLWH who may have lost their jobs as a result of illness to get back 
to work or to continue to financially support PLWH till they are able to support 
themselves should be considered. 
- The potentials of support groups of PLWH needs to be fully explored and harnessed 
given their  benefits particularly among the most vulnerable of PLWH. 
- More research to further understand and link the bio-psychosocial trajectory of 
HIV/AIDS is required to better delineate the different categories of PLWH and guide the 
precision and responsiveness of intervention programmes to suit the different 
categories.
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Appendix 2.1: WHOQOL-HIV domains and subscales 
 
 
  
200
Appendix 3.1: Study I information sheet and consent form (Pedi, Tsonga and Venda 
translations were provided). 
Validation and Longitudinal Application of the WHOQOL-HIV Questionnaire among People 
Living With HIV and AIDS in Limpopo Province, South Africa 
 
Introduction 
Good morning/afternoon. I am Mr. Jude Igumbor, a doctoral student at the University of the 
Witwatersrand. I am is gathering information about the health related quality of life and the 
experiences of PLWH with health and social services through this research study. I would be 
grateful if you would be willing to assist by responding to questions related to this research. 
You will be interviewed as a group with your support group members and it takes about 45 
minutes of your time. 
 
Purpose of the Study  
The aim of this study is to describe how you perceive your quality of life and your experiences 
in seeking care and support services. We started this study because we have seen the 
importance of involving you to help health care providers to better understanding your health 
and things that affect it. The Research Ethics Committee of the University of the Witwatersrand 
has approved the study protocol. This research is being conducted in hospitals based support 
groups across Limpopo Province including yours. 
 
Procedures  
We will interview you about your overall health, wellbeing and experience with health and 
social services. You will be asked to identify key issues influencing these things. To make sure 
that we properly capture what you have told us, we will like to record what the group says 
using a tape recorder. We will also like to make sure that your personal information is not 
captured in the recording by asking that you do not mention names during the discussion 
instead would like to give each other numbers that we can refer to each other in.   
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Your responses will remain confidential. Your personal information like your name or address 
will not be included in our data and report. The information that you will give us might also be 
inspected by the University of Witwatersrand, Human Research Ethics Committee (HREC) or 
other persons appointed by the HREC. Their involvement will be to make sure that your right 
and dignity is being protected by this research study. Your taking part in this study will not 
benefit you directly, but it may benefit others in the future.   
 
Right to Refuse or Withdraw 
Your participation in this study is voluntary.  If at any time you do not want to answer an 
interview question, you may skip that question.  Your decision to take part or not to take part in 
the interview or your decision not to answer any question will have no impact on your care in 
this hospital. 
 
The researcher will only interview you after you have agreed to participate and have signed this 
consent form.  You are free to ask questions before agreeing to participate 
 
Contact Numbers 
You are free to ask questions before agreeing to participate.  In case you have any questions 
you may contact Mr Jude Igumbor 011 717 5459 or 072 320 2155.  
 
This research has been approved protocol by the University of the Witwatersrand, Human 
Research Ethics Committee (HREC). This study has been structured in accordance with the 
Declaration of Helsinki (last updated: October, 2000) which deals with the recommendations 
guiding health researchers  involving human beings.  If you want any information regarding 
your rights as a research participant, or complaints regarding this research study you may also 
contact the Chairperson of the HREC, which is an independent committee established to help 
protect rights of research participants at (011) 717 2229 
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I would like to invite you to consider participating in this research study, entitled: “Measures of 
Quality of Life and Experiences with Care and Support Services among Persons Living with HIV 
Infection in Limpopo Province, South Africa”. 
 
 
Consent (Pedi, Tsonga and Venda translations were provided). 
 
We will require your approval by writing your name and signing in the space provided below: 
 
I ……………………………………… certify that the consent form has been read out to me and any 
questions I had, have been answered.  I give my consent and agree to participate in this study 
about the health related quality of life and experiences with health and social services among 
PLWH in Limpopo Province. 
 
Name of Hospital …………………. …………………………………………………………. 
  
 
Signature of Participant………………………                       Date………………………............... 
 
 
 
 
Signature of interviewer ………………      Date………………………............... 
 
 
 
 
 
 
  
203
Consent to audio tape the focus group discussion  
(Pedi, Tsonga and Venda translations were provided). 
 
The discussions regarding the research described above will be audio-taped to allow for an 
accurate recording of your responses to the questions.  
 
 
I ………………………………………................... certify that the consent form and information sheet of 
the study has been read out to me and any questions I had, have been answered.  I hereby give 
my consent to be audio-taped in this study about the health related quality of life and 
experiences with health and social services among people living with HIV and AIDS in Limpopo 
Province and I have been given a copy of this consent form.  
 
 
 
Signature of Participant………………………                                       Date………………………............... 
 
 
 
 
Signature of interviewer ………………      Date………………………............... 
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Appendix 3.4: Health and demographic data of Study II participants 
 
 
Interviews Schedule for Quality of Life and Access to Services  
 
Code 
number: 
      
 
Demographic Information  
1. What is your age in years? _____________________yrs. 
 
2. What is your sex  Male  Female  
3. What is your marital status? 
Married  Never married  Divorced   
Separated  Widowed     
  
4. Do have children Yes  No  
 
5. How many children do you have? _____________________ 
 
6. What is the highest level of education you have attained?  
No education  Primary 
certificate  
 Matric   
Tertiary 
certificate  
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7. Are your currently employed? Yes  No  
     
8. Where do you live (please ask for name of town\village and leave the name of location in 
the bracket only)? __________________________________________   
(___________________________________) 
9. The accommodation you live in is?    owned by your family        rented by your family  
 sharing with another family 
10. The accommodation you live in is a?   shack   roundavel  formal  
11. What is your occupation? 
_______________________________________________________ 
12. What was your last occupation? 
__________________________________________________ 
13. What is your source of income and financial support? 
__________________________________ 
14. Do have medical aid? ________________________________________________  
15. Does your medical aid pay for all your medical expenses? _________________________   
16. What is your monthly household income? 
R__________________________________________ 
 
17. Have you disclosed your  HIV 
status to anyone ? 
Yes  No  
 
18. How many people have you disclosed your HIV status to: ____________________  
 
 
19. If you have not disclosed your HIV status, are you planning to 
disclose soon? 
Yes  No 
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20. Do you belong to a support group? Yes  No  
 
21. When were you diagnosed with 
HIV?___________________________________(years/months/weeks/days)  
 
22. How long have been on 
treatment___________________________________(years/months/weeks/days)   
 
23. What is your viral load: ______________________________________ 
 
24. What is your CD4 count: ______________________________________ 
25. Did you experience any side effect since you started treatment? 
Yes  No  
 
26. Have the side(s) effects been resolved?  
I have not experienced any side effects  
No the side effect has not been resolved  
Yes the side effects have been resolved  
 
27. If you experienced any side effect since you started treatment, kindly list the kind of side 
effect starting from the most serious to the least serious 
____________________________________ 
____________________________________ 
____________________________________ 
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28. In the last two weeks have you ever been to the hospital or clinic because you were sick 
and how many times?________________________ 
 
29. In the last two weeks have you ever been admitted to the hospital or clinic because you 
were sick and how many times? ________________________ 
 
30. Do you experience any health problem? 
Yes  No  
 
31. If you experience health problems, what are the common health problems that you 
experience? 
____________________________________ 
____________________________________ 
____________________________________ 
 
 Yes No 
32. Do you sometimes find it difficult to remember to take your 
medicine? 
  
33. When you feel better, do you sometimes stop taking your medicine?    
34. Thinking back over the past four days, have you missed any of your 
doses? 
  
35. Sometimes if you feel worse when you take the medicine, do you 
stop taking it? 
  
 
36. Ask the client to think back over the past four days and identify the times when he or she 
either missed a dose or took it at the wrong time. Show the client a copy of this visual 
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analogue scale, or an unmarked enlarged version. While placing your finger on the 
appropriate place, tell the client that if he or she had taken all medicine doses to point to 
10. If the client missed all the doses, he or she would point to 0—in the meantime, you 
move your finger to 0. Now give the client an opportunity to point out their level of 
adherence. The health care worker then marks the visual analogue scale. If the scale is 
marked off at 4, then the percentage adherence would be 40 percent. 
 
 
 
37. In the last few months have you ever come for treatment and were unable to get 
treatment?   
Yes  No  
  
38. If yes give reason: ________________________________________________________ 
 
39. Did you ever miss getting your treatment in the last four months because of the doctor’s 
strike? 
Yes  No  
 
 
40. When was the last time the patient was given treatment? _________________ 
(dd/mm/yyyy) 
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41. How many tablets was the patient given during his/her last visit to the clinic for the 
different medications?  
 
__________________________ _____________________ 
 
_________________________  _____________________ 
 
__________________________ _____________________ 
 
__________________________ _____________________ 
 
__________________________ _____________________ 
 
42. Did the patient return any treatment today and how many did they return for the different 
medications? 
 
__________________________ _____________________ 
 
_________________________  _____________________ 
 
__________________________ _____________________ 
 
__________________________ _____________________ 
 
__________________________ _____________________ 
 
43. Has the patient’s treatment regimen been changed in the last four months? 
Yes  No  
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44. What is the patient’s old treatment regimen if they have changed?  
 
 
45. What is the patient’s new treatment regimen if they have changed? 
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Appendix 3.5: Study II information sheet and consent form  
Validation and Longitudinal Application of the WHOQOL-HIV Questionnaire among People 
Living With HIV and AIDS in Limpopo Province, South Africa 
 
Introduction 
Good morning/afternoon. I am Mr. Jude Igumbor, a student at the University of the 
Witwatersrand. I am gathering information on the wellbeing and the experiences of people 
living with HIV (PLWH). I would be grateful if you would be willing to assist by responding to 
questions related to this issue. The interview will take about 30 minutes of your time. 
 
Purpose of the Study  
The study aims to describe the general wellbeing and experiences of people living with HIV and 
AIDS. This study is driven by the need to generate the necessary information to help improve 
the health related quality of life of people living with HIV and AIDS and their access to needed 
services.  
 
The study will follow up patients who have just started receiving ART for a period of one year. 
The patient that will take part in this study will be interviewed three times during the one year 
period. The interviews will be conducted at 6 monthly intervals and will include the first one at 
the beginning of treatment, the one at six months after treatment initiation and the last one at 
12 months. 
 
Your responses to this study will be confidential. The information you are going to provide will 
not have any personal information linked to it, that is, no information such as your name or 
address will be reported with the data and the information might also be inspected by the 
University of Witwatersrand, Human Research Ethics Committee, auditors/ authorised persons.  
 
Your taking part in this study will not benefit you directly, but it may benefit others in the 
future. This information will be used to find ways to improve the access to health and support 
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services and the health related quality of life of people living with HIV and AIDS. You will not 
receive payment for taking part in this study.   
 
Right to Refuse or Withdraw 
Your participation in this study is voluntary.  If at any time you do not want to answer an 
interview question, you may skip that question.  Your decision to take part or not to take part in 
the interview or your decision not to answer any question will have no impact on your care in 
this hospital. 
 
The researcher will only interview you after you have agreed to participate and have signed this 
consent form.  You are free to ask questions before agreeing to participate. 
 
Contact Numbers 
You are free to ask questions before agreeing to participate.  In case you have any questions 
you may contact Jude Igumbor on 072 320 2155 or his supervisor Professor A. Stewart on 011 
717 3718.  
 
This study protocol has been submitted to the University of the Witwatersrand, Human 
Research Ethics Committee and has been approved. This study has been structured in 
accordance with the Declaration of Helsinki (last updated: October, 2000) which deals with the 
recommendations guiding health research involving human beings.  If you want any 
information regarding your rights as a research participant, or complaints regarding this 
research study, you may also contact the Chairperson of the Human Research Ethic Committee, 
which is an independent committee established to help protect rights of research participants 
at (011) 717 2229. 
 
I would like to invite you to consider participating in this research study, entitled: “Measures of 
Quality of Life and Experiences with Care and Support Services among Persons Living with HIV 
Infection in Limpopo Province, South Africa”. 
  
247
 
 
Consent form 
 
We will require your approval by writing your name and signing in the space provided below: 
 
 
I ………………………………………................... certify that the information sheet form has been read 
out to me and any questions I had, have been answered.  I give my consent and agree to 
participate in this study about the health related quality of life and experiences with health and 
social services among people living with HIV and AIDS in Limpopo Province and I have been 
given a copy of this consent form and information sheet. 
 
  
 
Signature of Participant…………………………………………….                        
 
 
 
Name of interviewer…………………..........................................                
 
 
 
Signature of interviewer ………………………………………….. 
 
Date…………………………....................................................... 
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Appendix 3.6: Permission to conduct research: Limpopo Provincial Department of Health 
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Appendix 3.7: Ethical approval for the study  
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Appendix 5.1: Reliability analysis for the WHOQOL HIV domains 
Item   Cronbach’s  alpha 
Physical Domain  .92 
Pain and discomfort  .87 
Energy and fatigue .84 
Sleep and rest .75 
Symptoms of PLWH .86 
Psychological Domain   .86 
Positive feelings  .57 
Thinking, learning, memory and concentration  .67 
Self-esteem  .72 
Bodily image and appearance  .66 
Negative feelings  .90 
Level of Independence Domain   .89 
Mobility   .65 
Activities of daily living  .79 
Dependence on medication or treatments  .76 
Work capacity  .96 
Social Relationship Domain   .76 
Personal relationships  .61 
Social support  .66 
Sexual activity  .53 
Social Inclusion  .68 
Environmental Domain   .89 
Physical safety and security  .67 
Home environment  .69 
Financial resources  .82 
Health and social care: accessibility and quality  .74 
Opportunities for acquiring new information and skills  .84 
Participation in and opportunities for recreation/ leisure activities  .61 
Physical environment (pollution/noise/traffic/climate)  .43 
Transport  .81 
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Spirituality/Religion/Personal Belief (SRPB)  Domain   .94 
SRPB  .70 
Forgiveness and Blame  .92 
Concerns about the Future  .84 
Death and Dying  .96 
Overall quality of life and general health perceptions  .81 
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Appendix 5.2: Mean WHOQOL-HIV scale and domain scores by ethnic group 
WHOQOL-HIV scales and 
domains  
Ethnic 
group 
n Mean SD F Sig. 
Pain and discomfort Pedi 414 2.44 .586 342.845 .000 
Venda 241 2.27 1.004   
Tsonga 218 4.03 .933   
Energy and fatigue Pedi 421 2.56 .525 178.944 .000 
Venda 242 2.52 .606   
Tsonga 216 3.40 .639   
Sleep and rest Pedi 416 2.99 .422 244.174 .000 
Venda 239 2.89 1.060   
Tsonga 216 4.21 .733   
Symptoms of PLWH Pedi 422 2.45 .609 349.217 .000 
Venda 243 2.34 .976   
Tsonga 219 4.06 .914   
Positive feelings Pedi 419 2.93 .735 22.016 .000 
Venda 240 3.05 .849   
Tsonga 218 2.59 .794   
Thinking, learning, memory and 
concentration 
Pedi 421 3.48 .596 18.599 .000 
Venda 240 3.32 .848   
Tsonga 216 3.71 .656   
Self-esteem Pedi 416 3.47 .604 6.292 .002 
Venda 240 3.41 1.117   
Tsonga 215 3.67 .730   
Bodily image and appearance Pedi 420 3.30 .739 168.114 .000 
Venda 242 2.91 .587   
Tsonga 210 4.15 .856   
Negative feelings Pedi 420 2.76 .787 174.277 .000 
Venda 237 2.46 1.148   
Tsonga 220 3.94 .834   
Mobility Pedi 422 3.14 .647 82.457 .000 
Venda 242 2.68 .876   
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Tsonga 223 3.57 .768   
Activities of daily living Pedi 415 2.75 .496 184.056 .000 
Venda 241 2.57 .994   
Tsonga 211 3.87 .972   
Dependence on medication or 
treatments 
Pedi 416 1.48 .658 90.961 .000 
Venda 242 1.67 .635   
Tsonga 217 2.26 .828   
Work capacity Pedi 423 2.95 .459 120.516 .000 
Venda 243 2.39 1.135   
Tsonga 220 3.67 1.152   
Personal relationships Pedi 422 3.30 .551 176.869 .000 
Venda 241 3.32 .782   
Tsonga 219 4.29 .752   
Social support Pedi 423 2.51 .674 174.666 .000 
Venda 242 3.37 .921   
Tsonga 217 3.63 .873   
Sexual activity Pedi 417 2.60 .752 38.393 .000 
Venda 237 2.79 .726   
Tsonga 220 3.18 .912   
Social Inclusion Pedi 415 3.34 .721 126.273 .000 
Venda 240 3.28 .654   
Tsonga 218 4.21 .773   
Physical safety and security Pedi 423 3.31 .606 24.894 .000 
Venda 241 3.16 .887   
Tsonga 221 3.63 .773   
Home environment Pedi 417 3.26 .514 7.465 .001 
Venda 243 3.47 .864   
Tsonga 216 3.31 .767   
Financial resources Pedi 419 1.37 .704 135.466 .000 
Venda 237 1.44 .782   
Tsonga 218 2.43 1.006   
Health and social care: Pedi 418 3.51 .935 12.799 .000 
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accessibility and quality Venda 239 3.48 .814   
Tsonga 220 3.83 .674   
Opportunities for acquiring new 
information and skills 
Pedi 426 3.85 .715 11.870 .000 
Venda 241 3.55 .921   
Tsonga 218 3.85 .831   
Participation in and 
opportunities for recreation/ 
leisure activities 
Pedi 416 3.17 .520 16.306 .000 
Venda 241 3.00 .849   
Tsonga 217 3.36 .739   
Physical environment 
(pollution/noise/traffic/climate) 
Pedi 421 3.45 .618 16.909 .000 
Venda 238 3.19 .640   
Tsonga 219 3.53 .791   
Transport Pedi 421 3.38 .860 100.281 .000 
Venda 242 2.44 .793   
Tsonga 217 3.38 1.003   
SRPB Pedi 415 3.68 .699 21.440 .000 
Venda 0 . .   
Tsonga 224 3.94 .636   
Forgiveness and Blame Pedi 424 2.54 1.089 391.297 .000 
Venda 238 2.00 1.006   
Tsonga 221 4.48 .856   
Concerns about the Future Pedi 426 2.49 1.032 251.702 .000 
Venda 237 1.82 .845   
Tsonga 220 3.77 .872   
Death and Dying Pedi 426 2.50 1.098 168.386 .000 
Venda 240 2.21 1.161   
Tsonga 222 3.99 1.175   
Overall quality of life and general 
health perceptions 
Pedi 423 3.30 .629 18.829 .000 
Venda 239 3.39 .998   
Tsonga 219 3.69 .762   
Physical Pedi 399 10.43 1.468 424.807 .000 
Venda 236 10.01 3.181   
Tsonga 203 15.74 2.542   
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Psychological Pedi 401 12.78 1.773 65.156 .000 
Venda 230 12.17 2.823   
Tsonga 193 14.52 2.116   
Level of Independence Pedi 397 10.32 1.230 206.873 .000 
Venda 238 9.31 2.952   
Tsonga 202 13.45 2.667   
Social Relationships Pedi 401 11.73 1.427 232.618 .000 
Venda 232 12.80 2.284   
Tsonga 205 15.28 2.271   
Environment Pedi 385 12.74 1.363 48.847 .000 
Venda 225 11.92 2.274   
Tsonga 196 13.74 2.243   
Spirituality/Religion/ Personal 
Beliefs 
Pedi 410 11.18 2.975 424.345 .000 
Venda 0 . .   
Tsonga 213 16.21 2.719   
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Appendix 5.3: LSD post hoc comparison of the mean WHOQOL-HIV scale and domain scores 
by ethnic group 
Scale and 
domains 
(I) Ethnic group (J) Ethnic group Mean Difference (I-J) Sig. 
Pain and 
discomfort 
Pedi Venda .166
*
 .012 
Tsonga -1.592
*
 .000 
Venda Pedi -.166
*
 .012 
Tsonga -1.758
*
 .000 
Energy and 
fatigue 
Pedi Venda .035 .451 
Tsonga -.842
*
 .000 
Venda Pedi -.035 .451 
Tsonga -.877
*
 .000 
Sleep and 
rest 
Pedi Venda .099 .092 
Tsonga -1.218
*
 .000 
Venda Pedi -.099 .092 
Tsonga -1.317
*
 .000 
Symptoms of 
PLWH 
Pedi  Venda .104 .109 
Tsonga -1.614
*
 .000 
Venda Pedi -.104 .109 
Tsonga -1.718
*
 .000 
Positive 
feelings 
Pedi Venda -.126
*
 .047 
Tsonga .341
*
 .000 
Venda Pedi .126
*
 .047 
Tsonga .467
*
 .000 
Thinking, 
learning, 
memory and 
concentration 
Pedi Venda .158
*
 .005 
Tsonga -.233
*
 .000 
Venda Pedi -.158
*
 .005 
Tsonga -.392
*
 .000 
Self-esteem Pedi Venda .054 .410 
Tsonga -.199
*
 .003 
Venda Pedi -.054 .410 
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Tsonga -.253
*
 .001 
Bodily image 
and 
appearance 
Pedi Venda .392
*
 .000 
Tsonga -.848
*
 .000 
Venda Pedi -.392
*
 .000 
Tsonga -1.239
*
 .000 
Negative 
feelings 
Pedi Venda .297
*
 .000 
Tsonga -1.184
*
 .000 
Venda Pedi -.297
*
 .000 
Tsonga -1.481
*
 .000 
Mobility Pedi Venda .467
*
 .000 
Tsonga -.420
*
 .000 
Venda Pedi -.467
*
 .000 
Tsonga -.887
*
 .000 
Activities of 
daily living 
Pedi Venda .181
*
 .005 
Tsonga -1.118
*
 .000 
Venda Pedi -.181
*
 .005 
Tsonga -1.299
*
 .000 
Dependence 
on 
medication or 
treatments 
Pedi Venda -.195
*
 .001 
Tsonga -.784
*
 .000 
Venda Pedi .195
*
 .001 
Tsonga -.589
*
 .000 
Work 
capacity 
Pedi Venda .562
*
 .000 
Tsonga -.715
*
 .000 
Venda Pedi -.562
*
 .000 
Tsonga -1.277
*
 .000 
Personal 
relationships 
Pedi Venda -.027 .614 
Tsonga -.996
*
 .000 
Venda Pedi .027 .614 
Tsonga -.969
*
 .000 
Social 
support 
Pedi Venda -.866
*
 .000 
Tsonga -1.125
*
 .000 
Venda Pedi .866
*
 .000 
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Tsonga -.259
*
 .001 
Sexual 
activity 
Pedi Venda -.190
*
 .003 
Tsonga -.576
*
 .000 
Venda Pedi .190
*
 .003 
Tsonga -.386
*
 .000 
Social 
Inclusion 
Pedi Venda .061 .298 
Tsonga -.867
*
 .000 
Venda Pedi -.061 .298 
Tsonga -.927
*
 .000 
Physical 
safety and 
security 
Pedi Venda .153
*
 .010 
Tsonga -.319
*
 .000 
Venda Pedi -.153
*
 .010 
Tsonga -.472
*
 .000 
Home 
environment 
Pedi Venda -.214
*
 .000 
Tsonga -.056 .336 
Venda Pedi .214
*
 .000 
Tsonga .158
*
 .014 
Financial 
resources 
Pedi Venda -.074 .263 
Tsonga -1.066
*
 .000 
Venda Pedi .074 .263 
Tsonga -.992
*
 .000 
Health and 
social care: 
accessibility 
and quality 
Pedi Venda .030 .659 
Tsonga -.320
*
 .000 
Venda Pedi -.030 .659 
Tsonga -.350
*
 .000 
Opportunities 
for acquiring 
new 
information 
and skills 
Pedi Venda .296
*
 .000 
Tsonga -.001 .986 
Venda Pedi -.296
*
 .000 
Tsonga -.297
*
 .000 
Participation 
in and 
opportunities 
Pedi Venda .172
*
 .002 
Tsonga -.191
*
 .001 
Venda Pedi -.172
*
 .002 
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for 
recreation/ 
leisure 
activities 
Tsonga -.364
*
 .000 
Physical 
environment 
(pollution/noi
se/traffic/cli
mate) 
Pedi Venda .258
*
 .000 
Tsonga -.083 .138 
Venda Pedi -.258
*
 .000 
Tsonga -.341
*
 .000 
Transport Pedi Venda .940
*
 .000 
Tsonga -.005 .948 
Venda Pedi -.940
*
 .000 
Tsonga -.944
*
 .000 
Forgiveness 
and Blame 
Pedi Venda .538
*
 .000 
Tsonga -1.946
*
 .000 
Venda Pedi -.538
*
 .000 
Tsonga -2.484
*
 .000 
Concerns 
about the 
Future 
Pedi Venda .663
*
 .000 
Tsonga -1.287
*
 .000 
Venda Pedi -.663
*
 .000 
Tsonga -1.950
*
 .000 
Death and 
Dying 
Pedi Venda .288
*
 .002 
Tsonga -1.486
*
 .000 
Venda Pedi -.288
*
 .002 
Tsonga -1.774
*
 .000 
Overall 
quality of life 
and general 
health 
perceptions 
Pedi Venda -.089 .158 
Tsonga -.394
*
 .000 
Venda Pedi .089 .158 
Tsonga -.305
*
 .000 
Physical Pedi Venda .423
*
 .028 
Tsonga -5.308
*
 .000 
Venda Pedi -.423
*
 .028 
Tsonga -5.730
*
 .000 
  
260
Psychological Pedi Venda .609
*
 .001 
Tsonga -1.744
*
 .000 
Venda Pedi -.609
*
 .001 
Tsonga -2.353
*
 .000 
Level of 
Independenc
e 
Pedi Venda 1.014
*
 .000 
Tsonga -3.121
*
 .000 
Venda Pedi -1.014
*
 .000 
Tsonga -4.135
*
 .000 
Social 
Relationships 
Pedi Venda -1.065
*
 .000 
Tsonga -3.549
*
 .000 
Venda Pedi 1.065
*
 .000 
Tsonga -2.484
*
 .000 
Environment Pedi Venda .818
*
 .000 
Tsonga -1.002
*
 .000 
Venda Pedi -.818
*
 .000 
Tsonga -1.820
*
 .000 
 
 
  
261
Appendix 5.4: Mean WHOQOL-HIV scale and domain scores showing significant difference by 
marital status 
 Marital status  N Mean SD F Sig. 
Symptoms of 
PLWH 
Married 358 2.84 1.112 3.106 .045 
Never married 308 2.70 .903   
Divorced/Separated/ 
Widowed 
198 2.94 1.241 
  
Positive 
feelings 
Married 359 2.88 .798 5.795 .003 
Never married 306 2.99 .770   
Divorced/Separated/ 
Widowed 
194 2.74 .830 
  
Social support Married 356 3.13 .957 8.321 .000 
Never married 309 2.85 .841   
Divorced/Separated/ 
Widowed 
198 3.09 1.021 
  
Sexual activity Married 353 2.91 .859 10.289 .000 
Never married 306 2.80 .781   
Divorced/Separated/ 
Widowed 
195 2.58 .773 
  
Social 
Inclusion 
Married 351 3.56 .804 5.293 .005 
Never married 308 3.44 .815   
Divorced/Separated/ 
Widowed 
195 3.68 .794 
  
Financial 
resources 
Married 350 1.70 .926 3.512 .030 
Never married 306 1.53 .842   
Divorced/Separated/ 
Widowed 
198 1.70 1.031 
  
Health and 
social care: 
accessibility 
and quality 
Married 356 3.56 .811 4.821 .008 
Never married 304 3.51 .901   
Divorced/Separated/ 
Widowed 
198 3.75 .829 
  
Participation 
in and 
Married 355 3.11 .744 3.093 .046 
Never married 302 3.18 .602   
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opportunities 
for recreation/ 
leisure 
activities 
Divorced/Separated/ 
Widowed 
198 3.26 .726 
  
Transport Married 354 3.01 .968 4.843 .008 
Never married 309 3.23 .979   
Divorced/Separated/ 
Widowed 
198 3.19 .967 
  
SRPB Married 224 3.71 .770 4.291 .014 
Never married 258 3.76 .682   
Divorced/Separated/ 
Widowed 
140 3.92 .537 
  
Social 
Relationships 
Married 329 13.23 2.554 6.242 .002 
Never married 301 12.56 2.104   
Divorced/Separated/ 
Widowed 
190 12.87 2.481 
  
Spirituality/Rel
igion/ Personal 
Beliefs 
Married 216 13.33 3.847 6.802 .001 
Never married 253 12.27 3.538   
Divorced/Separated/ 
Widowed 
137 13.48 3.716 
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Appendix 5.5: LSD post hoc comparison of the mean WHOQOL-HIV scale and domain scores 
that differed significantly by marital status 
Dependent Variable (I) Marital groups (J) Marital groups 
Mean 
Difference (I-
J) Sig. 
Symptoms of PLWH Married Never married .134 .109 
Divorced/Separated/ 
Widowed 
-.104 .274 
Never married Married -.134 .109 
Divorced/Separated/ 
Widowed 
-.238
*
 .015 
Positive feelings Married Never married -.110 .076 
Divorced/Separated/ 
Widowed 
.138 .052 
Never married Married .110 .076 
Divorced/Separated/ 
Widowed 
.248
*
 .001 
Social support Married Never married .284
*
 .000 
Divorced/Separated/ 
Widowed 
.046 .577 
Never married Married -.284
*
 .000 
Divorced/Separated/ 
Widowed 
-.238
*
 .005 
Sexual activity Married Never married .115 .071 
Divorced/Separated/ 
Widowed 
.329
*
 .000 
Never married Married -.115 .071 
Divorced/Separated/ 
Widowed 
.214
*
 .004 
Social Inclusion Married Never married .119 .058 
Divorced/Separated/ 
Widowed 
-.118 .102 
Never married Married -.119 .058 
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Divorced/Separated/ 
Widowed 
-.237
*
 .001 
Financial resources Married Never married .174
*
 .016 
Divorced/Separated/ 
Widowed 
-.002 .980 
Never married Married -.174
*
 .016 
Divorced/Separated/ 
Widowed 
-.176
*
 .037 
Health and social care: 
accessibility and quality 
Married Never married .051 .437 
Divorced/Separated/ 
Widowed 
-.183
*
 .015 
Never married Married -.051 .437 
Divorced/Separated/ 
Widowed 
-.234
*
 .003 
Participation in and 
opportunities for 
recreation/ leisure 
activities 
Married Never married -.075 .167 
Divorced/Separated/ 
Widowed 
-.151
*
 .014 
Never married Married .075 .167 
Divorced/Separated/ 
Widowed 
-.075 .234 
Transport Married Never married -.225
*
 .003 
Divorced/Separated/ 
Widowed 
-.178
*
 .039 
Never married Married .225
*
 .003 
Divorced/Separated/ 
Widowed 
.046 .602 
SRPB Married Never married -.046 .464 
Divorced/Separated/ 
Widowed 
-.212
*
 .004 
Never married Married .046 .464 
Divorced/Separated/ 
Widowed 
-.166
*
 .022 
Social Relationships Married Never married .670
*
 .000 
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Divorced/Separated/ 
Widowed 
.364 .094 
Never married Married -.670
*
 .000 
Divorced/Separated/ 
Widowed 
-.306 .166 
Spirituality/Religion/ 
Personal Beliefs 
Married Never married 1.056
*
 .002 
Divorced/Separated/ 
Widowed 
-.153 .704 
Never married Married -1.056
*
 .002 
Divorced/Separated/ 
Widowed 
-1.209
*
 .002 
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Appendix 5.6: Mean WHOQOL-HIV scale and domain scores showing significant difference 
between people with and without children 
 Do you have 
children 
n Mean SD T Sig. 
Pain and discomfort Yes 643 2.91 1.144 6.060 .000 
No 193 2.38 .748   
Energy and fatigue Yes 647 2.81 .706 5.558 .000 
No 197 2.51 .521   
Sleep and rest Yes 642 3.34 .950 4.860 .000 
No 192 2.99 .631   
Symptoms of PLWH Yes 649 2.94 1.122 6.555 .000 
No 198 2.38 .742   
No 198 3.35 .778   
Negative feelings Yes 644 3.07 1.105 5.389 .000 
No 196 2.60 .862   
Activities of daily living Yes 637 3.04 .978 4.617 .000 
No 195 2.69 .687   
Dependence on medication or 
treatments 
Yes 644 1.81 .785 7.077 .000 
No 195 1.38 .609   
Work capacity Yes 649 3.02 1.055 2.309 .021 
No 199 2.83 .709   
Personal relationships Yes 649 3.61 .820 4.901 .000 
No 196 3.31 .589   
Social support Yes 647 3.12 .932 6.759 .000 
No 197 2.62 .809   
Sexual activity Yes 645 2.89 .818 5.621 .000 
No 193 2.52 .783   
Financial resources Yes 642 1.74 .952 5.232 .000 
No 196 1.35 .773   
Health and social care: 
accessibility and quality 
Yes 645 3.53 .862 -3.439 .001 
No 196 3.77 .812   
Opportunities for acquiring Yes 650 3.72 .816 -3.522 .000 
  
267
new information and skills No 197 3.95 .720   
No 197 3.46 .842   
Forgiveness and Blame Yes 649 2.93 1.446 2.409 .016 
No 196 2.66 1.091   
Death and Dying Yes 652 2.83 1.383 2.308 .021 
No 199 2.59 1.035   
Physical Yes 618 11.97 3.488 6.416 .000 
No 186 10.24 2.067   
Psychological Yes 597 13.15 2.400 2.251 .025 
No 194 12.71 2.135   
Level of Independence Yes 611 11.02 2.853 4.915 .000 
No 192 9.94 1.896   
Social Relationships Yes 619 13.16 2.430 6.649 .000 
No 188 11.89 1.785   
Spirituality/Religion/ Personal 
Beliefs 
Yes 431 13.23 3.921 4.140 .000 
No 164 11.85 2.712   
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Appendix  5.7: Mean WHOQOL-HIV scale and domain scores showing significant difference by 
support group membership 
 Belong to support group N Mean SD T Sig 
Pain and discomfort Yes 291 2.72 .899 -2.634 .009 
No 440 2.94 1.217   
Energy and fatigue Yes 295 2.66 .590 -3.416 .001 
No 441 2.84 .760   
Symptoms of PLWH Yes 299 2.65 .859s -4.140 .000 
No 443 2.99 1.242   
Positive feelings Yes 294 2.99 .784 2.273 .023 
No 443 2.84 .862   
Thinking, learning, 
memory and 
concentration 
Yes 295 3.58 .594 2.382 .017 
No 439 3.46 .760   
Self-esteem Yes 294 3.61 .656 2.387 .017 
No 436 3.46 .915   
Bodily image and 
appearance 
Yes 297 3.54 .716 2.272 .023 
No 434 3.39 .924   
Negative feelings Yes 294 2.72 .841 -4.410 .000 
No 439 3.08 1.203   
Dependence on 
medication or 
treatments 
Yes 297 1.60 .742 -4.572 .000 
No 436 1.87 .785   
Personal relationships Yes 297 3.40 .624 -4.653 .000 
No 441 3.68 .895   
Social support Yes 297 2.76 .901 -7.961 .000 
No 442 3.31 .931   
Sexual activity Yes 295 2.61 .806 -4.865 .000 
No 439 2.92 .839   
Financial resources Yes 295 1.45 .806 -5.203 .000 
No 437 1.82 1.011   
Health and social care: 
accessibility and quality 
Yes 298 3.87 .737 4.085 .000 
No 439 3.64 .784   
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Opportunities for 
acquiring new 
information and skills 
Yes 297 3.96 .746 4.188 .000 
No 443 3.70 .883   
Participation in and 
opportunities for 
recreation/ leisure 
activities 
Yes 298 3.27 .604 2.394 .017 
No 435 3.14 .778   
Physical environment 
(pollution/noise/traffic/
climate) 
Yes 298 3.50 .604 2.503 .013 
No 441 3.37 .731   
Transport Yes 300 3.52 .848 7.012 .000 
No 438 3.03 .997   
Overall quality of life 
and general health 
perceptions 
Yes 298 3.55 .676 2.465 .014 
No 441 3.40 .874   
Psychological Yes 282 13.18 1.886 -2.944 .003 
No 411 12.99 2.678   
Social Relationships Yes 285 12.44 2.038 -5.781 .000 
No 420 13.49 2.572   
Environment Yes 288 13.15 1.561 2.617 .009 
No 399 12.74 2.298   
Spirituality/Religion/ 
Personal Beliefs 
Yes 251 12.39 3.254 -6.905 .000 
No 254 14.52 3.673   
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Appendix 5.8: LSD post hoc comparison of the average WHOQOL-HIV domain scores at the 
three interview times 
Scale and domains  (I) Time of 
interview 
(J) Time of 
interview 
Mean difference (I-J) Sig. 
Physical Baseline 6 months -3.079
*
 .000 
12 months -2.229
*
 .000 
6 months Baseline 3.079
*
 .000 
12 months .849
*
 .001 
Psychological Baseline 6 months -1.712
*
 .000 
12 months -1.735
*
 .000 
6 months Baseline 1.712
*
 .000 
12 months -.023 .904 
Level of Independence Baseline 6 months -2.504
*
 .000 
12 months -2.320
*
 .000 
6 months Baseline 2.504
*
 .000 
12 months .184 .382 
Social Relationships Baseline 6 months -1.771
*
 .000 
12 months -1.325
*
 .000 
6 months Baseline 1.771
*
 .000 
12 months .446
*
 .022 
Environment Baseline 6 months -2.095
*
 .000 
12 months -2.172
*
 .000 
6 months Baseline 2.095
*
 .000 
12 months -.077 .607 
Spirituality/Religion/ 
Personal Beliefs 
Baseline 6 months -5.050
*
 .000 
12 months -4.277
*
 .000 
6 months Baseline 5.050
*
 .000 
12 months .773
*
 .008 
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Appendix 5.9 LDS Post hoc comparison of the average WHOQOL-HIV domains cores by CD4 
count level 
Dependent Variable (I) CD4 cell 
count grouping 
(J) CD4 cell count 
grouping 
Mean Difference (I-
J) 
Sig. 
Physical 0 - 200 cells/µl 201 - 349 cells/µl -1.354
*
 .000 
350 - 500 cells/µl -1.250
*
 .000 
> 500 cells/µl -2.156
*
 .000 
201 - 349 
cells/µl 
0 - 200 cells/µl 1.354
*
 .000 
350 - 500 cells/µl .104 .770 
> 500 cells/µl -.801 .100 
350 - 500 
cells/µl 
0 - 200 cells/µl 1.250
*
 .000 
201 - 349 cells/µl -.104 .770 
> 500 cells/µl -.905 .076 
Psychological 0 - 200 cells/µl 201 - 349 cells/µl -.907
*
 .000 
350 - 500 cells/µl -1.093
*
 .000 
> 500 cells/µl -2.138
*
 .000 
201 - 349 
cells/µl 
0 - 200 cells/µl .907
*
 .000 
350 - 500 cells/µl -.186 .452 
> 500 cells/µl -1.231
*
 .000 
350 - 500 
cells/µl 
0 - 200 cells/µl 1.093
*
 .000 
201 - 349 cells/µl .186 .452 
> 500 cells/µl -1.046
*
 .003 
Level of Independence 0 - 200 cells/µl 201 - 349 cells/µl -1.103
*
 .000 
350 - 500 cells/µl -1.164
*
 .000 
> 500 cells/µl -2.087
*
 .000 
201 - 349 
cells/µl 
0 - 200 cells/µl 1.103
*
 .000 
350 - 500 cells/µl -.060 .833 
> 500 cells/µl -.983
*
 .012 
350 - 500 
cells/µl 
0 - 200 cells/µl 1.164
*
 .000 
201 - 349 cells/µl .060 .833 
> 500 cells/µl -.923
*
 .024 
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Social Relationships 0 - 200 cells/µl 201 - 349 cells/µl -.726
*
 .000 
350 - 500 cells/µl -.405 .076 
> 500 cells/µl -1.100
*
 .001 
201 - 349 
cells/µl 
0 - 200 cells/µl .726
*
 .000 
350 - 500 cells/µl .321 .208 
> 500 cells/µl -.374 .290 
350 - 500 
cells/µl 
0 - 200 cells/µl .405 .076 
201 - 349 cells/µl -.321 .208 
> 500 cells/µl -.695 .060 
Environment 0 - 200 cells/µl 201 - 349 cells/µl -1.033
*
 .000 
350 - 500 cells/µl -1.419
*
 .000 
> 500 cells/µl -1.610
*
 .000 
201 - 349 
cells/µl 
0 - 200 cells/µl 1.033
*
 .000 
350 - 500 cells/µl -.387 .059 
> 500 cells/µl -.578
*
 .039 
350 - 500 
cells/µl 
0 - 200 cells/µl 1.419
*
 .000 
201 - 349 cells/µl .387 .059 
> 500 cells/µl -.191 .514 
Spirituality/Religion/ 
Personal Beliefs 
0 - 200 cells/µl 201 - 349 cells/µl -1.580
*
 .000 
350 - 500 cells/µl -1.330
*
 .001 
> 500 cells/µl -2.865
*
 .000 
201 - 349 
cells/µl 
0 - 200 cells/µl 1.580
*
 .000 
350 - 500 cells/µl .250 .555 
> 500 cells/µl -1.284
*
 .040 
350 - 500 
cells/µl 
0 - 200 cells/µl 1.330
*
 .001 
201 - 349 cells/µl -.250 .555 
> 500 cells/µl -1.534
*
 .018 
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Appendix 5.10: Selection of Physical domain items using item – total correlation and Cronbach’s Alpha if item deleted  
Items 
 
Baseline 6 months 12 months 
Corrected 
Item-Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Corrected 
Item-Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Do you have any difficulties with sleeping? .771 .888 .746 .909 .776 .904 
Do you have enough for everyday life? -.578 .928 -.568 .940 -.764 .941 
Do you worry about your pain or 
discomfort? 
.701 .891 .813 .908 .885 .900 
How difficult is it for you to handle any 
pain or discomfort?  
.690 .891 .741 .910 .808 .903 
How easily do you get tired? .709 .891 .826 .908 .801 .904 
How much are bothered by any 
unpleasant by any physical problems 
related to your HIV infection? 
.758 .888 .819 .907 .873 .900 
How much are you bothered by fatigue? .744 .889 .834 .906 .886 .900 
How much do any sleep problems worry 
you? 
.680 .891 .346 .920 .279 .919 
How often do you suffer (physical) pain? .530 .897 .620 .913 .636 .909 
How satisfied are you with the energy that 
you have? 
.603 .894 .522 .916 .503 .913 
How satisfied are you with your sleep? .383 .901 .552 .915 .427 .915 
How well do you sleep? .469 .899 .571 .915 .530 .913 
To what extent are you bothered by fears 
of developing any physical problem? 
.727 .890 .779 .908 .835 .902 
To what extent do you fear possible future 
(physical) pain? 
.703 .890 .806 .907 .567 .911 
To what extent do you feel any unpleasant 
physical problems prevent you from doing 
things that are important to you? 
.473 .898 .591 .914 .700 .907 
To what extent do you feel that (physical) 
pain prevents you from doing what you 
need to do? 
.776 .888 .706 .911 .838 .902 
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Appendix 5.11:  Selection of psychological domain items using item – total correlation and Cronbach’s Alpha if item deleted  
Items 
 
Baseline 6 months 12 months 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Corrected 
Item-Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Are you able to accept your bodily 
appearance? 
-.299 .873 .680 .845 -.142 .860 
Do you feel inhibited by your looks? .444 .846 .520 .852 .453 .826 
Do you generally feel content? .267 .852 -.391 .895 -.126 .862 
How much confidence do you have in 
yourself? 
.504 .844 .672 .849 .583 .823 
How much do any feelings of 
depression bother you? 
.528 .842 .491 .853 .677 .813 
How much do any feelings of sadness 
or depression interfere with your 
everyday functioning? 
.606 .838 .456 .854 .699 .812 
How much do you enjoy life? .375 .849 .569 .850 .598 .821 
How much do you experience positive 
feelings in your life? 
.120 .859 .243 .863 -.224 .857 
How much do you value yourself? .613 .839 .308 .859 .356 .831 
How often do you have negative 
feelings, such as blue mood, despair, 
anxiety, depression? 
.504 .844 .528 .851 .582 .819 
How positive do you feel about the 
future? 
.530 .842 .623 .848 .586 .821 
How satisfied are you with the way 
your body looks? 
.480 .845 .757 .844 .703 .819 
How satisfied are you with your 
abilities? 
.533 .843 .676 .846 .572 .824 
How satisfied are you with your ability 
to learn new information? 
.404 .848 .428 .855 .385 .830 
How satisfied are you with your ability 
to make decisions? 
.503 .844 .645 .850 .573 .824 
How satisfied are you with yourself? .553 .841 .726 .845 .591 .824 
How well are you able to concentrate .509 .843 .206 .862 .375 .830 
How worried do you feel? .589 .839 .521 .851 .639 .815 
How would you rate your memory? .500 .844 .538 .852 .641 .823 
Is there any part of your appearance 
which makes you feel uncomfortable? 
.521 .842 .552 .850 .577 .820 
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Appendix 5.12:  Selection of level of dependence domain items using item – total correlation and Cronbach’s Alpha if item 
deleted  
Items 
 
Baseline 6 months 12 months 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Are you able to work? .771 .848 .722 .840 .746 .904 
Do you feel able to carry out your 
duties? 
.728 .850 .727 .839 .777 .903 
How dependent are you on 
medications? 
.237 .871 -.087 .871 -.032 .920 
How much are you bothered by any 
limitations in performing everyday 
living activities? 
.718 .850 .714 .837 .802 .900 
How much do you any difficulties in 
mobility bother you? 
.381 .867 .268 .867 .684 .905 
How much do you need any medical 
treatment to function in your daily 
life? 
.253 .869 .586 .845 .731 .903 
How much do you need any 
medication to function in your daily 
life? 
.238 .872 .521 .848 .754 .903 
How satisfied are with your ability to 
perform your daily living activities? 
.732 .850 .476 .851 .584 .909 
How satisfied are you with your ability 
to move around? 
.442 .864 .228 .860 .146 .918 
How satisfied are you with your 
capacity to work? 
.770 .848 .732 .840 .798 .903 
How well are you able to get around? .634 .854 .455 .852 .405 .913 
How would you rate your ability to 
work? 
.754 .849 .706 .841 .810 .903 
To what extent are you able to carry 
out your daily activities? 
.380 .866 .561 .847 .548 .909 
To what extent do any difficulties in 
movement affect your way of life? 
.274 .873 .272 .867 .666 .906 
To what extent do you have difficulty 
in performing your routine activities? 
.612 .855 .673 .840 .500 .911 
To what extent does your quality of 
life depend on the use of medical 
substances or medical? 
.168 .874 .467 .851 .553 .909 
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Appendix 5.13:  Selection of social relationship domain items using item – total correlation and Cronbach’s Alpha if item deleted  
Items 
 
Baseline 6 months 12 months 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
How alone do you feel in your life? .112 .650 .202 .758 .216 .828 
Do you feel happy about your 
relationship with your family members? 
.437 .602 .532 .742 .568 .814 
How satisfied are you with your personal 
relationships? 
.540 .585 .594 .719 .675 .798 
How satisfied are you with your ability to 
provide for or support others? 
.530 .595 .523 .740 .571 .814 
Do you get the kind of support from 
others that you need? 
.368 .612 .428 .740 .587 .813 
To what extent can you count on your 
friends when you need them? 
.279 .622 .235 .762 .576 .807 
How satisfied are you with the support 
you get from your family? 
.471 .597 .540 .738 .570 .813 
How satisfied are you with the support 
you get from your friends? 
.456 .593 .421 .740 .676 .798 
How would you rate your sex life? .236 .629 .447 .737 .674 .799 
How well are your sexual needs fulfilled? .088 .651 .173 .761 .290 .827 
How satisfied are you with your sex life? .541 .584 .365 .746 .670 .800 
Are you bothered by any difficulties in 
your sex life? 
.029 .664 .080 .772 .132 .838 
To what extent do you feel accepted by 
the people you know? 
.478 .596 .547 .733 .564 .814 
How often do you feel you are 
discriminated against because of your 
health condition? 
-.072 .666 .280 .752 -.061 .837 
To what extent do you feel accepted by 
your community? 
.423 .605 .470 .738 .448 .818 
How much do you feel alienated from 
those around you? 
-.532 .721 .245 .759 .096 .834 
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Appendix 5.14: Selection of environmental domain items using item – total correlation and Cronbach’s Alpha if item deleted 
Items 
 
Baseline 6 months 12 months 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Do you feel you are living in a safe and 
secure environment? 
.604 .786 .564 .867 .680 .851 
Do you have financial difficulties? .011 .810 .296 .873 .169 .865 
Have available to you is the information 
that you need in your day-to-day life? 
.418 .794 .478 .868 .496 .856 
Have you enough money to meet your 
needs? 
.012 .810 .210 .875 .064 .866 
How comfortable is the place where you 
live? 
.700 .783 .498 .867 .600 .854 
How concerned are you with the noise 
in the area you live in? 
.015 .809 .205 .875 -.022 .870 
How easily are you able to get good 
medical care? 
.265 .800 .318 .871 .330 .859 
How healthy is your physical 
environment? 
.296 .799 .461 .868 .636 .853 
How much are you able to relax and 
enjoy yourself? 
.413 .794 .554 .866 .569 .854 
How much do difficulties with transport 
restrict your life? 
.133 .805 .305 .872 .261 .863 
How much do you enjoy your free time? .535 .789 .504 .867 .504 .855 
How much do you like it where you live? .554 .790 .382 .870 .598 .854 
How much do you worry about money? -.032 .811 .313 .873 .182 .865 
How much do you worry about your 
safety and security? 
-.062 .817 .251 .875 .254 .864 
How safe do you feel in your daily life? .542 .788 .578 .866 .575 .854 
How satisfied are you with the climate 
of the place where you live? 
.602 .786 .586 .866 .548 .855 
How satisfied are you with the social 
care services? 
.546 .790 .563 .867 .555 .854 
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Appendix 5.14:  Selection of environmental domain items using item – total correlation and Cronbach’s Alpha if item deleted 
(continued) 
Items 
 
Baseline 6 months 12 months 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
How satisfied are you with the way you 
spend your spare time? 
.645 .785 .611 .866 .527 .855 
How satisfied are you with your access 
to health services? 
.167 .807 .528 .867 .595 .855 
How satisfied are you with your financial 
situation? 
.084 .806 .265 .875 .119 .868 
How satisfied are you with your 
opportunities for acquiring new skills? 
.611 .787 .621 .866 .480 .857 
How satisfied are you with your 
opportunities to learn new information? 
.663 .785 .579 .867 .436 .858 
How satisfied are you with your physical 
environment (e.g. pollution, climate, 
noise, attractiveness? 
-.045 .814 .568 .866 .391 .858 
How satisfied are you with your physical 
safety and security? 
.594 .788 .590 .867 .526 .856 
How satisfied are you with your the 
conditions of your living place? 
.569 .789 .631 .866 .598 .855 
How satisfied are you with your 
transport? 
.231 .801 .529 .866 .410 .857 
How would you rate the quality of social 
services available to you? 
.367 .797 .471 .869 .556 .855 
To what degree does the quality of your 
home meet your needs? 
.285 .799 .041 .879 .205 .863 
To what extent do you have 
opportunities for acquiring the 
information that you feel you need? 
.504 .792 .433 .869 .560 .854 
To what extent do you have problems 
with transport? 
.049 .808 .511 .866 .312 .861 
To what extent do you have the 
opportunities for leisure activities? 
-.013 .810 .021 .879 .399 .857 
To what extent do you have adequate 
means of transport? 
.098 .806 .515 .866 .390 .858 
 
 
  
279
Appendix 5.15:  Selection of SRPB domain items using item – total correlation and Cronbach’s Alpha if item deleted  
Items 
 
Baseline 6 months 12 months 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Corrected Item-
Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Do your personal beliefs give meaning 
to your life? 
.263 .890 .220 .917 .197 .961 
How bothered are you by the thought 
of not being able to die the way you 
would want to? 
.872 .866 .850 .900 .924 .948 
How concerned are you about how 
where you will die? 
.828 .868 .845 .900 .935 .948 
How guilty do you feel about being 
HIV positive? 
.690 .874 .792 .902 .943 .948 
How much do you blame yourself for 
your HIV infection? 
.745 .871 .800 .902 .931 .948 
How much do you fear the future? .539 .881 .747 .904 .664 .954 
How much do you worry about 
death? 
.716 .873 .862 .899 .864 .950 
How much preoccupied are you about 
suffering before dying? 
.803 .869 .706 .905 .882 .949 
To what extent are you bothered by 
people blaming you for your HIV 
status? 
.637 .877 .686 .906 .815 .951 
To what extent are you concerned 
about how people will remember you 
when you are dead? 
.558 .880 .741 .904 .942 .948 
To what extent are you concerned 
about your HIV status breaking your 
family line and your future 
generations? 
.622 .877 .712 .905 .883 .949 
To what extent do any feelings you 
are suffering from fate or destiny 
bother you? 
.650 .876 .138 .925 .587 .955 
To what extent do you feel guilty 
when you need the help and care of 
others? 
.398 .886 .767 .903 .806 .951 
To what extent do your personal 
beliefs give you the strength to face 
difficulties? 
-.145 .906 .059 .925 .257 .960 
To what extent do your personal 
beliefs help you to understand 
difficulties in life? 
.013 .899 .155 .920 .209 .960 
 
 
